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Abstract 
The work presented in this thesis is concerned with the characterisation of the UL32 gene 
of herpes simplex virus type 1 (HSV-1). UL32 encodes an essential 596 amino acid 
cysteine-rich, zinc-binding protein that is highly conserved throughout the herpesviruses. 
The UL32 protein is essential for the cleavage of concatemeric viral DNA into monomeric 
genomes and their packaging into preformed capsids. Conservation is highest at the C-
terminus and three CxxC motifs are present in almost all known herpesvirus UL32 
sequences 
The UL32 antibodies available in the laboratory at the beginning of the project were 
incapable of detecting small amounts of UL32 protein and so new rabbit antisera were 
created. Soluble extracts from insect cells infected with a UL32-expressing baculovirus 
(AcUL32) were fractionated by anion exchange chromatography and the UL32-containing 
fractions used to immunise rabbits. The resultant antisera successfully recognised UL32 
from transfected, HSV-1 infected and baculovirus infected cells on western blots, and 
UL32 in transfected cells by immunofluorescence. 
I performed random mutagenesis of the UL32 gene in an effort to examine structure-
function relationships within this protein, and generated a panel of 37 mutants containing 5 
amino acid insertions at distinct positions. The abilities of these mutants to complement the 
DNA packaging and growth defects of a virus lacking a functional copy of UL32 (the null 
mutant hr64) were examined and 15 of the mutants retained functionality in both assays. A 
complete correlation was found between the ability of mutants to support growth and DNA 
packaging, suggesting that the key functions of UL32 are confined to the DNA packaging 
pathway. There was also good correlation with the degree of amino acid conservation 
within UL32, with most of the mutants which abolished functionality being located in the 
highly conserved regions, and the functional mutants in less conserved regions. A number 
of site-specific mutants were also created, in which the paired cysteine residues were 
replaced with serines (i.e. CxxC to SxxS). Mutation of the first and third cysteine pairs 
(from the N-terminus) completely abrogated growth and packaging, whereas significant 
functionality was maintained following mutagenesis of the central pair. Finally, removal of 
the C-terminal 4 amino acids also resulted in generation of a non-functional protein.  
Generation of an HA-tagged UL32 construct and the introduction of this into HSV-1 
allowed the localisation of UL32 in infected cells to be studied. In contrast to previous 
Abstract    
 
iii
reports, I detected UL32 predominantly in the nuclei of infected cells, co-localising with 
ICP8 in replication compartments. DNA packaging has previously been shown to occur 
within the replication compartments and a number of the other packaging proteins also 
localise to these sites. It was previously reported that UL32 played a role in the localisation 
of capsids to the replication compartments. However, work presented in this thesis shows 
this not to be the case, and that capsid proteins VP5 and VP19C were correctly localised in 
replication compartments during infections with the UL32 mutant hr64. I found no 
evidence of UL32 interaction with the UL6, UL25 or UL17 DNA packaging proteins in 
HSV-1 infected or transfected cells, or using immunoprecipitation from baculovirus-
expressed cells.  
Immunofluorescence studies of co-transfected cells showed that UL15 could direct the 
partial re-localisation of UL32 from the cytoplasm to the nucleus. The addition of the other 
terminase subunits UL28 and UL33 caused the complete re-localisation of UL32 to the 
nucleus, suggesting that UL32 might interact with the terminase complex. Fifteen of the 
insertional mutants were completely re-localised to the nucleus in the presence of UL15, 
UL33 and UL28, with eleven further mutants showing an intermediate phenotype of partial 
nuclear localisation. The ability to at least partially co-localise with the terminase complex 
appeared necessary for the ability of the mutants to support virus growth and DNA 
packaging, suggesting that this interaction may be essential for the function of UL32. 
However, no interaction could be demonstrated between UL32 and any of the individual 
terminase subunits using immunoprecipitation from insect cells. 
A series of experiments was undertaken to further characterise the UL32 protein. A new 
UL32 mutant virus (∆32EP) was generated by insertion of a kanamycin resistance cassette 
in place of a large portion of the UL32 gene. This mutant had an indistinguishable 
phenotype from hr64, confirming that the main function of UL32 is within DNA 
packaging. The functional conservation between HSV-1 UL32 and the homologues from 
HCMV and VZV was examined, but neither protein could support the growth of ∆32EP. 
DNA fragments from replicated concatemeric DNA from ∆32EP infected cells behaved 
similarly to wt HSV-1 fragments in PFGE, suggesting that UL32 is not involved in the 
resolution of branched structures within the genome prior to packaging.  
UL32 had previously been reported to bind zinc, and this was confirmed using a zinc-
release colourimetric assay. The amount of zinc bound to soluble baculovirus-expressed 
UL32 was quantified, showing that UL32 bound zinc in a 1:1 molar ratio. UL32 does not 
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share all of the characteristics of a zinc finger motif, but the results of the mutagenesis 
experiments suggest that the outer CxxC/CxxxC motifs may be important for zinc binding.  
Because of its zinc-binding properties and potential interaction with the terminase 
complex, the DNA binding properties of UL32 were also investigated. It was found that 
UL32 did not bind to dsDNA containing either the minimal packaging sequence (Uc-DR1-
Ub) or an unrelated non-HSV-1 sequence using an electrophoretic mobility shift assay 
(EMSA).
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1 Introduction 
The work presented in this thesis is concerned with the characterisation of the herpes 
simplex virus type 1 (HSV-1) UL32 protein and its role within the viral DNA cleavage and 
packaging process. This introduction discusses the general properties of herpesviruses and 
gives an outline of the viral life cycle. The process of DNA packaging in herpesviruses and 
related bacteriophage is also described in detail, including an outline of our current 
knowledge of the UL32 protein. Finally the aims of this project are introduced. 
1.1 Herpesviruses 
The herpesviruses comprise an abundant group of large double-stranded DNA (dsDNA) 
viruses infecting a wide range of hosts. Morphologically, herpesviruses have a unique 
virion architecture and historically the definition of a herpesvirus was based upon this. A 
large linear dsDNA genome of between 124 kbp (simian varicella virus) and 295 kbp 
(cyprinid herpesvirus 1) is tightly packed within an icosahedral capsid, which is encased in 
an amorphous protein layer known as the tegument. This is surrounded by the host-derived 
lipid envelope containing virus encoded membrane-associated glycoproteins.  
Over 100 herpesviruses have been identified, infecting a wide range of vertebrate hosts 
including mammals, birds, amphibians and fish. More recently a single herpesvirus has 
been described that infects a number of marine bivalve species (Arzul et al., 2001; Davison 
et al., 2005). Despite the varied host range within the family, each individual herpesvirus 
appears to infect very few host species (often only one natural host). Herpesviruses are 
very well adapted to their natural hosts, and severe infection is usually observed only in the 
very young, the foetus or the immuno-compromised. Viruses can, however, occasionally 
cross species and here more severe disease may be seen. An example of this is B virus 
(Macacine herpesvirus 1, previously Cercopithecine herpesvirus 1) which is endemic in 
macaques and causes no disease, although zoonotic infection of humans can result in 
encephalitis with a fatality rate of over 70% if not treated (Huff & Barry, 2003). 
Many herpesviruses have the ability to establish a persistent infection (latency) in the host. 
During latency, the genome exists in a 'dormant' state as a circular episome within cells 
and can persist for the lifetime of the infected individual, evading detection by the immune 
system. Reactivation from latency leads to productive infection and recurrence of disease. 
Chapter 1   2 
 
 
1.1.1 Classification of herpesviruses 
Recently the International Committee on Taxonomy of Viruses (ICTV) has accepted a new 
taxonomy of herpesviruses, whereby the former family Herpesviridae has been split into 
three families (Herpesviridae, Alloherpesviridae and Malacoherpesviridae), which are 
now incorporated into the new order of Herpesvirales. This new classification was 
proposed by the Herpesviridae study group (Davison et al., 2009) and is based on 
phylogenetic data. New genera have also been formed within families by the transfer of 
species from previously established genera and identification of new species, along with 
the renaming of some herpesviruses infecting non-human primates to reflect the host genus 
rather than the host sub-family. 
The first group within the Herpesvirales, the family Herpesviridae, encompasses viruses 
infecting birds, mammals and reptiles. This is split into three subfamilies of 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae. 
The Alphaherpesvirinae sub-family includes, among others, herpes simplex viruses 1 and 2 
(genus: Simplexvirus) and varicella-zoster virus and pseudorabies virus (genus: 
Varicellovirus). The Alphaherpesvirinae are neurotropic and establish latency in neuronal 
ganglia innervating the site of initial infection. They replicate relatively rapidly and 
efficiently in a number of cell lines in tissue culture.  
The Betaherpesvirinae includes human cytomegalovirus (genus: Cytomegalovirus) and 
human herpesviruses 6 and 7 (genus: Roseolovirus). This sub-family also now includes a 
newly created genus, the Proboscivirus - the only representative of which is a herpesvirus 
infecting elephants (Richman et al., 1999). The Betaherpesvirinae are characterised by a 
slower replication and more restricted host range in culture and the establishment of 
latency in cells of the monocyte lineage.  
The Gammaherpesvirinae sub-family includes Epstein-Barr virus (genus: 
lymphocryptovirus) and Kaposi’s sarcoma-associated herpesvirus (genus: Rhadinovirus). 
Two new genera, the Macavirus and Percavirus have been created within the 
Gammaherpesvirinae. This sub-family of viruses are lymphotrophic, with a variation in 
replication cycle length. They have a more restricted host range in vitro than either of the 
other sub-families and establish latency in T or B lymphocytes. 
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The estimated number of protein-coding genes in the Herpesviridae varies from 70 in VZV 
to 165 in HCMV. 43 genes, which are denoted ‘core’ genes, are present in each of the sub-
families, providing evidence of a common evolutionary ancestor (McGeoch & Davison, 
1999). Many of these core genes are involved in the replication or packaging of the viral 
DNA, or encode proteins that are present in the virion. 
The newly-formed Alloherpesviridae family consists of herpesviruses infecting amphibians 
and bony fish. These form a group that are essentially unrelated to the Herpesviridae by 
analysis of amino acid conservation and as such they have been classified as a separate 
family in the new taxonomy (Davison et al., 2009).  However, their identification as a 
family of the Herpesvirales can be demonstrated by similarity in virion morphology and 
maturation (Booy et al., 1996; Davison & Davison, 1995). 
The third family is the Malacoherpesviridae, whose only member is a herpesvirus 
infecting invertebrates, named Ostreid herpesvirus 1 (OsHV-1) (Davison et al., 2005). 
Again, the Malacoherpesviridae are very distantly related to the Herpesviridae and 
sequence analysis did not demonstrate any similarity between the structural proteins of 
OsHV-1 and other herpesviruses. Despite these differences in amino acid sequence, the 
virions of OsHV show the characteristic herpes virus morphology and OsHV-1 was first 
identified as a herpesvirus by the presence of these virions in lesions of infected oysters 
(Farley et al., 1972). Studies of the virion by cryo-electron microscopy (cryo-EM) 
confirmed the structural similarity between OsHV-1 capsids and other herpesviruses 
(Davison et al., 2005). 
As mentioned, there is very little sequence similarity between the three families of 
herpesviruses and genetically they are only tenuously related to each other. Although many 
core genes can be identified as conserved within families, only one protein has an amino 
acid sequence that is conserved among the three families in a way to suggest a common 
ancestor. This gene, which encodes the ATPase of the DNA packaging complex, also has 
relatives in T4-like bacteriophage (Davison, 1992; Davison, 2002; Rao & Black, 1988). It 
is therefore not completely Herpesvirales-specific, although similarities in capsid assembly 
and the DNA packaging process between herpesviruses and dsDNA bacteriophage suggest 
that they too have a common evolutionary ancestor.  
Phylogenetic trees of herpesviruses show similarity with the phylogeny of the 
corresponding host organisms, which is taken as evidence for co-evolutionary development 
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of virus and host lineages (McGeoch et al., 1995). This co-evolution may also explain the 
restricted host-range of many herpesviruses. 
1.1.2 Human Herpesviridae 
Eight herpesviruses have been identified that infect human hosts (Human herpesviruses 
[HHV] 1-8), encompassing all three subfamilies of the Herpesviridae. In general, these 
viruses do not cause serious illness upon primary infection of immuno-competent hosts, 
and infections can often be asymptomatic.  
Herpes simplex virus type 1 (HSV-1, HHV-1) is the prototype in the Alphaherpesvirinae, 
and as such has been extensively studied. Primary infection occurs in the epithelial cells of 
the skin and mucosa near the mouth, and life-long latency is established in ganglia 
innervating the site of primary infection (Stevens & Cook, 1971). HSV-2 (HHV-2) is very 
similar to HSV-1 in its pattern of infection, but is primarily associated with infections of 
the genitalia. The third human alphaherpesvirus is varicella-zoster virus (VZV, HHV-3). 
This is the causative agent of chickenpox in children (varicella), which is characterised by 
a vesicular skin rash. Later reactivation of the virus from the neurons in which VZV 
establishes latent infection results in the adult disease shingles (zoster). 
Three members of the Betaherpesvirinae also have human hosts. Human cytomegalovirus 
(HCMV, HHV-5) is most widely studied of this family. Infection is asymptomatic in most 
individuals and acute disease is mainly seen in those who are immuno-compromised or 
immuno-suppressed. HCMV can establish latent infection in blood monocytes (Sinclair & 
Sissons, 2006). HCMV is also a major cause of neonatal disease through congential 
infection, often resulting in damage to the brain and nervous system. Human herpesviruses 
6 and 7 (HHV-6 and HHV-7) are lesser-studied viruses that are the causative agents of 
exanthema subitum (Roseola), a near-universal childhood disease associated with the 
appearance of a rash. 
Two viruses within the Gammaherpesvirinae are known to infect humans, and these have 
both been associated with various tumours. The first is Epstein Barr virus (EBV, HHV-4). 
EBV is one of the most prevalent herpesviruses and many individuals become infected in 
childhood, showing no symptoms. When primary infection with EBV occurs during 
adolescence or young adulthood, it can cause infectious mononucleosis (glandular fever), 
characterized by fever, sore throat and fatigue. EBV establishes latency in B-lymphocytes 
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and can transform B-lymphocytes in vitro. It has been implicated in nasopharyngeal 
carcinoma, Hodgkin’s disease and Burkitt’s lymphoma, although establishment of these 
cancers is also dependent on many other factors (Joseph, 1999). Human herpesvirus 8, 
otherwise known as Kaposi’s sarcoma-associated herpesvirus (KSHV), again causes very 
few symptoms in healthy individuals. In AIDS patients, however, KSHV is the causative 
agent of Kaposi’s sarcoma, a tumour characterised by lesions on the skin, respiratory tract 
or intestinal tract. 
 
1.2   Herpes simplex virus type 1 
HSV-1 is the prototype member of the Alphaherpesvirinae, and has been one of the most 
intensely studied herpesviruses. Primary infection with HSV-1 of healthy individuals is not 
a serious global health issue, as it is normally asymptomatic.  It is estimated, however, that 
between 60 and 95% of adults are latently infected with either HSV-1 or 2 (although HSV-
1 is predominant) (Brady & Bernstein, 2004).  The virus can then lie dormant for the 
individual’s lifetime, periodically reactivating to disseminate viral particles.  Symptoms 
occur when the virus is reactivated, caused normally by physical trauma, stress or nerve 
damage.  A variety of symptomatic diseases are associated with primary HSV-1 infection 
or reactivation (Dwyer & Cunningham, 2002), including most commonly orolabial lesions 
(coldsores) and genital ulcers (although HSV-2 is still the main cause of genital herpes).  
More serious manifestations can include herpetic keratitis (leading to keratoconjuctivitis 
and corneal scarring), herpes encephalitis caused by replication of HSV-1 in the brain, and 
neonatal infection.  Some correlational evidence has also implicated HSV-1 infection with 
Alzheimer's disease, when combined with a particular allele of the gene encoding 
apolipoprotein E. However, the full importance of the virus in the disease and the 
mechanisms by which it contributes to Alzheimer's are still unclear (Itzhaki, 2004). 
1.3 HSV-1 virion 
As with all herpesviruses, the mature infectious HSV-1 virion is composed of four distinct 
structural components. The dsDNA genome is enclosed within an icosahedral capsid, 
which is surrounded by a proteinaceous tegument and host-derived lipid envelope. An 
electron micrograph along with diagrammatic representation of the HSV-1 virion is shown 
in figure 1.1 
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Figure 1.1: The HSV-1 virion. 
Electron micrograph of a negatively stained HSV-1 virion and cartoon representation, 
showing the components comprising the virion. A DNA-filled icosahedral capsid is 
surrounded by a proteinaceous tegument and a host-derived lipid envelope studded 
with glycoproteins. Scale bar is 100 nm. (Adapted from Roizman and Knipe, 2001) 
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1.3.1 Genome 
The HSV-1 genome is a linear double-stranded DNA molecule, approximately 152 kbp in 
length. The genome comprises two covalently linked components, designated as L (long) 
and S (short), each containing a unique sequence (UL and US respectively). Inverted 
repeats flank the unique sequences, with UL flanked by TRL (terminal repeat long) and IRL 
(internal repeat short), and US flanked by TRS (terminal repeat long) and IRS (internal 
repeat short). The UL region is 107.9 kbp and US is 12 kbp and together these encode about 
72 proteins. The long and short repeat sequences are 9.2 kb and 6.6 kb respectively and 
encode a further three proteins, RL1 (ICP34.5) and RL2 (ICP0) within RL and RS1 (ICP4) 
within RS. The gene organisation and nomenclature of HSV-1 is shown in figure 1.2. 
Historically, the proteins of HSV-1 were assigned virion protein (VP) or infected cell 
protein (ICP) numbers, but sequencing of the genome has allowed identification of the 
corresponding genes for these proteins. The gene and protein nomenclature for proteins 
discussed in this thesis is shown in table 1.1  
A direct repeat of 250-500 bp (the a sequence) lies at the genomic termini and also in an 
inverted orientation at the junction between L and S
 
segments. There can be multiple 
copies of the a sequence at the L terminus and junction, with only a single copy at the S 
terminus. The remainder of TRL/IRL and TRS/IRS excluding the a sequence are referred to 
as the b and c sequences respectively. Therefore the full structure of the genome can be 
represented as am-b-UL-b'-a'n-c'-US-c-a, where ' indicates inverted orientation and n and m 
are the number of a sequence repeats (see figure 1.3A). It is within the a sequence that the 
cis-acting sequences required for packaging of the genome lie (see section  1.5.3).  
The repeat sequences allow inversion of the two unique regions relative to one another, 
generating four isomers of the genome, as shown in figure 1.3B. The significance of these 
inversion events in the replication of herpesviruses is unknown, but populations of virions 
have equimolar ratios of these isomers (Hayward et al., 1975) 
The HSV-1 genome also includes three cis-acting sequences that act as origins of 
replication for the genomic DNA.  One copy of oriL is present in the UL region, lying 
between ORFs UL29 and UL30 (Spaete & Frenkel, 1985). Two identical copies of oriS are 
found in the repeat regions flanking US between genes RS1 and either US1 or US12 (Stow, 
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1982). The two types of origin share considerable homology and many features, including 
binding sites for the viral UL9 protein on either side of a central A/T rich region. It is 
unclear why the HSV-1 genomes contain multiple origins. There is some redundancy as a 
virus deleted in both copies of oriS could replicate DNA in a tissue culture system, 
although the rate of DNA synthesis was slower than that of wt HSV-1 (Igarashi et al., 
1993). Furthermore, the single oriL has also shown to be dispensible in tissue culture 
(Polvino-Bodnar et al., 1987). 
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Figure 1.2: Gene organisation within HSV-1. 
The organisation and nomenclature of genes within the HSV-1 genome is shown, 
with the shaded arrows indicating protein coding regions (showing the direction 
of transcription). The genes encoded within the UL region have the prefix UL 
(UL1-UL56), and those encoded within US are denoted US1-US12. The thicker 
sections show the repeat regions (TRL, IRL, IRS and TRS), which encode a further 
three genes, RL1, RL2 and RS1. The position of the LAT transcript within RL is 
marked, as are the locations of the origins of replication (oriL and oriS). The 
vertical arrows indicate possible polyadenylation site for mRNAs. (Adapted from 
Davison & Clements, 1997) 
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Triplex protein
Major capsid protein
gE
gC
gD
gB
gH
gM
gL
Origin binding proteinUL9
Single stranded DNA binding proteinICP8UL29
Helicase-primase subunit (processivity factor)UL8
Primase subunit of helicase-primaseUL52
Helicase subunit of helicase-primase complexUL5
DNA polymerase processivity subunitUL42
DNA polymerase catalytic subunitUL30
DNA replication proteins
Initial attachment to cellsUL44
TAP transporter inhibitorICP47US12
Neurovirulence factorICP34.5RL1
Transcriptional activator and inhibition of mRNA splicingICP27UL54
Trasncriptional activatorICP22US1
Transcriptional regulator ICP4RS1
Transcriptional activation and de-repression of genomeICP0RL2
Infected cell proteins
Tegument protein –involved in nuclear entry and egressVP1/2UL36
Tegument protein – virion host shut-off proteinvhsUL41
Tegument protein – transactivator of IE gene expressionVP16
Maturational proteaseVP24*UL26
Minor scaffolding proteinVP21*UL26
Major scaffolding proteinVP22aUL26.5
Minor capisd protein bound to hexonsVP26UL35
Triplex proteinVP19CUL38
VP23UL18
VP5UL19
Capsid and tegument proteins
Acquisition of viral envelope during secondary envelopmentUS8
Receptor binding, membrane fusion and entryUS6
Initial attachment to cells and membrane fusionUL27
Membrane fusion and entry – interacts with gLUL22
Secondary envelopmentUL10
Membrane fusion and entry – interacts with gHUL1
Glycoproteins
Function
Protein name (if 
applicable)Gene
 
Table 1.1: Nomenclature of genes and proteins described within this thesis. 
* VP21 and VP24 are derived from the N and C terminal portions of the full-length 
UL26-encoded precursor. 
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Figure 1.3: HSV-1 genome structure and isomers. 
A. The structure of the HSV-1 genome is represented above (not to scale). The 
unique regions UL and US are shown as single horizontal lines with the flanking 
repeats, RL and RS, shown as rectangles. The regions of RL and RS lacking the 
a sequence are denoted b and c, respectively. Terminal (TRL and TRS) and 
internal (IRL and IRS) repeats are inverted with respect to each with their 
relative orientations indicated by arrows. The a sequence, required for DNA 
cleavage and packaging, is present at each terminus and in an inverted 
orientation (a’) separating IRL and IRS. m and n indicate that there can be 
multiple copies of the a sequence at the L terminus and the L-S junction. 
B. The unique regions of the genome can invert relative to each other, giving rise 
to four isomers of the genome. P = prototype; IS = inverted US; IL = inverted 
UL; ILS = inverted UL and US. 
Chapter 1   12 
 
 
 
1.3.2 Capsid 
As with all herpesviruses, the HSV-1 capsid is a T=16 icosahedral shell, with the genomic 
DNA packed tightly into the capsid in a liquid-crystalline array (Booy et al., 1991). The 
capsid structures of widely diverged members of the herpesviruses are similar, even when 
there is no sequence similarity between the proteins making up the capsid (for example 
HSV-1 and CCV) and despite a wide variation of genome lengths, all Herpesviridae have a 
capsid diameter between 125 nm (HSV-1) and 130 nm (HCMV) (Butcher et al., 1998). In 
agreement with this, electron microscopy has shown that HCMV (the largest genome in the 
Herpesviridae) is more densely packed than the HSV-1 genome (Bhella et al., 2000).  
The HSV-1 capsid is 125 nm in diameter and approximately 15 nm thick (Booy et al., 
1991). A reconstruction of the HSV-1 capsid has been determined to 8.5 Å and is shown in 
figure 1.4. It consists of 162 capsomers made up of the major capsid protein VP5, 
comprising 150 hexons and 11 pentons. The hexons are the faces of the icosahedron, 
showing 6-fold rotational symmetry, with the penton vertices showing the 5-fold 
symmetry. The final vertex is the portal for DNA entry (discussed further in section  1.6.1). 
Hexons and pentons are connected in groups of three by complexes known as triplexes 
(320 in total). In HSV-1 the triplexes are heterodimers comprising two copies of VP19C 
and one copy of VP23. The final protein making up the capsid shell is VP26, with one 
molecule of this bound to each hexon-associated VP5. VP26 is believed to play a role 
tegument attachment, however it is not required for capsid assembly. The capsomers are 
assembled around a proteinaceous scaffold made up of the viral protease (encoded by the 
UL26 gene) and pre-VP22a (encoded by the UL26.5 gene). The structure of the HSV-1 
capsid is reviewed by Homa and Brown (1997). 
Four species of capsid have been identified by electron microscopy within HSV-1 infected 
cells, as shown in figure 1.5. The first species to form are the procapsids, which are 
spherical in shape and contain the internal scaffold. During infection, the maturation of 
procapsids due to cleavage of the internal scaffold can give rise to A-, B- and C- capsids, 
distinguishable by electron microscopy and sucrose gradient centrifugation (Gibson & 
Roizman, 1972). A-capsids are empty structures with no DNA or scaffold inside. B-
capsids have a proteinaceous core which is the cleaved form of the protein scaffold, but no  
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Figure 1.4: 3D reconstruction of HSV-1 capsid. 
Cryo-electron microscopy and 3D reconstruction of HSV-1 B capsid at 8.5 Å 
resolution. A shaded surface view showing the capsid consisting of 160 capsomers, 
showing the 150 hexons in blue. The 12 vertices (red) are 11 pentons and the portal. 
However, because of symmetry imposed during image reconstruction, the portal 
cannot be distinguished. The triplexes are shown in green. (adapted from Zhou et al., 
1999) 
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procapsid
B-capsid
A-capsid
C-capsid
UL26 (protease; pre-VP21 + VP24)
VP5 (hexons and pentons)
VP19C + VP23 (triplex)
UL6 (portal)
UL26.5 (pre-VP22a)
VP26
Figure 1.5: Capsid types found in HSV-1 infected cells. 
Four capsid species have been identified in HSV-1 infected cells. The first of these is 
the spherical procapsid, comprised of major capsid protein VP5 arranged in hexons 
and pentons, coordinated by triplex proteins VP19C and VP23. Procapsids also 
contain one unique vertex made up of a dodecamer of the portal protein UL6. The 
procapsid contains an internal scaffold made up of proteins encoded by genes UL26 
and UL26.5. Successful maturation of the procapsid results in the formation of 
angularised C-capsids which lack the internal scaffold, but instead contain the 
genomic DNA. A- and B- capsids are formed as dead-end products of the maturation 
process, with B-capsids containing cleaved scaffold protein and A- capsids containing 
neither scaffold nor DNA. (Adapted from Trus et al., 2007) 
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DNA. Both of these capsid types are dead-end products of the DNA packaging pathway. 
C-capsids, however, contain viral DNA and can mature into infectious virions. 
The processes of capsid assembly and maturation are believed to resemble that in 
bacteriophages, and are discussed further in section  1.4.6. 
1.3.3 Tegument 
All herpesviruses have a layer of protein called the tegument that lies between the virion 
envelope and the capsid. The tegument consists of multiple, virus-encoded proteins that 
can account for nearly half the total virion protein. A recent proteomics analysis suggested 
23 potential tegument proteins in HSV-1 (Loret et al., 2008) . Historically, the tegument 
has been described as amorphous, but there is growing evidence for an ordered addition of 
tegument during assembly, with multiple interactions driving tegumentation and virion 
formation (Mettenleiter, 2006). Although the tegument is not highly structured, the inner 
tegument does show a small degree of icosahedral symmetry where it interacts with the 
pentons of the capsid (Zhou et al., 1999). The highly conserved inner tegument protein 
UL36 has been shown to interact with VP5 and this interaction may act as the link that 
binds the capsid to the tegument in the infectious virion. The use of cryo-electron 
tomography has suggested that the tegument may be asymmetrically distributed around the 
capsid (Grunewald et al., 2003), and yeast-two-hybrid screens have been used to determine 
interactions between tegument proteins (Vittone et al., 2005). Tegument proteins enter the 
cell as part of the incoming virion and are involved in many processes both before and 
after viral protein synthesis, for example targeting of virus components to the nucleus, 
transactivation of viral gene expression, regulation of host cell gene expression. Other 
tegument proteins are involved in DNA packaging and assembly of virions at a later stage 
of infection (Kelly et al., 2009). 
1.3.4 Envelope 
The outer layer of the HSV-1 virion is a host-cell derived envelope. This envelope is a 
lipid-bilayer studded with virally-encoded glycoproteins, visible in negatively-stained 
electron microscope preparations as short spikes that are non-randomly distributed. The 
precise number of envelope glycoproteins varies among herpesviruses, with 13 described 
in HSV-1 (Loret et al., 2008). The glycoproteins have roles in attachment and entry into 
the cell (discussed in section  1.4.1). 
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The viral envelope is acquired through a two-step budding process, whereby the virus 
acquires a primary envelope whilst budding through the inner nuclear membrane, is de-
enveloped when budding from the lumen of the nuclear membrane into the cytoplasm, and 
is re-enveloped (secondary envelopment) at the trans-golgi network (TGN) before exit 
from the cell (discussed in section  1.4.7).  
 
1.4 HSV-1 replication cycle 
The lytic replication cycle has been studied most comprehensively in HSV-1, and appears 
to be similar in all herpesviruses. It is summarised in figure 1.6 and each stage is described 
in more detail in the following sections. 
1.4.1 Attachment and entry 
Alphaherpesviruses most commonly infect epithelial cells of mucosal membranes and the 
sensory neurons that innervate those epithelia. Entry involves attachment to specific and 
non-specific receptors on the surface of cells using the glycoproteins in the viral 
membrane. Of the 13 or more HSV-1 viral glycoproteins, infection in cell culture requires 
the co-ordinated action of at least four of these – gB, gD, and a heterodimer of gH/gL. 
The initial attachment to cells involves binding of the virion to the heparin sulphate (HS) 
moieties of the cell-surface proteoglycans, an interaction that can be mediated 
independently by either glycoprotein gC or gB. However, this binding has been shown to 
be reversible, and although it significantly enhances the efficiency of HSV-1 infection, it is 
not essential in cell culture. Viruses either lacking gC, or with a mutation in gB which 
abolishes its interaction with HS are still infectious, albeit at a much reduced level. 
However, deletion of both gB and gC together completely abrogates infectivity (Herold et 
al., 1994; Laquerre et al., 1998). Recently it has been suggested that another host receptor 
may also mediate interaction with gB, since a soluble form of gB was shown to interact 
with different cell types independent of HS (Bender et al., 2005). 
The next stage of entry involves the interaction of gD with one of several potential entry 
receptors. Three classes of receptors have been identified on mammalian cells by virtue of 
the fact that addition of these proteins allows virus entry into infection-resistant CHO cells.  
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Figure 1.6: The lytic replication cycle of HSV-1.
(1) The virion attaches to the cell plasma membrane via specific interactions between 
the viral glycoproteins and cellular receptors. The virion envelope then fuses with the 
plasma membrane, releasing the capsid and tegument proteins into the cytoplasm. (2) 
The capsid is translocated to the nuclear pore via microtubules, where the viral 
genome is released into the nucleus via the nuclear pore. (3) The virion host shut-off 
(vhs) protein causes degradation of host messenger RNA (mRNA). (4) The tegument 
protein VP16 localizes into the nucleus where it can act to transactivate the cascade of 
viral gene expression. (5) The viral DNA circularizes prior to DNA transcription and 
replication. (6) There is temporal expression of the three classes of viral genes, 
transcribed by host RNA polymerase II. Firstly the immediate early (α) genes are 
transcribed and five of the six α proteins act to regulate subsequent viral gene 
expression in the nucleus. (7) The IE proteins transactivate early (β) gene 
transcription. (8) The β genes encode proteins required for replication of the viral 
genome. (9) Viral DNA synthesis stimulates L (γ) gene expression. (10) The γ
proteins are mainly structural proteins involved in assembly of the procapsid in the 
nucleus. (11) The concatemeric replicated DNA is cleaved into unit length genomes 
and packaged into the preformed procapsid, generating C-capsids. (12) The filled 
capsid acquires a primary envelope when budding through the inner nuclear 
membrane and is de-enveloped as it buds from the lumen of the nucelar membrane 
into the cytoplasm. This capsid acquires tegument proteins in the cytoplasm. The 
tegumented capsid then forms a final enveloped virion by budding into the trans-golgi
network and the virion exits from the cell through the secretary pathway (Adapted 
from Roizman & Knipe, 2001)
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These are the TNF family member Herpes Virus Entry Mediator (HVEM) (Montgomery et 
al., 1996), Ig superfamily members nectin-1 and -2 (Geraghty et al., 1998), and a 3-O-
modified form of heparin sulphate (Shukla et al., 1999). 
Following initial attachment and binding to the cell, the process of fusion occurs. Three 
different pathways for entry of HSV-1 into cells have been proposed, depending on the 
type of host cell. The first route identified was via fusion at the plasma membrane and this 
route can be visualised by electron microscopy in neurons and is well documented in Vero 
and Hep2 cells. Although this was long considered the only route of entry, in many other 
cell types, HSV-1 virions are endocytosed. Fusion with the endosomal membrane has been 
shown to occur via two possible entry mechanisms, both pH-dependent and pH-
independent (Nicola et al., 2003; Wittels & Spear, 1991). 
In all three routes of entry, binding of gD to one of its receptors is thought to cause a 
conformational change in gD and trigger fusion of the viral envelope with the appropriate 
cellular membrane, as reviewed by Garner (2003). Fusion requires gB and a heterodimer of 
glycoproteins, gH/gL, as deletion of these proteins produces mutant viruses that can bind 
to cells but not internalise. The key role in fusion is thought to be played by glycoproteins 
gB and gH, which are both conserved in the Herpesviridae, whereas gL is required for 
correct trafficking of gH to the viral envelope (Hutchinson et al., 1992). 
Fusion of the viral envelope with a cellular membrane releases the capsid and tegument 
into the cytoplasm. Some tegument proteins remain in the cytoplasm but the capsid and 
other associated inner tegument proteins are transported to the nucleus via microtubules. It 
has been shown that agents that de-stabilise microtubules block this transport of capsids in 
different cell types (Topp et al., 1996; Topp et al., 1994). This microtubule transport is 
mediated by the retrograde motor dynein, which is known to transport organelles towards 
the nucleus (Dohner et al., 2002). The viral proteins mediating this interaction with dynein 
have not been identified, but VP26 is thought to be involved, and it has been shown that 
some inner tegument proteins are needed for capsid transport along microtubules in vitro 
(André et al., 2006). 
Once the capsids have reached the nucleus, they dock at the nuclear pore and release the 
genome into the nucleus. This process of uncoating the genome is thought to involve 
cellular factors Ran-GTP and importin β (Ojala et al., 2000). Viral proteins including 
UL36 and UL25 are also essential for these early events following infection, as certain 
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virus mutants with lesions affecting these proteins fail to release viral DNA into the cell 
nucleus (Preston et al., 2008; Roberts et al., 2009). An interaction has been described 
between UL25 and a component of the nuclear pore complex, CAN/Nup214, and 
furthermore, depletion of CAN/Nup214 delayed the release of viral DNA into the nucleus 
(Pasdeloup et al., 2009). The portal protein UL6 is cleaved upon viral DNA exit from the 
capsid (Newcomb et al., 2007).  
1.4.2 Localisation of HSV-1 DNA in infection 
Upon entry into nucleus, incoming viral genomes can be seen as discrete spots surrounded 
by small nuclear substructures known as ND10 domains. ND10 domains comprise the 
major organising protein, PML, and several other cellular components including Daxx and 
Sp100, and their SUMO-modified isoforms (Negorev & Maul, 2001). These domains are 
also found in uninfected nuclei, and have a variety of functions including regulation of 
gene expression, chromatin dynamics, DNA repair and the interferon repsonse. It has been 
shown that ND10 are dynamic structures that move to accumulate around incoming 
genomes, rather than genomes localising to existing ND10 sites (Everett & Murray, 2005). 
ND10 are thought to make up part of an intrinsic cellular defence against viral infection 
formed around the viral DNA that act to repress the viral genome and restrict transcription.  
Very soon after infection with wt HSV-1, these ND10 domains are disrupted in a process 
that requires the viral immediate early protein ICP0 (Maul et al., 1993). ICP0 is an E3 
ubiquitin ligase which induces the proteosome-dependent degradation of PML and 
subsequent breakup of the ND10 domains (Everett et al., 1998). This disruption of ND10 
and associated de-repression of the genome allows the recruitment of cellular and viral 
factors needed for transcription of viral proteins, resulting in the formation of small pre-
replicative sites. Initial transcription and replication of HSV-1 DNA occurs in these small 
pre-replicative sites adjacent to the original ND10 site. 
After repeated rounds of transcription and DNA replication, the pre-replicative sites form 
into larger replication compartments (RCs). It is here in the replication compartments that 
DNA replication, late gene expression, capsid assembly and DNA packaging take place. 
Proteins involved in DNA replication and packaging, as well as virus capsids, have been 
shown to localise to RCs, (de Bruyn Kops et al., 1998; Lamberti & Weller, 1998; Phelan et 
al., 1997; Yu & Weller, 1998a). These replication compartments are often defined by the 
presence of the HSV-1 single stranded DNA binding protein ICP8 (Quinlan et al., 1984). 
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Many different cellular proteins have also been identified within or close to RCs, including 
those involved in DNA damage repair and chromatin remodelling (which interact with 
ICP8), and chaperones involved in the heat shock response and protein folding (Burch & 
Weller, 2004; Taylor & Knipe, 2004).  
1.4.3 Circularisation of DNA 
Soon after entry into the nucleus, the linear double stranded DNA viral genome circularises 
and it is this circular DNA which is thought to be the template for DNA replication (Garber 
et al., 1993; Poffenberger & Roizman, 1985). Endless molecules can be detected as early 
as one hour post infection and these endless molecules have been shown to be circularised 
genomes rather than simply genomes that are joined end to end. (Strang & Stow, 2005). It 
is thought that circularisation may occur via direct ligation of the termini, although this has 
not been demonstrated in vitro, and so it is possible that homologous recombination 
between terminal repeats is involved. This circularisation of the genome does not require 
viral DNA replication or protein synthesis, indicating that the process is mediated by 
cellular factors (Strang & Stow, 2005). The regulator of chromatin condensation 1 (RCC1) 
has been implicated in genome circularisation, and infection of cells lacking RCC1 led to a 
block in virus replication, due to a reduction in both genome circularisation and DNA 
synthesis (Strang & Stow, 2007; Umene & Nishimoto, 1996). RNAi-mediated knock down 
of DNA ligase IV and its cofactor XRCC4 also reduces the formation of endless genomes 
(Muylaert & Elias, 2007). It has been suggested that one of the viral immediate early 
proteins, ICP4 is essential for genome circularisation (Su et al., 2006), although this 
conflicts with the earlier data showing that no de novo protein synthesis is required for 
genome circularisation. 
1.4.4 HSV-1 gene expression 
All herpesviruses have a controlled temporal cascade of gene expression, with three classes 
of genes, designated immediate early (IE, α), early (E, β), and late (L, γ) (Honess & 
Roizman, 1974). Neither IE nor E genes are reliant on DNA replication for their 
expression, and all three classes of genes are transcribed by the host RNA polymerase II 
utilising viral and host transcription factors. 
The IE genes begin to be expressed very soon after infection. Many of these genes encode 
regulatory proteins needed for early gene expression and are activated by viral and cellular 
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transcription factors. The viral transactivator VP16 is brought into the cell as a component 
of the tegument and associates with the host protein HCF. This interaction of VP16 with 
HCF is required for the entry of VP16 into the nucleus (La Boissiere et al., 1999). This is 
followed by association of these two proteins with the host protein Oct-1 to form the 
immediate early transcription initiation complex.  This complex can then bind to conserved 
TAATGARAT motif (where R = purine) in the IE gene promoters to stimulate 
transcription of the IE genes, encoding proteins ICP0, ICP4, ICP22, ICP27, ICP47 and 
US1.5. 
The IE protein ICP0 acts as a promiscuous transactivator which can induce expression 
from all classes of herpesvirus genes. In transient expression assays, ICP0 was shown to 
act co-operatively with another IE protein, ICP4, to activate many cellular and viral genes 
(reviewed by Hagguland (2004).  
ICP4 is involved in both positive and negative regulation of viral gene expression, and is 
required for efficient expression of all post-IE genes at the transcriptional level (Watson & 
Clements, 1980). In the absence of ICP4, all post-IE gene expression is blocked. It has 
been shown to bind to DNA (both consensus and non-consensus sequences) (Kristie & 
Roizman, 1986; Michael et al., 1988). ICP4 also interacts with multiple transcription 
factors (TFs) and is thought to increase gene expression by facilitating the binding of TFs 
to the TATA box on viral β and γ promoters and enhancing formation of the pre-initiation 
complex (Grondin & DeLuca, 2000).  
As well as stimulating viral gene expression and protein production, a number of the IE 
genes act to decrease host protein expression and to improve the cellular environment for 
the viral life cycle. ICP27 is required for post-IE viral gene expression, but also inhibits 
transcription of many host genes, reviewed by Smith (2005). It can also act at a later stage, 
post-transcriptionally, to inhibit RNA splicing and promote the export of unspliced 
mRNAs (Hardwicke & Sandri-Goldin, 1994). This results in decreased host protein 
synthesis as the host intron-containing mRNAs are not exported into the nucleus for 
translation. As only four lytic HSV-1 genes are spliced, this has a minimal effect on viral 
gene expression. Three of the four spliced HSV-1 genes are expressed from IE promoters 
before maximal splicing inhibition, and the fourth, UL15, is expressed as a late (γ2) 
transcript. It is not yet certain how UL15 escapes this splicing inhibition, although it may 
be spliced using a different mechanism. 
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The ICP47 protein has no known role in regulating viral gene expression but is also 
involved in subversion of cellular processes. ICP47 acts to downregulate the host immune 
response by inhibiting the processing of viral peptides through the TAP pathway. This 
blocks the presentation of the viral peptides on MHC class I molecules to T cells and the 
establishment of an anti-viral T cell response (Fruh et al., 1995). 
Production of IE genes stimulates the next class of genes in the cascade – the early (β) 
genes. The E genes reach peak expression at 5-7 hours post infection. These encode the 
proteins responsible for viral DNA replication, and the appearance of these early gene 
products signals the onset of viral DNA synthesis. This stimulation of E gene expression is 
accompanied by a decrease in the transcription of IE genes, through a number of 
mechanisms. ICP4 negatively regulates its own expression by binding to DNA near the 
promoter. Some E genes (for example ICP8) also down regulate IE gene expression 
(Honess & Roizman, 1974). 
The late, or γ, genes are divided into two classes depending on their expression kinetics. 
Leaky late (γ1) genes are expressed at low levels prior to DNA synthesis, but true late (γ2) 
genes have an absolute requirement for DNA synthesis. The late genes encode components 
of the viral particle and proteins involved in capsid assembly, encapsidation and virion 
maturation. As with the early genes, their expression is dependent on the presence of 
earlier viral proteins, for example ICP4. 
1.4.5 DNA replication 
DNA replication takes place in replication compartments after the expression of immediate 
early and early genes, using the circularised DNA as a template. As described earlier, the 
genome contains two related cis-acting sequences, oriL and oriS, that act as origins of 
replication.  
The DNA is replicated using a virally-encoded replication complex comprising the 
proteins UL9, UL29 (ICP8), UL42, UL30, UL5, UL8 and UL52. These proteins were 
identified by studies which found that plasmids containing the viral origins of replication 
could be efficiently replicated upon co-transfection with cloned HSV-1 fragments 
encoding these genes (Wu et al., 1988). Studies using both temperature sensitive and viral 
null mutants targeted to each of these genes confirmed their essential role in the replication 
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of DNA. The function of each of these genes is discussed below and reviewed by Lehman 
(1999). 
UL9 encodes the origin binding protein (OBP) which exists as a homodimer and can bind 
to two inverted repeats within oriS in a co-operative fashion (Elias & Lehman, 1998). This 
DNA-binding activity resides in the C-terminal portion of the protein (Arbuckle & Stow, 
1993). The N-terminus of UL9 possesses ATP-dependent helicase activity, which enables 
the protein to unwind up to 1 kbp of DNA from the origin for replication.  
The UL29 gene encodes ICP8, the single-stranded DNA binding protein that is used as a 
marker for replication compartments. ICP8 binds single stranded DNA very effectively and 
cooperatively, with no sequence specificity. ICP8 interacts with the extreme C-terminus of 
UL9, greatly stimulating its ATPase and DNA helicase activities (Boehmer et al., 1993). In 
conjuction with UL9, ICP8 can open up the DNA around the viral origin of replication, 
allowing access to the remaining replication enzymes prior to the creation of a replication 
fork. ICP8 has been shown to stimulate the activity of both the DNA polymerase and the 
helicase-primase complexes (Hamatake et al., 1997; Ruyechan & Weir, 1984). The effect 
on the helicase-primase is mediated through an interaction between ICP8 and UL8. 
The viral DNA polymerase exists as a heterodimer within cells, made up of subunits UL30 
and UL42. The interaction of these two proteins is essential for viral replication (Digard et 
al., 1993; Stow, 1993). The polymerase activity is associated with the UL30 subunit and 
this protein shares extensive homology with other cellular and viral DNA polymerases 
(Blanco et al., 1991). UL30 also shows 3'-5' exonuclease activity, meaning that is has an 
intrinsic proof-reading ability (Knopf, 1979).  The UL42 subunit binds to DNA and 
increases the processivity of the catalytic subunit. UL42 binds to the polymerase through 
multiple interactions.  
The HSV-1 helicase-primase (primosome) consists of a 1:1:1 association of the UL5, UL8 
and UL52 gene products. A sub-assembly of UL5 and UL52 was shown to possess 
ATPase, primase and helicase activity and so constitutes the core enzyme (Calder & Stow, 
1990; Dodson & Lehman, 1991). UL5 specifies the helicase activity which uses either 
ATP or GTP to unwind DNA in the 5'-3' direction, whereas UL52 confers the primase 
activity of the complex. The UL8 subunit has no detectable enzymatic activities but has 
been shown to enhance both the helicase and primase activity of the UL5-UL52 complex. 
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DNA synthesis is proposed to be initiated by the interaction of UL9 and ICP8 and 
unwinding of the DNA at the origin of replication. ICP8 then coats the single stranded 
DNA and this allows the polymerase and helicase-primase complex to access the DNA and 
establish a replication fork. DNA replication proceeds via leading and lagging-strand 
synthesis.  
The current widely held model for the mechanism of HSV-1 DNA replication is that it 
initially progresses by a UL9- and origin-dependent theta mechanism to amplify the 
circularised viral genome and produce multiple circular templates. This is then followed by 
a switch to a rolling circle mode of replication. This model and the structure of the 
replication forks are shown in figure 1.7.  Attempts to reconstitute the origin-dependent 
HSV-1 theta DNA replication in a cell-free system have not been successful; however a 
number of factors are consistent with replication occurring via this mechanism. Genome 
circularisation is a pre-requisite for DNA replication, and UL9 is required at an early stage 
of DNA synthesis in HSV-1 infected cells (Blumel & Matz, 1995). Viral DNA also 
accumulates with non-linear kinetics at early stages, which cannot be accounted for by 
rolling circle replication alone. Furthermore, studies show that addition of a topoisomerase 
inhibitor can terminate DNA replication, presumably because the topoisomerase is needed 
for decatenation of circular molecules (Hammarsten et al., 1996). The rolling circle 
method of replication has been demonstrated using extracts from insect cells infected with 
recombinant baculoviruses expressing the seven HSV-1 DNA replication genes (Skaliter & 
Lehman, 1994). This study also confirmed that neither UL9 nor the origin of replication is 
required for this later stage of DNA replication, and demonstrated that addition of UL9 can 
inhibit rolling circle replication in the presence of oriS. Rolling circle replication generates 
long concatemers of the genome in head-to-tail fashion, and these are the substrates for 
DNA packaging.  
It is not yet clear what the mechanism is by which the replication switches from theta to 
rolling circle replication. This may require a recombinational event such is seen in the 
switch from theta to rolling circle replication in bacteriophage λ.  
Recombination during DNA replication leads to the creation of highly branched structures 
which need to be resolved before packaging. This function is carried out by the alkaline 
nuclease, UL12, discussed further in section  1.6.4. 
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Figure 1.7: Model of HSV-1 DNA replication:
A. HSV-1 DNA synthesis is thought to originate via bi-directional theta 
replication, before switching to rolling circle replication to generate 
concatemeric genomes.
B. Model of a replication fork. The helicase−primase complex, consisting of 
viral proteins UL5, UL8 and UL52, unwinds HSV DNA at the replication 
fork and primes both lagging-strand and leading-strand DNA synthesis (wavy 
grey lines). The single-stranded DNA binding protein, ICP8, binds to single-
stranded template DNA. HSV DNA polymerase (UL30) and its accessory 
protein, UL42, promote leading- and lagging-strand DNA synthesis (wavy 
black lines). The arrows indicate the direction of movement of the DNA 
replication proteins. Adapted from Crumpacker and Schaffer (2002)
Theta replication Rolling circle replication
A.
B.
ori
UL30
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1.4.6 Capsid assembly and DNA packaging 
Following repeated rounds of DNA synthesis, concatemeric genomes accumulate within 
the replication compartments. After the onset of DNA synthesis, the synthesis of γ genes 
encoding the proteins making up the capsid increases. As these capsid proteins accumulate, 
they also localise to replication compartments within the nucleus, where DNA packaging 
occurs. A complicated network of interactions controls the nuclear localisation of these 
proteins, with both preVP22a and VP19C containing nuclear localisation signals and 
between them recruiting the other capsid proteins into the nucleus (Rixon et al., 1996). 
Within the replication compartments, the capsid proteins are assembled into spherical 
procapsids with an internal scaffold (see section  1.3.2). 
Recombinant baculoviruses have been a very useful tool to study the process by which 
procapsids are assembled and allow identification of the proteins that are absolutely 
essential for this. Infection of insect cells with baculoviruses encoding the six capsid 
proteins (VP5, VP19C, VP23, VP26, preVP22a and the UL26-encoded protease) results in 
formation of capsids that are morphologically indistinguishable from B capsids. However, 
it has also been found that the minimal number of proteins needed for assembly of capsids 
is four – VP5, VP19C, VP23 and one of either preVP22a (UL26.5) or the protease (UL26) 
(Tatman et al., 1994). Omission of the UL26 protease resulted in the formation of large-
cored B capsids, containing the uncleaved form of preVP22a. In cells expressing preVP22a 
alone, a large number of core-like structures were found, indicating that the scaffold 
protein can self-assemble, and this property might be essential for the process of capsid 
assembly. 
Capsids have also been assembled in a cell-free system using extracts from cells infected 
with five recombinant baculoviruses expressing VP5, VP19C, VP23, preVP22a and the 
protease (Newcomb et al., 1996). Different stages of capsid assembly were seen by 
electron microscopy including partial capsids (thin angular wedges), procapsids and 
angularised capsids, as illustrated in figure 1.8. This provided the first evidence that the 
spherical procapsids were the progenitors to the angularised icosahedral capsids. This 
confirmed that assembly begins with a small partial capsid containing these five proteins, 
which grows by progressive addition of small amounts of shell and core to form a larger 
partial capsid and then a full procapsid. Further studies with purified components 
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confirmed that no cell proteins were required for assembly of capsids (Newcomb et al., 
1999). 
The portal, made up of UL6, is the only unique vertex within the capsid, and it appears to 
be the point at which assembly is initiated. The interaction between UL6 and the scaffold 
protein is essential for its incorporation (Singer et al., 2005). Although capsids can be 
assembled in the absence of portals, these are not competent for DNA packaging and the 
addition of the portal at a later stage did not allow its incorporation into the partially-
assembled capsids (Newcomb et al., 2005).  
The packaging of herpesvirus DNA into the preformed procapsid is accompanied by 
maturation of the capsid and the cleavage of the scaffolding proteins encoded by genes 
UL26 and UL26.5. These two proteins are encoded by overlapping transcripts and share 
identical C-termini which are where they both interact with the capsid floor (Hong et al., 
1996). Both proteins are cleaved within the C-terminal portion by the UL26 protease upon 
maturation of the capsid, releasing them from the capsid floor. Auto-cleavage of UL26 
generates the protease VP24 and scaffold protein VP21, whilst cleavage of preVP22a 
releases the major scaffolding protein VP22a. VP24 remains within the capsid whereas 
VP22a and VP21 are expelled. The cleavage of the internal scaffold is essential for DNA 
packaging and production of infectious virus. This was shown by studies using the 
temperature sensitive HSV-1 mutant ts1201 which has a lesion in the UL26 gene, resulting 
in an inactive protease. At the non-permissive temperature this mutant fails to cleave the 
scaffold and results in the accumulation of large-cored B capsids in the nucleus, with no 
production of C capsids (Preston et al., 1983). It has also recently been shown that the 
processes of scaffold cleavage and expulsion and DNA packaging stabilise the capsid 
(Roos et al., 2009).  
Capsid maturation overlaps with viral DNA packaging and the successful end product is 
the mature angularised C-capsid containing the full length viral genome. These are the only 
capsid type able to undergo nuclear egress and further maturation. As previously discussed, 
A and B capsids are both formed by abortive attempts at packaging and as such are dead 
end products. B-capsids are thought to be angularised shells containing cleaved scaffold 
that have not undergone a DNA packaging event, whereas empty A-capsids are found in 
cells infected with viruses able to initiate DNA packaging (e.g. wt HSV-1 and mutants in 
the UL12 and UL25 genes), but not in cells infected with other DNA packaging mutants. 
The process of DNA packaging is discussed in detail in section  1.5.2.
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Figure 1.8: In vitro assembly of the HSV-1 capsid.
Assembly begins with an early partial capsid comprising proteins VP5, VP23, 
VP19C and the scaffolding proteins encoded by UL26 and UL26.5. Subsequent 
addition of VP5-preVP22a wedges forms a late partial capsid which finally closes, 
forming the spherical procapsid. This procapsid can then mature to form a 
angularised polyhedral capsid. No further proteins are required for the structural 
transformation. (adapted from Newcomb et al., 1996)
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1.4.7 Maturation and egress 
The current widely-accepted model for the maturation and egress of capsids is that of 
envelopment, followed by de-envelopment and a second re-envelopment step. In this 
model, DNA-filled C capsids undergo a process of primary envelopment at the inner 
nuclear membrane and translocate across the lumen of the nuclear membrane. This is 
followed by deenvelopment at the outer nuclear membrane and release of the capsids into 
the cytoplasm where they obtain inner tegument proteins. The capsids then acquire 
secondary tegument and envelope in a secondary envelopment process before exiting the 
cell by exocytosis (reviewed by Mettenleiter (2002; 2009). 
In support of this model, stages of the envelopment and de-envelopment pathway have 
been visualised by electron microscopy of infected cells (Granzow et al., 2001) and 
nuclear egress has been reconstituted in vitro (Remillard-Labrosse et al., 2006). 
Furthermore, structural examination of the primary tegument of capsids within the lumen 
of the nuclear membrane has revealed it to be quite different to that of mature virions. The 
same is true of the primary envelope obtained from the INM, which has a different 
composition to the final envelope, containing among other proteins, UL34, but not any of 
the spike glycoproteins seen in the mature virion (Baines et al., 2007; Fuchs et al., 2002). 
In order to exit the nucleus DNA-filled capsids first have to reach the nuclear membrane, 
which may be done by utilising actin filaments. It has been shown that nuclear actin is 
induced in PrV-infected cells at late times post infection, and that capsids associate with 
these actin filaments (Feierbach et al., 2006). The first budding/envelopment step occurs at 
the inner nuclear membrane and requires both the UL31 and UL34 proteins. Homologues 
of these proteins are well conserved throughout the Herpesviridae, and HSV-1 or PrV 
mutants deleted in UL31 or UL34 do not undergo primary envelopment (Fuchs et al., 
2002; Klupp et al., 2000; Roller et al., 2000). These two proteins interact to form a 
complex which can break down the nuclear lamina and the layer of host chromatin at the 
periphery of the nucleus, possibly by interacting directly with nuclear lamins and recruiting 
cellular protein kinases as well as the viral protein kinase US3 (Mou et al., 2008; Park & 
Baines, 2006; Simpson-Holley et al., 2004). This disruption of the lamina allows the 
capsids to bud into the perinuclear space gaining a primary tegument and envelope. The 
capsid then translocates across the lumen of the nuclear membrane and the primary 
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envelope is lost by fusion with the outer nuclear membrane (ONM), releasing the capsid 
into the cytoplasm. Little is known about the molecular mechanisms of this fusion, but it 
appears to have a mechanism distinct from that of fusion during entry. A number of reports 
have suggested differing requirements for the gB and gH glycoproteins in the nuclear exit 
fusion of HSV-1 and PrV (Farnsworth et al., 2007; Granzow et al., 2001). US3 is also 
important for efficient nuclear exit. 
An alternative pathway has been suggested for nuclear exit whereby nucleocapsids can 
also gain access to the cytoplasm through nuclear pores which are grossly enlarged during 
HSV-1 infection (Leuzinger et al., 2005). However, other groups have demonstrated that 
the morphology of nuclear pores is not affected until very late in infection, and no electron 
microscopy images of capsids in transit through nuclear pores have been published. 
Overall, the great majority of the biochemical and morphological evidence supports the 
envelopment and de-envelopment pathway, as described above. 
After nuclear egress, the capsids have to acquire the full complement of tegument proteins 
in order to exit the cell. The acquisition of tegument is controlled by a complex network of 
protein-protein interactions. Numerous physical interactions have been identified which 
appear to have significant redundancy, as reviewed by Mettenleiter (2006), but only a few 
have been demonstrated during infection using mutant viruses. The highly conserved inner 
tegument protein, UL36, is essential for egress and has been shown to interact with both 
the major capsid protein, VP5, and another component of the inner tegument, UL37. UL36 
is a multifunctional protein involved in intracellular transport and vesicular transport of 
enveloped virions. Both UL36 and UL37 are essential for formation of virions, as deletion 
mutants of either of these proteins results in an accumulation of unenveloped C capsids 
within the cytoplasm (Desai et al., 2001; Desai, 2000; Roberts et al., 2009). Addition of 
UL36 to capsids may also be dependent on the capsid protein UL25 as these have been 
shown to interact following transient expression and co-immunoprecipitation (Coller et al., 
2007). UL36 and UL37, along with US3, constitute an inner tegument layer which coats 
the nucleocapsid first during tegumentation in the cytoplasm. 
Secondary envelopment is driven by proteins linking the inner tegument to the outer 
tegument/glycoprotein complexes. One of these proteins is VP16 (UL48), which is 
essential for outer tegument addition (Mossman et al., 2000). Yeast-two-hybrid studies 
have identified interactions between VP16 and a number of inner tegument and capsid 
proteins, including UL36, VP26 and VP19C. VP16 has also been shown to interact with 
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outer tegument proteins and the cytoplasmic tails of a number of glycoproteins. A 
complicated network of interactions has been described between the outer tegument and 
glycoproteins which may be responsible for secondary envelopment. However, many of 
these interactions show considerable redundancy and it is not yet clear which are of 
functional significance in viral assembly. 
As discussed earlier, herpesvirus entry requires dynein-mediated microtubule transport, 
and conversely, virus egress requires kinesin-mediated plus-end transport (Lyman & 
Enquist, 2009). It is still unclear as to whether herpesviruses use the cellular ESCRT 
pathway and how exactly intracytoplasmic capsids are directed to sites of secondary 
envelopment. The viral envelope is thought to be derived from the trans-Golgi network 
(TGN). HSV-1- glycoproteins are synthesised in the endoplasmic reticulum and then travel 
to the TGN for the final envelopment. The conserved gM glycoprotein may play a role in 
accumulation of viral glycoproteins at the TGN by collecting viral glycoproteins at the 
budding site or preventing their transport to the plasma membrane (Crump et al., 2004). 
However, gM is not required for virion formation. Several herpesvirus glycoproteins also 
contain endocytosis motifs in their cytoplasmic tails. This allows them to be endocytosed 
and so may play a role in their incorporation into the virus envelope (reviewed by Brideau 
(2000)). Up to 49 distinct host proteins have also been identified within HSV-1 
extracellular virions, which are presumably incorporated during the packaging, 
tegumentation and envelopment processes (Loret et al., 2008).  
Once tegumentation and secondary envelopment have occurred, the vesicles containing 
enveloped virions are transported to the plasma membrane and infectious virus released by 
exocytosis. Evidence suggests that cell-to-cell spread is also important in virus 
dissemination. This process requires gE/gI glycoproteins in addition to those needed for 
extracellular spread (reviewed by Johnson (2002)). 
1.4.8 Latent infection 
As well as the lytic replication cycle described above, herpesviruses also have the ability to 
establish latency, which in HSV-1 is in the ganglia innervating the site of primary 
infection(Stevens & Cook, 1971). The key factors in the establishment of latency are the 
repression of the HSV-1 genome and the failure to initiate productive immediate early 
gene expression. 
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This absence of IE gene expression is due to a lack of transcriptional activation, as 
evidenced by the fact that 'quiescent' infections are established by viruses defective in the 
major IE transactivators (Preston & Nicholl, 1997). This may be due to the activation 
complex of VP16, Oct1 and HCF not forming in the neuronal cell bodies.  It has been 
shown that HCF is located in the cytoplasm in neurons and can sequester VP16, thereby 
preventing it from entering the nucleus of the neuron and activating gene expression 
(Kristie et al., 1999). 
The latent genomic DNA is present as circular episome, and there is variation in latent 
DNA copy number in neurons (Rock & Fraser, 1983; Sawtell, 1997). Chromatin structure 
and modifying enzymes appear to play a role in the transcriptional activation and 
repression of regions of herpesvirus DNA. During productive infection, VP16 is thought to 
recruit activating histone acetylases and chromatin remodelling enzymes to IE promoters 
to allow gene expression. However in latency, the genome is maintained in a repressed 
state and the lytic gene promoters show a decreased association with acetylated histones 
(Kubat et al., 2004).  
During latency, only one set of viral gene products is expressed. These are the latency 
associated transcripts (LATs), a series of spliced RNAs expressed from the LAT gene 
transcription unit, which maps to the repeat sequences flanking the UL region. The LATs 
are stable non-polyadenylated RNAs and no proteins are translated from these transcripts. 
Despite much research, the precise role of the LATs during latency is still unclear. It has 
been suggested that LAT null viruses have reduced reactivation from latency, although this 
may also be due to decreased establishment of latency in these situations (Jones, 2003). A 
number of studies have also implicated LATs in protecting infected neurons from death. 
This may be by reducing lytic viral gene expression, as expression of LATs can reduce 
viral gene expression and replication in cultured cells. LATs have also been found to have 
an anti-apoptotic function in tissue culture cells and promote the survival of infected 
neurons in vivo (Ahmed et al., 2002).  
The control of the lytic-latent switch and the reactivation of latency is very complex, and 
not yet fully understood. As the establishment of latency is due to repression of the genome 
and the lack of immediate early gene expression, then conversely, reactivation from 
latency requires de-repression of the genome, followed by IE gene expression. In both 
tissue culture systems and infected individuals, the virus is reactivated after an external 
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stimulus; for example physical trauma to tissues, UV light, or physical or emotional stress 
to the infected individual. 
Cellular mechanisms must be involved for the initial de-repression of the genome, and 
HCF has been implicated in initiation of transcription after latency, as it is recruited to the 
IE promoters during reactivation (Whitlow & Kristie, 2009). After de-repression of the 
genome, IE gene expression needs to be activated and ICP0 may be involved through its 
transactivating ability and degradation of cellular components. This has been supported by 
studies confirming that ICP0 null mutant viruses show greatly reduced reactivation from 
latency (Halford & Schaffer, 2001). LATs have also been widely accepted to play a role in 
this process as LAT negative viruses reactivate less efficiently than wt HSV-1. It has 
recently been suggested that after the initial reactivation, de novo expression of VP16 also 
regulates entry into the lytic cycle (Thompson et al., 2009).  
 
1.5 DNA cleavage and packaging 
DNA packaging represents the convergence of two independent pathways taking place in 
the infected cell, those of DNA replication and capsid assembly. The replicated 
concatemeric DNA and preformed procapsids are brought together at RCs within the cell. 
Packaging signals in the DNA are recognised and cleaved by a protein complex known as 
a terminase and a unit genome is actively inserted into the capsid through a channel at one 
of the capsid vertices. The processes of DNA cleavage and packaging are very tightly 
coupled. As described previously, DNA packaging is accompanied by cleavage of the 
internal scaffold of the procapsid, and associated angularisation of the capsid.  
1.5.1 Bacteriophage DNA packaging 
Many parallels have been drawn between HSV-1 and dsDNA bacteriophage, and 
similarities between capsid architecture and the packaging process have led to suggestions 
of a possible common ancestry between them (Baker et al., 2005; Booy et al., 1991; 
Davison, 1992; Trus et al., 2004). Bacteriophage therefore represent a useful model for the 
study of DNA packaging within the herpesviruses. 
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The dsDNA phage can be split into three groups, according to differences in their 
genomes; 1.) Linear genomes with unique nucleotide sequence at the termini (for example 
λ, T7 and T3); 2.) Linear genomes with a non-unique nucleotide sequence at the ends (for 
example T4 and SPP1); 3.) Genomes with a covalently-attached terminal protein which 
primes DNA replication (for example Φ29).  
Despite these differences in genome organisation, many central features of DNA 
packaging and the proteins involved are conserved amongst most dsDNA phage. These are 
discussed in more detail below and have also been reviewed (Fujisawa & Morita, 1997; 
Rao & Feiss, 2008). 
The prohead in phage is the equivalent structure to the procapsid in herpesviruses and is 
assembled separately prior to DNA packaging. The prohead has one unique vertex, the 
portal, made up of a connector protein. To date, all connectors have been identified as a 
ring of 12 subunits surrounding a central channel through which the DNA is inserted. This 
similar structure is conserved despite very little similarity between the amino acid 
sequences of the different connector proteins. A narrow 'stalk' domain protrudes outside 
the prohead, which provides the surface for docking and assembly of the packaging motor. 
The prohead of Φ29 is unusual in that it also contains a small packaging RNA (pRNA). 
This pRNA has short complementary sequences that enable the formation of an oligomeric 
ring on the portal (Guo et al., 1987). This pRNA is required for the docking of the 
packaging complex onto the portal. As with herpesviruses, assembly of the prohead is 
initiated around the portal structure. In some phage, the proheads can assemble in the 
absence of the portal protein, but these prohead shells are not competent for DNA uptake.  
A packaging enzyme, known as the terminase, is essential for the encapsidation of DNA by 
all phage (and herpesviruses). This terminase is involved in the recognition and cleavage of 
viral DNA and the active translocation of the genomic DNA into the prohead. Terminases 
exhibit a DNA-dependent ATPase activity that is thought to provide the energy necessary 
to drive the thermodynamically unfavourable packaging process. In all bacteriophage 
studied so far, the terminase consists of a heterodimer comprising a large and small 
subunit. The two subunits of the terminase have been identified as encoding the different 
activities needed to cleave and package the DNA. The small subunit is needed for 
recognition of the packaging signal on the DNA concatemer, wherease the large subunit is 
required to bind to the connector protein on the prohead, and is responsible for cleavage 
and translocation of the DNA.  
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Several conserved motifs have been identified in the large subunits of all bacteriophage 
studied thus far. This includes a consensus sequence known as a Walker motif (amino 
acids GXXXXGKT/S), which can be found in many enzymes capable of ATP binding and 
hydrolysis (Walker et al., 1982). Mutational analysis in bacteriophage T4 has demonstrated 
the importance of these motifs for functional packaging (Kondabagil et al., 2006). The 
terminase complex also binds to the phage prohead, and by doing so, brings together the 
replicated DNA and the prohead shell for the packaging process. A recent paper has 
described the crystal structure of the small (DNA recognition) terminase subunit of phage 
SP6, gp1. The gp1 protein exists as an octamer in a ring-like structure with a channel 
through which the DNA is presumably translocated (Zhao et al., 2010). These authors 
suggest that the terminase may stack directly on top of the portal vertex to allow DNA 
packaging to occur. 
The different classes of dsDNA phage, based on the genome structures described above, 
employ slightly different methods of initiation and termination of DNA packaging. The 
group one phage use a sequence specific method of initiation and termination, whereby 
packaging is initiated by the recognition of a specific packaging signal (pac or cos) on the 
DNA. This is followed by an initial cleavage event to generate the genomic termini and 
unidirectional packaging of the genome. Packaging is terminated by a second site-specific 
cleavage at the packaging signal and one exact genome length of DNA is packaged. The 
situation in phage with group 2 genomes with non-unique terminal sequences (for example 
P1, P22 and T4) is slightly different. Initial cleavage occurs near to packaging signals (pac 
sites) in the genome and the DNA is packaged using the same mechanism as above. 
However, the termination event is not sequence dependent, and instead occurs only when 
the prohead is full and approximately 102% to 110% of the genome has been packaged 
(dependent on the phage). This results in genome ends in virions being non-identical and 
terminal redundancy of packaged DNA. Group 3 genomes replicate their DNA as 
monomers and in this case, there is no need for a DNA cleavage reaction. The protein 
covalently attached to the genomiC-terminus functions like the small terminase subunit, 
and this, the pRNA sequences and a large terminase subunit are essential for packaging 
(Bjornsti et al., 1982; Guo et al., 1987). 
In all phage that replicate their DNA as concatemers, the termination of packaging is 
closely linked to the capsid filling. Even those phage which make precise sequence-
specific cleavage events (for example λ) will ignore the termination sequences if 
significantly less than one genome length has been packaged (Catalano et al., 1995). It has 
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been proposed that DNA packaging causes a conformational change in the portal, and the 
portal acts as a "sensor" to detect the filling of the phage head and activate cleavage by the 
terminase. Specific mutation of the portal in SPP1 leads to packaging of less than unit-
length DNA (Tavares et al., 1995). 
Packaging is accompanied by an expansion in the prohead and rearrangement of the major 
capsid protein to generate the mature shell. The DNA is proposed to be cylindrically 
spooled around the axis of the portal channel. Cryo-electron microscopy has been used to 
examine the structural organisation of the encapsidated DNA and the DNA was found to 
form layers around the inside of the icosahedral shell (Cerritelli et al., 1997). The DNA is 
under very high pressure within the phage head and is present in a liquid-crystalline state. 
The phage that generate concatemers package their DNA genomes in a processive manner. 
After the termination cleavage, a second packaging event can be initiated from the cleaved 
genomic end. The terminase therefore disassociates from the DNA-filled head but remains 
associated with the DNA concatemer. This DNA/terminase complex is now free to bind to 
the next empty prohead and repeat the packaging process. 
Many phage also encode proteins not directly involved in the translocation of DNA but 
with other roles in the packaging process. These include proteins required at a later stage of 
encapsidation, which are involved in retention of the packaged DNA within the phage 
capsid. Some phage (for example P22 and SPP1) encode head completion proteins that act 
to plug the portal after the full genome has been packaged. The addition of the head 
completion proteins may also cause release of the terminase from the phage head and form 
a binding site for the tail. Other phage have stabilisation proteins which bind to various 
sites on the external surface of the phage head, for example Soc of phage T4 (Qin et al.). 
DNA packaging is accompanied by an expansion in the prohead, revealing binding sites 
for these proteins. 
Some phage depend on other accessory proteins for correct assembly of the prohead prior 
to DNA packaging. The E. coli host GroES-GroEL chaperone complex is required by 
many phage for growth and folding of their structural proteins (Tilly et al., 1981; Zeilstra-
Ryalls et al., 1991). However, phage T4 encodes its own chaperonin, gp31, homologous to 
the GroES protein, which is required for correct folding the T4 major capsid protein (van 
der Vies et al., 1994).  
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As in HSV-1, phage DNA replication can generate long head-to-tail concatemers which 
can undergo recombination, creating complex branched structures. These branches need to 
be resolved before the genome can be packaged. Nucleases have been identified in a 
number of bacteriophage, including endonuclease VII of phage T4 and endonuclease I of 
phage T7, where they are involved in the resolution of branches and junctions in double 
stranded DNA genomes (de Massy et al., 1987; Kemper & Janz, 1976). These nucleases 
are not absolutely essential for the process of DNA packaging, but can greatly increase the 
generation of viable virus.  
1.5.1.1 Bacteriophage lambda DNA packaging 
The packaging process in bacteriophage lambda is one of the most extensively studied and 
is reviewed by Feiss & Catalano (2005). Since the genomic termini are generated from 
concatemers by signal-specific cleavage, as occurs in herpesviruses, it represents a good 
model for DNA packaging in HSV-1. The incoming phage genome is circularised by 
ligation of its cohesive ends. The λ DNA is replicated by a bi-partite mode of DNA 
synthesis, as in HSV-1, initially via the theta mode and then proceeding to rolling circle 
replication. The packaging signal is the 200 bp cos site found at the junction between 
genomes in viral concatemers. Within this is the cosN site, where cleavage occurs. Other 
sequences within this site have also been shown to be important, with cosB required for 
initiation and termination cleavage events. cosB contains a series of repeat elements and a 
binding site for the host protein IHF (integration host factor).  A further site, cosQ, is 
located upstream from cosN and is needed for the termination cleavage.  
The terminase is made up of the large subunit, gpA, and small subunit, gpNu1. A 
recombinant terminase has been purified, showing the holoenzyme has the stoichiometry 
of one gpA to two gpNu1 (Maluf et al., 2005). gpNu1 is essential for the recognition of 
concatemeric DNA and assembly of the terminase complex at the portal. The N-terminal 
portion of gpNu1 can recognise and bind to the cosB site, whereas the C-terminal section is 
involved in binding to gpA. gpA encodes the enzymatic activities and has been shown to 
have endonuclease, ATPase and helicase properties (Hwang & Feiss, 1996). As with all 
other identified terminase large subunits, gpA contains a conserved Walker motif. 
Lambda packaging is initiated by the binding of a host protein, integration host factor 
(IHF), to the phage DNA, which induces a bend in the duplex, allowing recruitment of 
gpNu1 to cosB. gpA, through its interaction with gpNu1 and the repeat elements of cosB, 
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then binds to the cosN site. This complex nicks the two DNA strands within cosN to 
produce cohesive termini. The viral gpFI protein is an accessory protein that is directly 
required for the packaging process and is thought to increase the transition of the terminase 
from a complex that is stably bound to the cos sequence to a DNA packaging machine 
(Catalano & Tomka, 1995). ATP-dependent translocation of the DNA through the portal 
can then occur. Packaging occurs in a unidirectional manner with concurrent hydrolysis of 
ATP. Packaging is terminated when the terminase reaches the next cos site. The genome 
must again be nicked, the cohesive strands separated and the terminase dissociates from the 
phage shell.  It is thought that cosQ promotes a rearrangement of the terminase to allow 
cleavage of the DNA and termination of packaging (Feiss & Catalano, 2005). 
1.5.2 HSV-1 DNA packaging 
Although far less is known about HSV-1 packaging, there are many clear similarities 
between the processes in dsDNA phage and HSV-1. The HSV-1 procapsid and phage 
prohead share many structural similarities and maturation is thought to proceed via similar 
pathways. HSV-1 DNA packaging is reviewed by Homa and Brown (1997). 
All herpesviruses encode packaging signals at their genomic termini, in a similar manner to 
bacteriophage λ cos, and the initiation and termination cleavage events are performed in a 
sequence-specific manner. Several of the proteins required for HSV-1 packaging perform 
similar roles to those in phage packaging, for example the portal and terminase enzyme. 
HSV-1 also encodes a protein thought to be involved in stabilisation of filled capsid 
(UL25) and a nuclease, analogous to those in bacteriophage, that acts to resolve branched 
structures following DNA replication (UL12). 
A model for herpesvirus DNA packaging, consistent with the current literature, is 
presented in figure 1.9. Concatemeric DNA is generated by repeated rounds of DNA 
synthesis and preformed procapsids localise to the replication compartments by an as-yet 
unknown mechanism. Packaging is thought to initiate when a packaging signal on the 
concatemeric DNA is recognised by the viral terminase, leading to the assembly of a 
functional packaging complex of terminase, DNA and procapsid. The duplex is cleaved 
and DNA translocated through the unique portal vertex into the preformed procapsid. A 
second cleavage event to terminate packaging occurs when a unit length genome has been 
translocated. As previously mentioned, DNA packaging is accompanied by cleavage and 
expulsion of the scaffold protein, and angularisation of the capsid. As with bacteriophage, 
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Figure 1.9: DNA packaging by HSV-1.
A. DNA packaging is initiated when the terminase complex (UL15, UL28 and 
UL33) recognises the minimal packaging sequence, Uc-DR1-Ub (blue) on the 
replicated concatemeric DNA.
B. The terminase in turn can interact with the portal vertex (UL6) of a nascent 
procapsid. The terminase cleaves the DNA within DR1 and releases the S 
terminus (which is thought to be degraded). This results in a complex of the 
terminase with the L terminus of the genome, which is inserted into the 
procapsid.
C. Unidirectional packaging occurs, with the concurrent hydrolysis of ATP. This 
is accompanied by cleavage and loss of the procapsid scaffold and 
angularisation of the capsid.
D. When the terminase reaches the next Uc-DR1-Ub sequence, the termination 
cleavage releases the packaged genome inside the C capsid. Packaging is 
thought to be processive and the terminase remains associated with the L-
terminus of the concatemer, where is can initiate another round of packaging by 
interacting with another procapsid.
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herpesvirus packaging is thought to be processive, with multiple packaging events along a 
concatemer being initiated by a single terminase. The packaged DNA within the HSV-1 C-
capsids also adopts a liquid-crystalline conformation resembling that of packaged DNA 
within bacteriophage heads. 
The concatemeric DNA may also be undergoing active recombination and transcription 
and so is likely to be associated with numerous viral and cellular protein complexes. HSV-
1 DNA in infected cells is also associated with host nucleosomes, and these protein 
complexes all need to be removed from the DNA prior to, or concurrent with, the 
packaging process, as no protein is associated with the DNA inside the capsid. The 
packaged DNA within the capsid is coated with spermine, which has been proposed to 
partially neutralise the negatively charged DNA (Gibson & Roizman, 1971).  It is unclear 
how protein complexes are removed from the DNA, but it may be that the spermine is 
involved in this "stripping" of DNA prior to packaging.  
The following sections discuss in greater detail the current knowledge of the processes 
involved in herpesvirus DNA packaging and characterisation of the proteins involved. This 
information has mainly come from studies using HSV-1, but work on homologous proteins 
in other herpesviruses, for example HCMV and PrV, has also been invaluable in furthering 
the understanding of herpesvirus cleavage/packaging.  
1.5.3 Encapsidation signal 
The cis-acting DNA sequences required for packaging of the HSV-1 genome are located 
within the a sequences, which are present as direct repeats at the genomic termini and in 
inverted orientation at the junction of the L and S sequences (Stow et al., 1983). In HSV-1, 
the a sequence is 200-500 bp, depending on the virus strain (Davison & Wilkie, 1981) 
The structure of the a sequence is shown in 1.10B. Each a sequence is flanked by direct 
repeats known as DR1 and tandem a sequences are separated by a single DR1.  The central 
region of the a sequence comprises multiple repeats of one or two other short repeat 
sequences, DR2 and/or DR4. The a sequence also contains quasi-unique sequences of 
approximately 80 bp termed Ub and Uc. In virion DNA, the Uc element is adjacent to the 
L terminus and Ub adjacent to the S terminus.  
Chapter 1   42 
 
 
a
an’
a
UL
TRL
IRL
TRS
IRS
US
m
pac2
DR1
pac2
 co
nse
nsus
pac1
pac2
 T rich
 elem
e
nt
pac2
 G
C
 ele
m
e
nt
pac2
 u
nco
nse
rved
pac1
 p
ro
xim
al
 
G
C
 ele
m
e
nt
pac1
distal
 G
C
 
ele
m
e
nt
pac1
T rich
 elem
e
nt
C5G6 G8
Figure 1.10: Structure of the HSV-1 packaging sequence.
A. Structure of the HSV-1 genome showing the composition and position of the 
repeat sequences. The orientations of the a sequences are indicated by arrows.
B. Circularisation of the genome by ligation of the termini brings together the two 
a sequences (indicated by the dashed arrows), separated by a DR1 repeat. This 
gives rise to the novel minimal packaging signal Uc-DR1-Ub (highlighted in 
the blue box). The site of genome cleavage is indicated by the red arrow.
C. Motifs within the Uc-DR1-Ub minimal packaging signal, indicating the pac1 
and pac2 regions. The site of cleavage is indicated by the red arrow. Adapted 
from Hodge and Stow (2001).
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Within the Ub and Uc regions are two regions, pac1 and pac2 respectively, which 
comprise sequences necessary for cleavage of the viral genome (Deiss et al., 1986). These 
regions contain sequences that are highly conserved throughout the herpesviruses and it 
has been demonstrated that the HSV-1 a sequence can be functionally replaced by 
sequences encompassing the L-S junction of HCMV (Spaete & Mocarski, 1985). The 
compositions of pac1 and pac2 are shown in figure 1.10C. Pac1 comprises a highly 
conserved T rich element flanked by proximal and distal CG elements whereas pac2 has a 
consensus CGCCGCG motif with T-rich and GC-rich elements and an unconserved region. 
The cleavage event occurs towards one end of the DR1 repeat, creating genomic termini 
containing incomplete DR1s with a single nucleotide overhang at the 3’ end (Mocarski & 
Roizman, 1982). The majority of the DR1 sequence is associated with the L terminus. It 
has been suggested that the position of this cleavage is solely governed by the distance 
from the fixed pac1 and pac2 sequences (possibly the T elements) and that DR1 itself is 
not essential (Smiley et al., 1990; Varmuza & Smiley, 1985). However, it has recently 
been shown that the sequence of DR1 is also important for initiation of cleavage, but 
possibly dispensable for termination (Tong & Stow, 2010). Circularisation of the genome 
upon entry to the cell by direct ligation of the cohesive DR1 ends fuses the a sequences at 
each terminus and therefore recreates a complete DR1 and generates a novel fragment, Uc-
DR1-Ub, spanning the two end of the genome. This approximately 200 bp sequence has 
been identified as the minimal packaging signal (Hodge & Stow, 2001; Nasseri & 
Mocarski, 1988). It has been shown that a single Uc-DR1-Ub is sufficient for the 
packaging of viable HSV-1 genomes (Strang & Stow, 2005). 
A number of different approaches have been taken to allow detailed mutational analysis of 
the packaging signal and identification of those sequences within Ub and Uc that are 
essential for genome encapsidation. The first of these involves the transfection of 
amplicons (bacterial plasmids encoding an origin of replication and minimal packaging 
signal) into mammalian cells. The provision of virus helper functions, either through 
superinfection with virus particles or co-transfection of viral DNA, allows amplicon DNA 
to be replicated and packaged so long as a functional packaging signal is present (Stow et 
al., 1983). A second assay introduces an additional copy of the packaging signal at an 
ectopic site within the viral genome. The replicated DNA can then be examined to 
determine whether novel termini have been created due to cleavage and packaging at the 
ectopic site. A more recent approach involved mutating the packaging signal in the context 
of the viral genome, cloned as a recombinant bacterial artificial chromosome (BAC). A 
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cloned HSV-1 BAC from which all copies of the a sequence had been previously deleted 
(Saeki et al., 1998) was used for this. Single copies of wt or specifically mutated Uc-DR1-
Ub fragments were introduced into an ectopic site (the TK locus) by recombination in 
bacteria. The resulting recombinant BACs were transfected into mammalian cells and 
analysed for their ability to be cleaved at the Uc-DR1-Ub fragment and generate infectious 
progeny. This avoided the potential problem of recombination between ectopic and 
existing a sequences, and unlike the amplicon assays, the replicated DNA is viral and so 
will have a more typical frequency of packaging signals with concatemers (Tong & Stow, 
2010). The most comprehensively studied packaging signals are those of HSV-1 and the 
murine cytomegalovirus MCMV, which have been analysed by the introduction of 
deletions and substitutions throughout the pac1 and pac2 regions (Hodge & Stow, 2001; 
McVoy et al., 1998; McVoy et al., 2000; Tong & Stow, 2010; Varmuza & Smiley, 1985). 
These studies have suggested the following general mechanism by which concatemers are 
cleaved and packaged. 
The pac2 region is critical for DNA cleavage to initiate packaging in both HSV-1 and 
MCMV. Within pac2 the sequence of the T element is essential. Other important signals 
involved in initiation are located within the DR1 element and at or near the consensus 
region. The sequences of the elements flanking the pac2 T element are not important since 
extensive substitution mutations are tolerated. Deletion of these regions, however, severely 
impaired packaging, suggesting that the position of the T element relative to the DR1 and 
consensus signals is important in initiation of packaging and that all these motifs may 
function together. Following cleavage the pac2 end is inserted into the procapsid which 
means that in the case of HSV-1 the directionality of packaging is from the L to S end. In 
contrast, the pac1 region is important for the events involved in the termination of DNA 
packaging. All HSV-1 pac1 mutants package DNA but those affecting the proximal and 
distal pac1 elements, or deleting the pac1 T element are impaired in the termination of 
packaging, and fail to generate an S terminus. Experiments with MCMV suggest that the 
important sequences within the two GC-rich regions are the conserved G and C tracts that 
immediately flank the T element. The behaviour of the T element deletion suggests that the 
relative positioning of these tracts may also be crucial. More recent work has also indicated 
a crucial role for the DR1 element in the initiation cleavage (Tong & Stow, 2010). 
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1.6 HSV-1 packaging proteins 
In addition to the cis-acting DNA sequences and those proteins making up the procapsid, 
six additional viral proteins are absolutely essential for DNA packaging. These are UL15, 
UL17, UL25, UL28, UL32 and UL33. All of these proteins are expressed from late genes 
and none are required for viral DNA replication or capsid assembly. UL15, UL17, UL28, 
UL32 and UL33, as well as the portal protein, UL6, are essential for the initiation of DNA 
packaging. The UL25 protein, however is not required for initiation, but appears to play a 
role later in the packaging process. One further protein, UL12, is indirectly involved in 
packaging and increases its efficiency but is not absolutely essential. The roles of these 
proteins in DNA packaging have been elucidated by the creation of mutant viruses using 
complementing cell lines, and their subsequent characterisation in non-complementing 
cells. The packaging-negative viruses are characterised by an accumulation of endless 
DNase sensitive concatemers and B capsids within the nucleus. 
1.6.1 UL6 
The UL6 protein is now known to form the portal that occupies the space of a penton at a 
single unique vertex of the capsid. Although it is not essential for the formation of capsids, 
it is found on all three mature capsid types and the procapsid, suggesting it is an integral 
part of the capsid shell (Patel & Maclean, 1995; Sheaffer et al., 2001). In the absence of 
UL6, no viral DNA is cleaved or packaged, resulting in accumulation of endless 
concatemers of viral DNA, with no production of DNA-filled C capsids (Patel et al., 
1996a). UL6 is able to localise to the nucleus of the cell in the absence of any other viral 
proteins. Knock-down of the expression of the UL6 homologue in HCMV (UL104) also 
led to a decrease in virus growth and C capsid formation, confirming the importance of 
UL6 in the packaging process (Dittmer & Bogner, 2006). 
Many lines of evidence indicate that UL6 forms the portal for entry of DNA in a very 
similar fashion to those portals identified in bacteriophage. Immunogold labelling of HSV-
1 B capsids showed UL6 present at only one vertex of the capsid (Newcomb et al., 2001). 
This study also demonstrated by electron microscopy that UL6 purified from insect cells 
infected with a recombinant baculovirus could form rings in vitro. The majority of these 
structures comprised of 12 copies of UL6. The structure of the rings was found to resemble 
those of the portals from bacteriophages P22, T4 and Φ29, and had a central channel of 
approximately 5 nm diameter through which the DNA is proposed to enter the capsid. 
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Further examination of UL6 expressed from baculovirus-infected insect cells revealed that 
these rings are polymorphic, exhibiting 11-, 12-, 13- and 14-fold rotational symmetry and 
it was suggested that it is the dodecameric form of the complex that is incorporated into 
procapsids (Trus et al., 2004). This correlates with the situation in bacteriophage where 
portal variants with different numbers of subunits can be found but the only form 
competent to be inserted into capsids consist of a 12-membered ring. A leucine zipper 
motif within UL6 is essential for its self-association into stable ring structures and 
therefore successful DNA packaging (Nellissery et al., 2007). 
Much work has been carried out using cryo-electron microscopy and tomographic 
reconstructions to visualise the portal within the capsid shell, but there have been 
conflicting results. One study of A capsids identified the portal as projecting outwards 
from the shell (Cardone et al., 2007). However, another study analysing urea-extracted 
capsids (to remove the pentons) identified most of the density inside the capsid shell in a 
similar configuration to that seen in bacteriophage P22 and ε15 (Chang et al., 2007). 
Figure 1.11 shows a tomographic reconstruction from electron cryo-microscopy of the 
HSV-1 capsid and the 2 nm resolution cryo-electron microscopy of P22 bacteriophage, 
indicating the positions of the portals within each capsid shell. This inward-protruding 
model is also in agreement with the position of the portal as identified in KSHV (Deng et 
al., 2007). 
By analogy with dsDNA bacteriophage, the portal is assumed to form the docking site for 
the viral DNA and terminase on the capsid. Indeed immunofluorescence and 
immunoprecipitation studies have revealed that UL6 and the terminase subunits UL15 and 
UL28 interact (White et al., 2003). UL6 is also required for correct association of UL15 
with B capsids (Yu & Weller, 1998b). 
1.6.2 UL17 
The UL17 protein is dispensable for capsid assembly and viral DNA replication but 
required for DNA cleavage and packaging. Infection of cells with a UL17-null mutant 
results in an accumulation of B capsids (Salmon et al., 1998). 
UL17 was first identified as a component of the tegument, being the only packaging 
protein that is present in L particles (aberrant particles containing tegument and envelope 
with no capsid). It was subsequently found to also be present in the procapsid and all types  
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A.
B.
Figure 1.11: Comparison of herpesvirus and bacteriophage portal locations.
Tomographic reconstruction of the HSV-1 capsid (A). For comparison, the 2 nm 
resolution electron microscopy map of bacteriophage P22 is shown (B). The protal
structures are indicated in pink. These figures are to scale. (Chang et al., 2007)
20nm
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of angularised capsid as well as the mature virion. The presence of UL17 in the procapsid 
suggests an early role in packaging, but it is also found in much greater amounts in virions, 
and so also may be important at a later stage of virion maturation (Thurlow et al., 2005) 
It has been suggested that UL17 may play a role in the intracellular localisation of capsid 
components. As previously discussed, DNA packaging occurs in replication compartments 
(RCs) and in wt HSV-1 infected cells the major capsid proteins are found in these RCs. 
However, in cells infected with a UL17-null mutant, capsid proteins VP5 and preVP22a no 
longer co-localised with ICP8 in RCs, but instead formed dense aggregates at the edges of 
infected cell nuclei (Taus et al., 1998).  
Immunogold staining found UL17 at multiple points on wildtype B and C capsids, and it 
has been shown that UL17 is required for the association of another packaging protein, 
UL25, with capsids. In B capsids of viruses lacking a functional UL17, the levels of UL25 
were greatly decreased. This relationship appears to be reciprocal, because capsids lacking 
UL25 also had reduced amounts of UL17 (Thurlow et al., 2006). The localisation of both 
of these proteins at multiple points on the capsid led to the hypothesis that they may play 
an indirect role within the packaging process. 
1.6.3 UL25 
The UL25 gene encodes a protein with roles encompassing different stages of life cycle. In 
contrast to the other proteins essential for DNA packaging, disruption of the UL25 gene 
results in an accumulation of both A and B capsids, indicating a role at a distinct stage of 
the packaging process (McNab et al., 1998; Stow, 2001). Original studies found that 
during infection with a UL25 null virus, KUL25NS, the viral genome was cleaved into unit 
lengths with the same efficiency as wt HSV-1, but remained DNase sensitive, indicating 
that it was not packaged, and there was no production of C capsids. This led to the 
suggestion that UL25 may act to aid retention of the DNA in the capsid (McNab et al., 
1998).  
Stow (2001) furthered these studies and found, in contrast to the results from McNab, that 
KUL25NS could package DNA, albeit with reduced efficiency. Furthermore, there was no 
evidence for genomes that had been cleaved but not packaged. Analysis of total viral DNA 
in cells revealed that the S terminus was significantly under-represented and the L terminus 
over-represented in packaged KUL25NS DNA compared to the ratios seen in wt HSV-1 
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DNA. This provides support for the model of HSV-1 DNA packaging occurring in an L to 
S direction, and implicates UL25 at a late stage in this packaging process. Pulsed-field gel 
analysis of packaging of both KUL25NS and amplicon DNA revealed that the packaging 
of full-length genomes was impaired to a larger degree than the packaging of shorter DNA 
molecules (Stow, 2001). 
UL25 is a minor component of all capsid types and is found in greatest amounts in capsids 
containing DNA, with the most found in virions and C capsids, and decreasing amounts in 
A, B and then procapsids (Newcomb et al., 2006; Sheaffer et al., 2001). This, together with 
the phenotype of UL25 null viruses, has led to suggestions that UL25 acts to aid retention 
of the packaged genome in the same way as many bacteriophage proteins, either by acting 
as a 'plug' or to stabilise the DNA-filled capsid. One study reported that UL25 has the 
potential to bind double stranded DNA, supporting the theory that UL25 may act as a 'plug' 
at the portal (Ogasawara et al., 2001). However this DNA-binding activity of UL25 has not 
been replicated by other laboratories and UL25 is not thought to be a portal plug. 
Interestingly, similar to UL25, protein gpD of phage λ is required for correct packaging of 
full-length genomes, but gpD deletion mutants with genomes less than 80% of wt length 
are viable. gpD is known to act as a head stabilisation protein, and, like UL25, is required 
at the late stages of packaging as the internal pressure increases as packaging nears 
completion. 
As previously mentioned, the binding of UL25 to capsids is reliant on the presence of 
UL17, and this is a reciprocal interaction (Thurlow et al., 2006). The association of UL25 
with capsids is also mediated through interactions with other capsid proteins, VP5 and 
VP19C (Ogasawara et al., 2001).  The N-terminal 50 amino acids have been shown to be 
essential for the binding of UL25 to capsids (Cockrell et al., 2009). Cryo-
electromicroscopy has identified an extra mass on C capsids but not B capsids which is 
also absent from the A capsids of a UL25 null virus, which has been termed the C-capsid 
specific component (CCSC). This is proposed to be a heterodimer of UL17 and UL25 and 
is present around the vertices of the capsid (Trus et al., 2007). It was suggested that as with 
bacteriophage, as the capsid becomes filled with DNA, conformational changes occur. This 
may expose sites on the capsid surface that allow binding of the CCSC. More recent work 
has shown UL25 to be positioned distal to the penton vertex, contacting two triplex 
complexes and one adjacent hexon (Conway et al., 2010). A recent mutational analysis 
study identified some UL25 mutant proteins which could package full-length DNA but the 
resultant C capsids failed to be transported into the cytoplasm (O'Hara et al., 2010). This 
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suggests that UL25 has a role in nuclear egress, perhaps through interactions with the 
UL31/UL34 components during primary envelopment. 
UL25 is the only packaging protein that has had its crystal structure determined (Bowman 
et al., 2006). A truncated version lacking the N-terminal region was crystallised and 
showed a stable core with numerous flexible loops, which may be involved in the binding 
of different partners during the virus life cycle. As well as its interactions with proteins on 
the capsid, UL25 has also been reported to bind to the tegument protein UL36. It was 
suggested that UL25 may therefore have a role in tegumentation as it is essential for the 
recruitment of UL36 to the capsid (Coller et al., 2007). A recent study has also identified a 
role for UL25 that is very distinct from that of DNA cleavage and packaging. A 
temperature sensitive UL25 mutant (ts1249) shows an early block in infection, which was 
found to be due to a defect in uncoating of the viral genome at the NPT (Preston et al., 
2008). 
1.6.4 UL12 
Unlike the other proteins discussed here, UL12 is not absolutely essential for DNA 
cleavage and packaging, but it does greatly increase the efficiency of this process. The 
UL12 protein functions as a deoxyribonuclease with 5'-3' exonuclease and endonuclease 
activities, and is referred to as the viral alkaline nuclease (AN) as it is optimally effective 
under high pH conditions. A number of different HSV-1 mutants have been characterised 
with a disruption of the UL12 gene, and they all show a significant reduction in virus yield 
of 100-1000 fold (Patel et al., 1996a; Weller et al., 1990). However, no large decreases 
were seen in any one part of the virus life cycle – rather small reductions were observed in 
DNA replication, DNA packaging and egress of capsids from the nucleus (Martinez et al., 
1996b; Shao et al., 1993; Weller et al., 1990). Pulsed-field gel analysis of concatemeric 
DNA sythesised in the absence of UL12 showed that the DNA replication intermediates 
had a more complex structure than that found in wt HSV-1 infection, with an increased 
frequency of branches (Martinez et al., 1996a).  
As discussed earlier, during HSV-1 DNA replication the concatemeric DNA generated can 
undergo recombination events, creating complex branched structures. By analogy with 
dsDNA bacteriophage, which encode nucleases to resolve these branches before DNA 
packaging, it would be expected that HSV-1 would require a mechanism to remove the 
branches and junctions in the replicated DNA. 
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This function appears to be provided by the UL12 alkaline nuclease of HSV-1, and work 
on a further UL12 mutant supports this. The efficiency of both DNA replication and 
packaging was decreased in cells infected with an UL12 mutant compared to wt HSV-1, 
and the released virus had a far greater particle to p.f.u. ratio. Furthermore, gel analysis 
revealed abnormalities in the packaged DNA and this DNA was of reduced infectivity in 
transfection assays (Porter & Stow, 2004b). UL12 has also been shown to interact with the 
single stranded binding protein, ICP8, and this interaction mediates strand exchange in 
vitro and enhances the nuclease activity of UL12 (Reuven et al., 2003; Reuven & Weller, 
2005). However, no difference in intermolecular recombination was observed in cells 
infected with the UL12 mutant suggesting that UL12 is not required for recombination to 
occur during infection (Porter & Stow, 2004a) 
Together, this data has led to the proposals that in the absence of UL12, the branched 
structures in replicated DNA are not correctly resolved and that this results in a reduction 
in DNA replication and packaging. However, some resolution of branches presumably 
occurs by an aberrant, possibly cellular process and this results in the generation of DNA 
containing virions which exhibit reduced infectivity.  
1.6.5 Terminase – UL28, UL15, UL33 
As in bacteriophage, HSV-1 has a multi-subunit terminase directly involved in the 
translocation of DNA into the capsid. Three proteins, UL15, UL33 and UL28 make up the 
putative terminase and much work has been done on clarifying the roles of each of these 
proteins in the packaging process. There are many lines of evidence now supporting the 
hypothesis of a three-subunit terminase in HSV-1, as discussed below. 
The importance of each of these proteins in DNA encapsidation has been examined in null 
mutant viruses, isolated on complementing cell lines. Viruses disrupted in any one of these 
putative subunits fail to cleave or package concatemeric DNA and result in an 
accumulation of B capsids (Baines et al., 1997; Patel et al., 1996a; Tengelsen et al., 1993; 
Yu et al., 1997). 
The first indication that UL15 was involved in DNA packaging came from limited 
sequence similarity to the gp17 large subunit of the bacteriophage T4 terminase (Davison, 
1992). It has since been shown that mutations in this conserved ATP binding site of UL15 
render it unable to support DNA cleavage and packaging (Yu & Weller, 1998a). 
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Furthermore, mutation of residues conserved between UL15 and the large subunits of 
phage terminases also destroyed the function of UL15 (Przech et al., 2003). A direct 
requirement for ATP in packaging has also been shown, as depletion of ATP in infected 
cells prevented the encapsidation of DNA (Dasgupta & Wilson, 1999). These findings led 
to the proposal that UL15 is analogous to the large subunit of the terminase and provides 
the ATPase activity required for translocation of the DNA into the capsid.  These results 
have been further substantiated by studies of the UL15 homologue in HCMV, UL89. 
Electron microscopy of UL89 has shown it to have a toroidal structure in common with a 
number of DNA-metabolising proteins, and it has been found to possess nuclease activity 
(Scheffczik et al., 2002).  
The UL28 protein is also thought to be a member of the terminase complex, possibly 
involved in the recognition and binding of viral DNA. Koslowski and colleagues first 
demonstrated by immunofluorescence that UL15 and UL28 interact in the absence of other 
proteins and that UL15 could direct the localisation of UL28 from the cytoplasm to the 
nucleus in co-transfected cells (Koslowski et al., 1999). Furthermore, UL15 and UL28 
could be co-purified as a 1:1 heterodimer from HSV-1 infected cells, suggesting that these 
two proteins functionally interact and that UL28 might form part of a terminase complex. 
Mutational analysis of UL28 indicated that at least two separate regions are involved in its 
interaction with UL15 (Abbotts et al., 2000). 
UL28 has been demonstrated to bind to novel single stranded DNA structures formed by 
the pac1 region within the a sequence (Adelman et al., 2001). This, however, has not been 
confirmed, and appears to conflict with the findings that pac1 is required for termination 
but not initiation of packaging. Mutants lacking UL28 are defective in the initiation of 
packaging and as such it might be expected that UL28 would bind to the pac2 sequence. 
Recently, it was found that the regions of pac1 to which UL28 was reported to bind are 
defective in termination of packaging and so it is possible that UL28 is additionally 
involved in this process (Tong & Stow, 2010).  
Studies on the UL28 homologue in HCMV, UL56, support the hypothesis that this subunit 
is involved in the recognition and binding of viral DNA. UL56 has been shown to bind 
both pac1and pac2 within the HCMV packaging signal, an interaction that is dependent on 
the AT rich core regions of these DNA sequences. UL56 was also able to convert a 
supercoiled DNA molecule containing the a sequence into a linear form, indicating that it 
encodes a nuclease activity, although the exact site of cleavage was not mapped in this 
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study (Bogner et al., 1998). UL56 has also been demonstrated to have ATPase activity, a 
function that is enhanced by UL89 (Hwang & Bogner, 2002). 
In contrast to the heterodimeric terminase complexes identified in bacteriophage, the HSV-
1 terminase is proposed to have a third subunit, encoded by the UL33 gene. The first 
indication that UL33 was also a member of the terminase came from data showing that a 
complex of the three proteins (UL33, UL28 and UL15) could be precipitated from HSV-1 
infected cells or cells infected with recombinant baculoviruses expressing these proteins 
(Beard et al., 2002). However, it has also been reported that UL33 and UL15 interact only 
indirectly, and require UL28 to mediate this interaction (Yang & Baines, 2006). An 
analysis of the UL33 protein showed that mutations that destroyed binding to UL28 also 
abrogated cleavage and packaging, indicating that the UL33-UL28 interaction is essential 
but not sufficient for a functional terminase (Beilstein et al., 2009). Far less is known about 
the role of UL33 in the packaging process than either of the other two terminase subunits. 
All three terminase proteins show the same localisation in wt HSV-1 infected cells, 
colocalising with the single stranded binding protein, ICP8, in replication compartments 
(RCs). As previously discussed, DNA packaging takes place in these RCs, and it has been 
shown that UL15 is essential for localisation of UL33 and UL28 to the RCs (Higgs et al., 
2008). Yang and colleagues (2006) also demonstrated that the tripartate terminase complex 
forms in the cytoplasm and is then transported into the nucleus using the nuclear 
localisation signal (NLS) of UL15. Once in the nucleus, the terminase can interact with the 
viral DNA and procapsids, bringing these together for the DNA packaging process. UL28 
and UL15 have both been demonstrated to interact with the portal, UL6, in 
immunofluorescence and immunoprecipitation assays (White et al., 2003). 
By analogy to bacteriophage terminases, it would be expected that the terminase complex 
would have a transitory association with capsids during the packaging process. In 
agreement with this, none of the terminase subunits have been detected within the mature 
virion. UL28 and UL15 have both been identified as a component of procapsids and A, B 
and C capsids (Sheaffer et al., 2001). The association of UL15 with B capsids is dependent 
on UL6 and UL28, while, UL28 is able to associate with capsids independently of UL15. 
UL33 has also been shown to associate with all forms of angularised capsids and this was 
not dependent on UL15 or UL28 (Beard & Baines, 2004). Studies quantifying the amounts 
of these proteins on the different capsid types have shown that as the capsid matures, 
decreasing amounts of UL28, UL15 and UL33 can be detected, with each protein present 
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at only low levels on C capsids (Beard & Baines, 2004; Salmon & Baines, 1998; Sheaffer 
et al., 2001; Taus & Baines, 1998; Yu & Weller, 1998b). This is consistent with the 
transient nature of the interaction between the terminase and the capsid, and packaging 
being a highly processive event. Further analysis of different types of capsid suggested that 
UL15 is present on A capsids, whereas UL28 is not (Beard et al., 2004). This suggests that 
UL15 remains associated with the capsid after an abortive packaging event, whereas UL28 
dissociates along with the viral DNA. 
In summary, although no biochemical activities (ATPase, nuclease) have been 
demonstrated for the HSV-1 terminase proteins and no in vitro packaging system yet 
exists, a significant body of evidence supports the hypothesis that UL28, UL15 and UL33 
do form the terminase for packaging of HSV-1 DNA. 
 
1.7 Role of UL32 in HSV-1 DNA packaging 
1.7.1 Properties of UL32 
The UL32 open reading frame encompasses nucleotides 69162 to 67372 of HSV-1 and 
encodes a 596 amino acid protein expressed with late kinetics (McGeoch et al., 1988).  
The first indication that UL32 was involved in the DNA packaging process was from the 
studies of temperature sensitive viruses. Virus tsN20 (which has a lesion in the UL32 gene) 
was generated by UV irradiation of HSV-1 strain KOS and found to have a yield of over 
1000 fold lower than wt virus at the NPT and also to be defective in nucleocapsid 
assembly, although the levels of DNA replication were not affected (Schaeffer et al., 1973; 
Schaeffer et al., 1974). This virus was further characterised by Sherman and 
Bachenheimer. They found that upon infection with tsN20 at the NPT the accumulated 
viral DNA was "endless", indicating it had not been cleaved (Sherman & Bachenheimer, 
1987). Furthermore, characterisation of the capsids produced in tsN20 infected cells 
showed that only B capsids were produced at the NPT (Sherman & Bachenheimer, 1988).  
The requirement for UL32 in the cleavage and packaging of HSV-1 DNA was further 
confirmed by the generation of a UL32 null mutant, hr64. hr64 was isolated on 
complementing cell lines expressing UL32, and contains a lacZ cassette inserted in an 
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inverted orientation into the UL32 gene at codon 274, thereby disrupting this gene 
(Lamberti & Weller, 1998). The characterisation of this virus confirmed that in the absence 
of UL32, viral DNA is still synthesised at near wt levels but the genome is not cleaved or 
encapsidated. This phenotype is the same as seen in with null mutants of the packaging 
proteins UL6, UL15, UL17, UL28 and UL33. UL32 could not be detected as a component 
of B capsids or virions. Furthermore, UL32 was not required for the expression or capsid 
association of the other DNA packaging proteins UL6, UL15, UL25 and UL28, or the 
protease and scaffold proteins. 
An initial characterisation of the UL32 protein was carried out by Chang and colleagues. 
Sequence analysis identified a number of interesting motifs, including hydrophobic 
domains and a short sequence similar to that of aspartyl proteases. It was postulated that 
UL32 may be a membrane protein due to these hydrophobic stretches; however, it did not 
fractionate with known membrane proteins. Furthermore, UL32 does not show any 
protease activity, despite its similarity to some retroviral aspartyl proteases (Chang et al., 
1996).  
The sequence of UL32 is very cysteine rich with 22 cysteines, 7 of which are conserved 
throughout all Herpesviridae, and a further 4 conserved within the Alphaherpesvirinae 
(figure 1.12). These include three CxxC/CxxxC motifs (where x represents any amino acid 
other than cysteine) that are completely conserved (within the exception of two 
betaherpesvirus sequences) and are reminiscent of motifs found in many zinc finger 
domains. Chang et al. therefore investigated the zinc binding activity of UL32 using an 
indirect zinc blot assay. UL32 protein expressed both in HSV-1 infected cells and from a 
recombinant baculovirus was blotted onto membranes which were then incubated with 
65ZnCl2. The radioactive zinc bound specifically to regions on the blot where UL32 was 
present, indicating that UL32 does indeed bind zinc. 
There have been differing accounts of the localisation of UL32 within HSV-1 infected 
cells. Chang and colleagues produced antisera raised against UL32 and in 
immunofluorescence studies found that UL32 localised mainly to cytoplasm of infected 
cells, possibly indicating a function separate to that of other cleavage/packing proteins, 
which are all found in replication compartments (Chang et al., 1996). Lamberti and Weller 
(1998) examined the localisation of UL32 by transfection of cells with a plasmid encoding 
an EE epitope-tagged UL32 construct, followed by superinfection with hr64. They found, 
in contrast to Chang et al., that although UL32 localised predominantly in the cytoplasm of  
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infected cells, a portion was also present in the nucleus, co-localising with ICP8 at 
replication compartments. 
As discussed earlier, Lamberti and Weller also reported that cleavage and packaging of the 
genome occurs in replication compartments. They noted that in hr64 infected cells, the 
capsids were instead localised throughout the nucleus, especially at the periphery, leading 
them to speculate that UL32 was essential for correct localisation of capsids for DNA 
packaging. However, these results have not been subsequently confirmed, and an 
interaction between UL32 and capsids or virions has not yet been demonstrated. 
The CxxC/CxxxC motifs have also led to proposals that UL32 may act as a redox 
chaperone to aid the folding or localisation of other proteins. The CxxC motif is one of the 
most common redox motifs and is involved in the formation, isomerisation and reduction 
of disulphide bonds in target proteins (Fomenko & Gladyshev, 2003). This can promote 
correct folding of target proteins and prevent the formation of aggregates of mis-folded 
proteins. Disulphide bonds have been shown to be important for stability of a number of 
virus capsids, and disulphide bonds have also been reported in HSV-2 capsids, which have 
very similar morphology to HSV-1 capsids (Zweig et al., 1979). Other viruses have been 
found to encode viral chaperones required for correct folding and localisation of capsid 
and/or envelope proteins, for example gp31 of bacteriophage T4, as previously discussed. 
Some of these proteins also contain conserved cysteine residues, used in the folding of 
their target proteins, for example E3 of Sindbis virus which is required for correct folding 
of the virus glycoprotein spike (Parrott et al., 2009). A number of chaperones have also 
been identified within African Swine Fever Virus which are required for folding of the 
major capsid protein and other structural proteins (Cobbold et al., 2001; Rodriguez et al., 
2006). All of these proteins use formation and isomerisation of disulphide bonds to direct 
the correct folding of proteins needed for assembly of their respective virions. It has been 
suggested that UL32 may be involved in the localisation and folding of the triplex protein 
VP19C as it was found that a portion of VP19C was mislocalised in cytoplasmic 
aggregates in cells infected with hr64 (S. Weller, personal communication). However, 
these observations have not been subsequently repeated and no disulphide bonds have been 
reported in HSV-1 capsids.  
Recently, it has been reported that UL32 has a role in correct localisation of UL25 to the 
nucleus of infected cells (Scholtes & Baines, 2009). These authors found that in cells 
infected with hr64, significant amounts of UL25 were present in the cytoplasm. They also 
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found that in the absence of UL32, the ratio of soluble UL25 to UL17 was increased. No 
interaction between UL32 and UL25 has yet been identified. 
Homologues of UL32 in other herpesviruses have also been studied in an effort to 
elucidate its function in the viral life cycle. The UL32 homologue in HCMV, UL52, is also 
essential for cleavage and packaging, as in its absence no cleaved genomes or DNA-filled 
C capsids could be seen (Borst et al., 2008). In contrast to HSV-1 UL32, the majority of 
UL52 was found to localise in the nucleus, surrounding the nuclear replication 
compartments but not co-localising with them, perhaps indicating a slightly different role 
in the packaging process. It was also suggested that this localisation was dependent on the 
integrity of the C-terminus of UL52, as insertion of an HA tag between the final and stop 
codons resulted in the protein being detected throughout the cytoplasm of the cell.  
The UL32 homologue of the alphaherpesvirus pseudorabies virus (PrV) is also essential for 
cleavage and packaging of viral DNA (Fuchs et al., 2009). UL32 was found to localise in 
the nucleus of transfected cells, but could not be detected in large enough amounts in PrV 
infected cells to analyse its localisation. Interestingly, HSV-1 UL32 was able to 
complement the growth of a UL32 null PrV mutant virus, but the reciprocal 
complementation was not seen. This suggests similar functions of the UL32 protein in both 
viruses, but that UL32 of HSV-1 may execute additional functions that cannot be fulfilled 
by PrV UL32. Alternatively, the incomplete complementation could simply be due to the 
PrV UL32 being unable to interact with viral protein partners that are essential for the 
correct function of UL32 (Fuchs et al., 2009). 
In summary, the requirement for UL32 for HSV-1 DNA packaging is now well 
established, but the exact role it plays in this process is still very poorly understood. 
Studies have shown that it is not required for correct expression of the packaging proteins 
UL6, UL15, UL17, UL28, UL33 or the scaffold or protease. Unlike the other packaging 
proteins it cannot be detected as a component of B capsids. However, the different 
localisation of UL32 in infected cells compared to the other cleavage/packaging proteins 
has led to suggestions that it has a function distinct from those proteins already 
characterised. More work is required to fully understand the role of UL32 within the viral 
life cycle and to resolve some of the conflicting observations seen to date. 
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1.8 Aims of my project 
The major aims of my project were to further characterise HSV-1 UL32 and investigate its 
role in DNA packaging. 
The following four main approaches were used, and the data obtained are discussed in 
separate chapters of the results section. 
(i) Expression and purification of the UL32 protein and the generation of new rabbit 
antisera. 
(ii) Generation and characterisation of a panel of UL32 mutants to identify regions of the 
protein important for function. This included random insertional mutagenesis and also site-
directed mutagenesis targeted at the conserved CxxC/CxxxC motifs and the extreme C-
terminus. 
(iii) Examination of the localisation of UL32 in HSV-1 infected cells, and investigation of 
the possible interaction of UL32 with other packaging and capsid proteins, including the 
terminase complex. 
(iv) Characterisation of the UL32 protein, including direct measurement of bound zinc, 
analysis of potential DNA binding properties and the ability of herpesvirus UL32 
homologues to functionally substitute for HSV-1 UL32. 
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2 Materials and methods 
2.1 Materials  
2.1.1 Chemicals and reagents 
All chemicals and reagents were purchased from Sigma-Aldrich Co Ltd., except where 
listed below: 
BDH Laboratory supplies - Dimethyl sulphoxide (DMSO) 
- Dimethyl formamide (DMF) 
Bio-Rad Laboratories - 40% Acrylamide solution 
- 40% Acrylamide solution: N, N'-methylene-bis 
acrylamide 19:1 
- Ammonium persulphate 
- TEMED 
- Coomassie brilliant blue 
- PFGE certified agarose 
- LGT agarose 
- CleanCut Agarose 
Citiflour - AF1 mounting agent 
GE Healthcare - High-range rainbow molecular weight markers 
- Hybond-P membrane 
- Hybond-XL membrane 
- G-50 Microspin columns 
- Ribonuclease A (Gel filtration calibration kit) 
Invitrogen Ltd. - Lipofectamine 2000 reagent 
- Optimem 
Kodak - X-omat film 
Fujifilm - Phosphorimager screens 
Finnzymes - Mutation Generation SystemTM Kit 
Promega - pGEM T vector 
Roche - Complete mini EDTA-free protease inhibitor cocktail 
tablets 
- Random primed DNA labelling kit 
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- dNTPs  
- Proteinase K 
MWG - Oligonucleotides 
Pierce - Surfact-AmpsTM NP40 
 
2.1.2 Buffer solutions 
Buffer A 20 mM Tris-HCl, 50 mM NaCl, 10% (v/v) glycerol, 
0.05% NP40, pH 7.5 
Acid glycine wash 0.14 M NaCl, 0.1 M glycine, pH 3.0 
Alkaline transfer buffer 0.4 M NaOH, 0.6 M NaCl 
β-galactosidase fix PBS containing 2% (w/v) formaldehyde and 0.2% (w/v) 
gluteraldehyde 
β-galactosidase stain PBS containing 5 mM potassium ferricyanide, 5 mM 
potassium ferrocyanide, 2 mM MgCl2, 0.5 mg/ml X-gal. 
Buffer B  20 mM Tris-HCl,  1 M NaCl, 10% (v/v) glycerol, 0.05% 
NP40, pH 7.5 
Blocking solution TBST containing 5% (w/v) Marvel, 10% (v/v) glycerol 
and 10% (v/v) FCS 
STET buffer  8% (w/v) sucrose, 0.1% (v/v) Triton X-100, 50 mM 
EDTA, 10 mM Tris-HCl, pH 8 
Chloroform:Isoamyl alcohol 24 parts chloroform:1 part isoamyl alcohol (v/v) 
Cell lysis buffer (CLB) (2X) 20 mM Tris-HCl, 2 mM EDTA,  
1.2% (w/v) SDS, pH 7.5 
Destain 10% (v/v) methanol, 5% (v/v) glacial acetic acid 
 
DNA loading buffer (4X) 0.1 M EDTA, 0.25% (w/v) bromophenol blue,  
50% (w/v) sucrose 
ECL I 0.4 mM coumaric acid, 2.5 mM luminol,  
100 mM Tris-HCl, pH 8.5 
ECL II 0.02% H202,100 mM Tris-HCl, pH 8.5 
EZ buffer 100 mM KCl, 10% (v/v) glycerol, 1% (v/v) NP40,  
100 mM Tris-HCl, pH 8.0,.  1 mini protease inhibitor 
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cocktail tablet per 10 ml buffer 
Formaldehyde fix 5% (w/v) formaldehyde, 2% (w/v) sucrose in PBS 
HEPES-buffered saline 
(HeBS) 
137 mM NaCl, 5 mM KCl, 0.7 mM NaH2PO4, 55 mM 
D-glucose, 21 mM HEPES, pH 6.95-7.15 
 
L-Broth (LB) Medium 170 mM NaCl, 1% (w/v) Bactopeptone, 0.5% (w/v) 
yeast extract 
LB-agar L-broth plus 1.5% (w/v) agar 
Loening’s buffer (1 X) 40 mM NaH2PO4, 36 mM Tris, 1mM EDTA 
Membrane wash buffer 0.2 X SSC, 0.1% (w/v) SDS 
Buffer M 20 mM HEPES, 5mM MgCl2, 1 mM DTT, 10% (v/v) 
glycerol, 100 mM NaCl, 0.5 mM EDTA 
Neutralising solution  0.5 M Tris-HCl, pH 7.0 
Polyacrylamide gel 
electrophoresis (PAGE) 
buffer  
52 mM Tris-HCl, 53 mM glycine, 0.1% (w/v) SDS 
Phosphate-buffered saline 
(PBS) 
170 mM NaCl, 3.4 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.2 
PBS/1% FCS PBS containing 1% (v/v) foetal calf serum 
Permeabilisation solution 0.5% (v/v) NP40, 10% (w/v) sucrose in PBS 
PFGE cell suspension buffer 20 mM NaCl, 50 mM EDTA, 10 mM Tris-HCl, pH 7.2 
PFGE WASH 50 mM EDTA, 20 mM Tris-HCl, pH 8.0 
Phosphate buffer (10 X) 58 mM Na2HPO4, 17 mM NaH2PO4, 68 mM NaCl, pH 
7.5 
Protease 20 mg/ml grade XIV protease 
Proteinase K reaction buffer 100 mM EDTA, 0.2% (w/v) sodium deoxycholate,  
1% (w/v) sodium lauryl sarcosine 
Resolving gel buffer (RGB) 
(4 X) 
0.4% (w/v) SDS, 1.5 M Tris-HCl, pH 8.8 
RNase mix (200 X ) 1 mg/ml RNaseA, 100,000 units/ml RNase T1 in TE 
SDS PAGE sample buffer 
(3X) 
6% (w/v) SDS, 30% (v/v) glycerol, 0.3% (w/v) 
bromophenol blue, 210 mM β-mercaptoethanol 
Stacking gel buffer (SGB)  
(4 X) 
0.4% (w/v) SDS, 488 mM Tris-HCl pH 6.8, 
Chapter 2   63 
 
 
Southern hybridisation buffer 7% (w/v) SDS, 0.5 M sodium phosphate buffer,  0.01 
mg/ml denatured sheared calf thymus DNA, pH 7.4 
Southern prehybridisation 
buffer 
7 (w/v)% SDS, 0.5 M sodium phosphate buffer, pH 7.4 
Tris-borate-EDTA (TBE) 90 mM Tris base, 89 mM boric acid, 1 mM EDTA 
Tris-buffered saline (PBS) 137 mM NaCl, 5 mM KCl, 0.7 mM NaH2PO4, 5.5 mM 
glucose, 25 mM Tris-HCl, pH 7.4 
TBS-Tween (TBST) TBS with 0.25% (v/v) Tween-20 
Tris-EDTA (TE) 10 mM Tris-HCl,  1mM EDTA pH 8.0 
Towbin buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol 
Versene 0.6 mM EDTA, 0.002% phenol red in PBS 
X-gal stock solution 20 mg/ml X-gal in dimethyl formamide 
  
  
 
2.1.3 Cells and culture media 
Baby hamster kidney 21 clone-13 (BHK) cells (MacPherson & Stoker, 1962) were 
obtained from the Unit’s cytology department. The rabbit skin cell-derived complementing 
cell line UL32-5 was created by J. Thurlow (unpublished) and contains the HSV-1 UL32 
gene under the control of the HSV-1 ribonucleotide reductase large subunit promoter. 
Spodoptera frugiperda (Sf21) cells were obtained from the Unit’s cytology department. 
The following tissue culture media were used in cultivation of these cells: 
Invitrogen Ltd. - Glasgow modified Essential Medium (GMEM) 
- Dulbecco’s modified Eagle’s medium (DMEM) 
- TC100 
- Foetal calf serum (FCS) 
- Newborn Calf Serum (NBCS) 
- Penicillin/Streptomycin (P/S) 
MP Biomedicals LLC - Human Serum (HS) 
Sigma-Aldrich Co. Ltd. - Trypsin 
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The compositions of the tissue culture media used are listed below: 
ETC10 - GMEM plus 10% NBCS, 7% tryptose phosphate broth 
and 1% P/S 
EC5 - GMEM plus 5% NBCS and 1% P/S 
EPS 
EC2Hu3 
EFC10 
EFPS 
EFC2Hu3 
Sf21 growth medium 
Sf21 overlay 
- GMEM plus 1% P/S 
- GMEM plus 3% HS, 2% NBCS and 1% P/S 
- DMEM plus 10% FCS and 1% P/S 
- DMEM plus 1% P/S 
- DMEM plus 3% HS, 2% FCS and 1% PS 
- TC100 plus 5% FCS and 1% P/S  
- Sf21 growth medium with a 1:50 dilution of neutral red 
 
2.1.4 Viruses 
Viruses used in this work are listed below: 
HSV-1 strain 17 syn+ (McGeoch et al., 1988) 
hr64 (HSV-1 UL32 null mutant) (Lamberti & Weller, 1998) 
ambUL12 (HSV-1 UL12 null mutant) (Patel et al., 1996b) 
 
2.1.5 BAC genomes  
Three bacterial artificial chromosomes containing HSV-1 genomes were used in the course 
of this work: 
fHSV-1∆pac - BAC of HSV-1 genome with a sequences deleted 
(Saeki et al., 1998) 
fHSV-1pac+ - fHSV-1∆pac with a sequence re-inserted in PacI 
restriction site (Saeki et al., 1998) 
BAC O - fHSV-1∆pac containing the rpsL-neo cassette (Tong & 
Stow, 2010) 
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2.1.6 Baculoviruses 
The following baculoviruses were used in the course of this work. 
AcUL6 Expressing the wt HSV-1 UL6 protein (Patel et al., 1996a) 
AcUL15 Expressing the wt HSV-1 UL15 protein (Abbotts et al., 2000) 
AcUL17 Expressing the wt HSV-1 UL17 protein (Dr V. Preston, unpublished) 
AcUL25 Exopressing the wt HSV-1 UL25 protein (Thurlow et al., 2005) 
AcUL28 Expressing the wt HSV-1 UL28 protein (Abbotts et al., 2000) 
AcUL32 Expressing the wt HSV-1 UL32 protein (Dr A. Patel, unpublished) 
AcUL33 Expressing the wt HSV-1 UL33 protein (Beilstein et al., 2009) 
AcUL12 Expressing the wt HSV-1 UL12 protein (Dr N. Stow, unpublished) 
pac6 Parental baculovirus encoding the β-galactosidase gene (Bishop, 
1992) 
 
2.1.7 Bacterial strains 
Transformations were performed using XL-1 Blue supercompetent cells, (Stratagene: 
catalogue number 200236) or electrocompetent  DH10 cells (One Shot Electrocomp 
GeneHogs, Invitrogen Ltd.). 
2.1.8 Antibiotics 
The antibiotics used in this study are listed below, together with their suppliers. 
SmithKline Beecham Research - Ampicillin (Penbritin) 
Sigma-Aldrich Co. Ltd. - Chloramphenicol 
- Kanamycin 
- Tetracyclin 
Invitrogen Ltd. - Penicillin/Streptomycin (P/S) 
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2.1.9 Enzymes 
All restriction enzymes and their appropriate buffers were supplied by Roche Diagnostics 
Ltd. or New England Biolabs. Other enzymes are listed below. 
Sigma-Aldrich Co. Ltd.: - RNase T1 
- RNase A 
- DNase I 
- Lysozyme 
- Protease XVI 
New England Biolabs: - DNA polymerase I 
- DNA polymerase I Large (Klenow) fragment 
- T4 DNA ligase 
Promega: - GoTaq DNA polymerase (PCR) 
      
2.1.10 Plasmids 
Plasmids used in this work are listed below. Plasmids were supplied by Dr N. Stow unless 
otherwise stated. Nucleotide co-ordinates for inserted HSV-1 fragments are taken from 
McGeoch et al., (1988). 
pAT153 Vector derived from pBR322 containing ampicillin and 
tetracycline resistance loci (Twigg & Sherratt, 1980). 
pCMV10 Mammalian expression vector specifying ampicillin resistance, 
and containing a MCS flanked by the HCMV major IE promoter 
and splicing/polyadenylation signals from SV40 (Arbuckle & 
Stow, 1993) 
pAS30 The HSV-1 UL6 gene (nucleotides 15120 to 17323) inserted into 
the MCS of pCMV10 (Patel et al., 1996a) 
pE12 The HSV-1 UL12 gene (nucleotides 24755 to 27012) inserted into 
the MCS of pCMV10 (Porter & Stow, 2004a) 
pElacZ pCMV10 containing the E. coli lacZ gene 
pIM96 The HSV-1 UL25 gene cloned into the BamHI site of pCMV10 
(Dr V. Preston, MRC Virology Unit) 
pJM9 A cDNA fragment equivalent to the spliced mRNA of UL15 in 
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pCMV10 (Abbotts et al., 2000). 
pJM19 pJM9 with the pp65 epitope (ERKTPRVTGG) added to the C-
terminus of the UL15 ORF (Abbotts et al., 2000). 
pMH19 The HSV-1 UL17 gene inserted into pCMV10 (Thurlow et al., 
2005). 
pSA1 pAT153 with an HSV-1 oriS fragment cloned into the BamHI site, 
and the HSV-1 minimum packaging signal Uc-DR1-Ub fragment 
cloned between the EcoRI and HindIII sites (Abbotts et al., 2000). 
pUL28 The HSV-1 UL28 gene (nucleotides 58182 to 55761) cloned into 
the SmaI site of pCMV10 (Abbotts et al., 2000). 
pUL28-GFP pUL28 with a GFP tag inserted at the N-terminus of the UL28 
ORF (Beilstein et al., 2009). 
pUL32 The HSV-1 UL32 gene (nucleotides 69159-67201) inserted into 
the MCS of pCMV10 (Dr A. Patel, MRC Virology Unit). 
pUL33 The HSV-1 UL33 gene (nucleotides 69110 to 69576) cloned into 
the BamHI site of pCMV10 (Beilstein et al., 2009). 
pUL33-His6 pUL33 with a His6 tag inserted at the C-terminus of the UL33 
ORF (Dr G. Reid, MRC Virology Unit). 
pGX2 The HSV-1 BamHI K fragment spanning L-S junction inserted 
into the BamHI site of pAT153 (Stow, 2001) 
pVZV-KpnI f KpnI f fragment of VZV, spanning nucleotides 43943 to 49984 of 
the VZV genome inserted into the PstI site of pAT153 (Davison 
& Scott, 1983). 
pHCMV-
HindIII f 
HindIII f fragment of HCMV, spanning nucleotides 65813 to 
86163, inserted into pAT153. 
 
2.1.11 Radiochemicals 
α-
32P dCTP and α-32P dGTP used were purchased from GE Healthcare, UK, at 10 µCi/µl 
(3000 Ci/mMole). 
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2.1.12 Antibodies 
The following antibodies were used in this work. 
 
Antibody:  Immunogen:     Source/reference: 
Rabbit polyclonal antibodies: 
RC12 UL32 – peptide corresponding to 
amino acids 580-594 
Dr A. Patel, MRC Virology 
Unit 
R605 UL15 - amino acids 551-917* Dr V. Preston, MRC 
Virology Unit 
R148 UL33-His6 purified from inclusion 
bodies* 
Dr V. Preston, MRC 
Virology Unit 
R123 UL28 – amino acids 138-785* (Abbotts et al., 2000) 
R1218 UL17 - amino acids 154-703* (Thurlow et al., 2006) 
R335 UL25 - amino acids 342-580 * (Thurlow et al., 2006) 
R992 UL6 - amino acids 379-676 * (Thurlow et al., 2006) 
Anti-capsid HSV-1 C capsids Gift from Dr D. Pasdeloup, 
MRC Virology Unit 
*these immunogens were bacterially expressed fragments. 
 
Mouse Monoclonal antibodies: 
M7381 HSV-1 ICP8 (UL29) (Everett et al., 2004) 
M2040 HSV-1 VP19C (Adamson et al., 2006) 
DM165 HSV-1 VP5 (UL19) (McClelland et al., 2002) 
Q1 HSV-1 UL12 (Banks et al., 1983) 
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Epitope-specific mouse monoclonal antibodies: 
Mouse anti-pp65 HCMV pp65 epitope 
(ERKTPRVTGG) 
Capricorn Products 
Mouse anti-HA 
(F-7) 
Eleven amino acid peptide derived 
from influenza protein haemagglutinin 
(YPYDVPDYA) 
Santa Cruz Biotechnology 
Ltd 
Mouse anti-actin 
(AC-40) 
Synthetic actin C-terminal epitope 
(SGPSIVHRKCF) 
Sigma-Aldrich Co. Ltd 
 
Secondary antibodies: 
Protein A-horseradish peroxidase conjugate Sigma-Aldrich Co. Ltd 
Goat anti-mouse IgG-horseradish peroxidase conjugate Sigma-Aldrich Co. Ltd 
Goat anti-mouse IgG-Cy5 conjugate (m-Cy5) GE Healthcare 
Goat anti-rabbit IgG-FITC conjugate (r-FITC) Sigma-Aldrich Co. Ltd 
Goat anti-mouse IgG-FITC conjugate (m-FITC) Sigma-Aldrich Co. Ltd 
Goat anti-rabbit IgG Cy5 conjugate (r-Cy5) 
AlexaFluor goat anti-rabbit IgG-555 (A21428) 
AlexaFluor goat anti-mouse IgG-633 (A21050) 
GE Healthcare 
Invitrogen Ltd 
Invitrogen Ltd 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Mammalian cell culture 
BHK cells were grown and passaged in 175 cm2 tissue culture flasks containing ETC10 
(section  2.1.3). Confluent monolayers were washed in versene, trypsinised with 1 x trypsin 
in versene and resuspended in 10 ml fresh ETC10. 175 cm2 flasks containing 50 ml fresh 
growth medium were seeded with 5x106 cells and incubated at 37°C in an atmosphere 
containing 5% CO2 until confluent. 
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RSC-derived cell lines were grown and passaged in 175 cm2 tissue culture flasks as above, 
but the growth medium used was EFC10. 
2.2.1.2 Insect cell culture 
Sf21 cells were grown and passaged in 175 cm2 flasks containing Sf21 growth medium. 
Confluent monolayers were washed in TC100 and the cells suspended by gentle agitation 
into 10 ml medium. Approximately 2x107 cells were seeded into new flasks containing 50 
ml fresh Sf21 growth medium and incubated at 28°C without CO2. 
2.2.1.3 Transient transfection of BHK cells by the calcium phosphate 
procedure 
Monolayers of 1x106 BHK cells in 35 mm dishes were set up the day before transfection. 
Transfection mixtures were made up of 0.5 ml Hepes-buffered saline (HeBS), 10 µg carrier 
calf thymus DNA (3 mg/ml) and 1 µg plasmid. 35 µl 2 M CaCl2 was added, the mixture 
vortexed and left for 5 minutes for the calcium phosphate precipitate to form, and added to 
the cell monolayers from which the medium was removed. The cells were incubated at 
37ºC for 45 minutes and 2 ml EC5 added. After 4 hours at 37ºC, the cells were washed and 
22.5% DMSO in HeBS added to boost the transfections for 4 minutes (Stow & Wilkie, 
1976). The cells were washed once again in EPS and 2 ml EC5 added. Incubation was 
continued overnight at 37°C. 
2.2.1.4 Transfection of BHK cells using Lipofectamine 2000 
Glass coverslips in 24 well plates were seeded with 1x105 BHK cells per well the day 
before transfection. Transfections were carried out using Lipofectamine 2000 according to 
the manufacturer's instructions. The indicated amount of plasmid was mixed with 25 µl 
optimem for 5 minutes at room temperature. A mixture of 21 µl optimem and 4 µl 
Lipofectamine 2000 was added and incubated for a further 20 minutes at room 
temperature. Cells were washed twice with GMEM and overlaid with 200 µl GMEM, 
before addition of 50 µl of the transfection mixture. After 3 hours at 37°C, 1 ml ETC10 
was added and the cells incubated for 18 hours at 37ºC. 
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2.2.1.5 Staining for β-gal expression 
To determine the efficiency of transfection by the above methods, monolayers of BHK 
cells were also transfected in parallel with pElacZ. 18 hours post transfection, cells were 
washed in PBS and 1 ml β-galactosidase fix added for 5 min. Cells were then washed twice 
with PBS before addition of 1 ml β-galactosidase stain. The plates were incubated at 37°C 
for 4-12 hours until blue-stained cells were evident. Relative transfection efficiency was 
calculated by determining the average number of positive (blue) cells from 5 fields of view 
(each field was 1 mm2). 
2.2.2 Maintenance and manipulation of E. coli 
2.2.2.1 Transformation 
For transformation of supercompetent XL1 Blue E. coli (Stratagene), 2 µl ligation mixture 
was mixed with 20 µl bacterial cells (as supplied) and incubated for 30 minutes on ice, 
followed by a brief heat shock (42ºC for 45 seconds, on ice for 2 minutes), and the addition 
of 200 µl LB without antibiotics. Bacteria were shaken at 37ºC, 225 rpm for one hour. The 
reaction was diluted 10 fold in LB and 100 µl plated onto LB-agar plates containing the 
appropriate antibiotics and incubated overnight at 37ºC.  A selection of colonies was 
picked, inoculated into 5 ml LB (with appropriate antibiotics) and incubated at 37°C, 225 
rpm, overnight. DNA was purified and analysed as described in section  2.2.3. 
For transformation of electrocompetent DH10 E. coli (OneShot Electrocomp GeneHogs, 
Invitrogen Ltd.), 10 µl of a 1:10 dilution of ligation was added to 50 µl bacterial cells (as 
supplied) and transferred to a chilled electroporation cuvette. The cells were electroporated 
using a Hybaid CellShock CS-100 at 1.8 kV. 250 µl of room temperature LB without 
antibiotics was added and the cells incubated at 37°C, 225 rpm for one hour. The 
transformation was then diluted 100 fold in LB, plated onto LB-agar plates with the 
appropriate antibiotics and incubated at 37°C overnight. A selection of colonies was 
picked, cultured and DNA purified as described.  
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2.2.2.2 Storage of E. coli 
5 ml LB containing the appropriate antibiotics was inoculated with E. coli and incubated at 
37°C overnight, 225 rpm. 900 µl of the culture was added to 100 µl sterile glycerol and 
stored at -70°C. 
2.2.3 DNA manipulation 
2.2.3.1 Small scale DNA preparation (Qiagen) 
DNA was purified from overnight 5 ml cultures using the Qiagen QIAprep Spin Miniprep 
kit according to the manufacturer's instructions. Briefly, cells were harvested by 
centrifugation and resuspended in buffer P1 (resuspension buffer), before alkaline lysis and 
neutralisation and incubation on ice. The debris was removed by centrifugation and the 
supernatant adsorbed to a silica membrane, washed, and plasmid DNA was eluted using 
30-50 µl H20.  
2.2.3.2 Boiling lysis DNA preparation  
Cells from 5 ml overnight bacterial cultures were harvested by centrifugation and DNA 
prepared by boiling lysis preparation (Holmes & Quigley, 1981). The cells were 
resuspended in 350 µl STET buffer. 25 µl 10 mg/ml lysosyme was added and the sample 
vortexed for 20 sec, boiled for 45 sec and the debris removed by centrifugation for 10 min 
at 14,100 x g. The supernatant was transferred to a sterile eppendorf tube, NaOAc added 
and nucleic acids precipitated by isopropanol and the sample centrifuged for a further 10 
min. The pellet was washed in 70% ethanol and resuspended in 100 µl TE + RNase. DNA 
samples were stored at -20°C. 
2.2.3.3 Large scale DNA preparation 
Large scale DNA preparations were carried out from 25 ml bacterial cultures using the 
Qiagen Midi Kit (Tip 100) according to the manufacturer's instructions. Briefly, cells were 
harvested by centrifugation and resuspended in buffer P1 (resuspension buffer) before 
addition of P2 (an NaOH/SDS buffer) and precipitation on ice with buffer P3 (a high salt 
buffer with acidic pH). Precipitated material was removed by two centrifugation steps and 
the supernatant applied to a Tip 100 column and allowed to enter the resin by gravity flow. 
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The column was washed and DNA was eluted, precipitated with isopropanol and pelleted 
by centrifugation. The DNA pellet was then washed in 70% ethanol and resuspended in 
300-500 µl H2O. 
2.2.3.4  Restriction enzyme digests 
Typically, restriction enzyme digests were set up using 10 units of the specified enzyme, 1 
x enzyme buffer and where appropriate, 100 µg/ml BSA, with the indicated amount of 
DNA in a total volume of  20 µl (unless otherwise indicated) and incubated at 37ºC for 2 
hours. 
If further modification of the digested DNA was required, the DNA was purified using the 
Qiagen QIAquick PCR Purification Kit according to the manufacturer’s instructions. Five 
volumes buffer PB was added to the DNA and mixed. The DNA was adsorbed onto the 
silca membrane, washed and eluted in 50 µl 10mM Tris-HCl, pH 8.5. 
2.2.3.5 Agarose gel electrophoresis 
Loening's Buffer (0.5 x) or TBE buffer (1 x) containing the desired percentage of agarose 
was boiled and allowed to cool. Ethidium bromide was added to a concentration of 0.5 
µg/ml and the agarose poured into a mould containing a well-forming comb and allowed to 
set. Once set, the gel was placed in a tank containing the appropriate buffer. DNA samples 
containing 1 x loading dye were added to individual wells and separated by electrophoresis 
at a constant voltage of 100 V for one hour or 20 V overnight. The DNA bands were 
visualised using UV light. 
2.2.3.6 Purification of DNA fragments 
Plasmid DNA was digested with the appropriate restriction enzymes to release the desired 
fragment of DNA (section  2.2.3.4). The fragments were separated by agarose gel 
electrophoresis and viewed using long wave UV light, and the desired fragment excised 
from the gel. The DNA was purified using the Qiagen QIAquick Gel Extraction Kit 
according to the manufacturer’s instructions. Briefly, the gel slice was weighed, 3 gel 
volumes buffer QG added, and incubated at 50°C for 10 min with occasional vortexing. 
When the agarose had completely dissolved, 1 gel volume isopropanol was added and the 
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DNA adsorbed to the silca membrane. The membrane was washed, and the DNA eluted 
using 50 µl 10 mM Tris-HCl pH 8.5. 
2.2.3.7 Ligation 
Gel purified DNA fragments were ligated using T4 DNA ligase, using a molar ratio of 1:3 
vector:insert. Ligations were set up in a final reaction volume of 10 µl including 1 µl T4 
DNA ligase and 1x ligase buffer, at 16ºC overnight. 
2.2.3.8 Polymerase Chain Reaction (PCR) 
PCR reactions were carried out in a volume of 50 µl, containing final concentrations of 
approx 1 ng DNA, 0.2 mM each dNTP, forward and reverse primers at 0.2 µM, and 1 U 
Taq polymerase in 1 x buffer (supplemented with MgCl2). 0.5 M betaine was included 
where specified. PCR reactions were as follows: 
95ºC for 5 minutes        25 cycles of (95ºC for 30 seconds        XºC for 60 seconds  
               72ºC forY seconds)   72ºC for 7 minutes 
X (re-annealing temperature) was calculated as 5ºC below the melting temperature (Tm) of 
the primers. Tm for each primer = 2°C x (A+T) + 4°C x (G+C). 
Y (extension time) was calculated at the rate of 60 seconds per 1000 bp. 
Small aliquots of PCR products were run on 0.8% agarose gels to check that theDNA had 
been amplified. PCR fragments were then purified using the Qiagen QIAquick PCR 
purification kit.  
2.2.3.9 Sub-cloning of DNA fragments 
Purified PCR products were inserted into the sub-cloning vector pGEM T (Promega) to 
facilitate further cloning steps. Ligation reactions were set up with 1 µl T vector, 1 µl PCR 
fragment, 2 µl T4 DNA ligase and 5 µl 2 x rapid ligation buffer in a total volume of 10 µl 
and left at room temperature for one hour. 2 µl ligation reaction was used to transform 20 
µl XL1-blue E. coli as described in section  2.2.2.1. After incubation for one hour, IPTG 
was added to the cultures (at 1% w/v) which were plated onto LB-agar plates containing 
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amp (100 µg/ml) and 2% (w/v) X-gal and incubated overnight at 37°C.  White colonies 
were picked and used to inoculate 5 ml cultures of LB + amp. The bacteria were cultured 
overnight at 37°C, 225 rpm. DNA was prepared from these overnight cultures by Qiagen 
Spin MiniPrep (section  2.2.3.1). An aliquot of DNA was screened by restriction enzyme 
digestion or sequencing for presence of the PCR fragment. The PCR fragment was then 
excised from the T vector by cleavage with suitable restriction enzymes on either side of 
the insertion site and gel purified (section  2.2.3.6) prior to further cloning steps. 
2.2.3.10 Insertional mutagenesis 
Transposon mutagenesis was carried out using the Finnzymes Mutation Generation System 
according to the manufacturer’s instructions. 270 ng pUL32 plasmid was incubated with 
the MuA transposase and the M1-KanR Entransposon in 1 x reaction buffer at 30°C for one 
hour. The reaction was stopped by heat inactivation of the transposase at 75°C for 10 min. 
The reaction was diluted 1:10 in H20 and four aliquots (of 10 µl each) were transformed 
into DH10 E.coli by electroporation as described in section  2.2.2.1. Bacteria were plated 
onto four LB plates containing amp (100 µg/ml) and kan (50 µg/ml) and incubated 
overnight at 37°C. 
Colonies were picked and inoculated into 5 ml LB cultures overnight, and DNA isolated 
by small scale boiling lysis (section  2.2.3.2). Clones containing the Entransposon within 
the UL32 gene were identified by restriction digestion with XbaI and KpnI. An aliquot of 
each such clone was digested with NotI to remove the transposon. This DNA was then self-
ligated and retransformed into DH10 cells (sections  2.2.3.7 and  2.2.2.1). Colonies were 
picked, inoculated into 25 ml LB containing the appropriate antibiotics and plasmid DNA 
isolated by large scale DNA preparation (section  2.2.3.3). 
 
2.2.4 Virus techniques 
2.2.4.1 Growth of HSV-1 virus stocks 
Typically, 5 x 175 cm2 flasks of BHK cells at a confluency of approximately 80% were 
infected with wt HSV-1 at a multiplicity of 0.01 p.f.u./cell in 40 ml EC5. Cells were 
incubated at 31ºC for 4-7 days until they showed cytopathic effect. The infected cells were 
tapped into the media, pooled and centrifuged at 835 x g for 10 min. The pellets were 
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resuspended in 5 ml EC5 and repeatedly freeze-thawed and sonicated to prepare the cell-
associated virus stock (CAV). The supernatant was centrifuged again at 21,860 x g for 3 
hours and the resulting pellet resuspended in 5 ml EC5 and sonicated extensively to 
prepare the cell-released virus stock (CRV). Both stocks of virus were tested for sterility 
on blood agar plates and titrated as described (section  2.2.4.2). Stocks of HSV-1 were 
stored at -70°C in aliquots, to avoid repeated freeze-thawing. Stocks of the UL32 null 
mutants (32∆EP and hr64) were similarly prepared following infection of UL32-5 cells 
except that EFC5 medium was used. 
2.2.4.2 Titration of HSV-1 
To determine the titre of virus preparations, 10-fold serial dilutions were made in EC5. 
Duplicate 35 mm dishes of BHK cells were inoculated with 100 µl diluted virus for 1 hour 
with gentle rocking of dishes every 15 min. 2 ml of EC2Hu3 was added and the 
monolayers incubated at 37ºC for 3 days.  The overlay was removed and 1 ml Geimsa stain 
added for 30 min. The Geimsa stain was washed off and the number of plaques in each 
dilution counted. The titre was determined as the average of the duplicate plates using the 
calculation: 
Titre = number of plaques on 10-n dilution x 10n x 10 p.f.u./ml 
The UL32 null mutant virus stocks were titrated onto UL32-5 cells in the same way, except 
that the serial dilutions were made in EFC5 and the cells overlaid with EFC2Hu3. 
2.2.4.3 Infection of BHK cells 
BHK cells were seeded at 1x106 cells per 35 mm plate or 1x105 cells per linbro well (on 
glass coverslips) the day before infection. Virus was diluted to achieve a multiplicity of 5 
p.f.u./cell in an inoculum of 100µl (unless otherwise stated) and adsorbed for one hour at 
37ºC.  During adsorption, plates were gently rocked every 15 min. 2 ml EC5 was then 
added and the cells incubated at 37ºC for 6 or 18 hours (as specified).  
2.2.4.4 Growth of baculovirus stocks 
Typically, 175 cm2 flasks of Sf21 cells at approximately 50% confluency were infected at a 
multiplicity of 1 p.f.u./cell in 20 ml Sf21 growth medium. Cells were incubated at 28ºC for 
four days and harvested by shaking into the medium. Cells were pelleted at 835 x g for 5 
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min. To obtain concentrated virus stock, the supernatant from this spin was centrifuged at 
38,725 x g for 90 min and the resultant pellet resuspended in 4 ml Sf21 growth medium. 
Baculovirus stocks were sonicated extensively, checked for sterility on blood agar plates 
and stored at -70ºC. 
2.2.4.5 Determination of baculovirus stock titres 
To determine the titre of baculovirus stocks, 10-fold serial dilutions were made in Sf21 
growth medium. Duplicate 35 mm dishes of Sf21 cells were inoculated with 100 µl diluted 
virus for 1 hour. 1.5% LGT agarose in Sf21 growth medium was melted and 2 ml of this 
overlaid onto the monolayers. After the agarose had set, 1.5 ml Sf21 growth medium was 
added to each dish and the cells incubated at 28°C for four days. To visualise plaques, the 
medium was removed from the plates and 0.5 ml of Sf21 overlay containing 1:50 dilution 
of neutral red was added to the plates for 24 hours. Plaques could then be counted and 
titres determined as above. 
2.2.5 Complementation yield assay 
BHK cells were transfected using the calcium phosphate method (as described in section 
 2.2.1.3) with 1 µg each test plasmid. Six hours post transfection, the cells were infected 
with the appropriate virus at a multiplicity of 5 p.f.u./cell (section  2.2.4.3) and returned to 
37ºC. One hour after infection the cells were washed once with 0.14 M NaCl, exposed to 
acid glycine wash for one minute, then washed with EC5 (Rosenthal et al., 1984). The 
cells were then incubated in 2 ml fresh EC5 at 37ºC overnight. 18 hours post infection, the 
cells were scraped into the medium, sonicated and viral progeny titrated on the 
complementing cell line, UL32-5, for 4 days at 37ºC (section  2.2.4.2). 
2.2.6 Amplicon packaging assay 
2.2.6.1 Transfection and superinfection of BHK cells 
Monolayers of BHK cells were transfected using the calcium phosphate method (section 
 2.2.1.3), with 1 µg test plasmid and 0.5 µg pSA1 plasmid. 6 hours post transfection, the 
cells were infected with the appropriate virus at 5 p.f.u./cell (section  2.2.4.3) and returned 
to 37ºC for 18 hours. 
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2.2.6.2 Preparation of total and DNase resistant DNA 
The cells were scraped into 2 ml TBS and each sample split into two equal portions for the 
preparation of total DNA (sample A) and DNase resistant DNA (sample B). The cells were 
pelleted and each A sample resuspended in 184 µl RSB containing 0.5% NP40, followed 
by addition of 184 µl of 2 x CLB containing 1 mg/ml protease, and incubated at 37°C for 
one hour. Each B sample was resuspended in 184 µl RSB containing 0.5% NP40 and 200 
µg/ml DNase and incubated at 37°C for 20 minutes with occasional vortexing. This was 
followed by addition of 184 µl of 2 x CLB with 1 mg/ml protease for one hour at 37°C. 32 
µl 4 M NaCl/0.5 M EDTA was added to all samples (A and B) which were sequentially 
extracted with phenol and chloroform:isoamyl-alcohol and precipitated in 1 ml EtOH for 1 
hour at -80ºC or overnight at -20ºC.  The DNA was pelleted by centrifugation and the 
pellets resuspended in 120 µl (A samples) or 60 µl (B samples) TE+RNase. One sixth of 
the A samples and one third of B samples (20 µl each) were digested with 5 U EcoRI and 5 
U DpnI in a total reaction volume of 40 µl for 4 hours at 37ºC. The reaction was stopped 
by addition of 5 x loading dye and the samples separated by electrophoresis on a large 
0.8% agarose gel containing 0.5 µg/ml ethidium bromide in 0.5 x Loening's buffer at 20 V 
overnight.  
2.2.6.3 Southern Blotting 
Agarose gels were examined by UV light to confirm digestion had occurred and DNA had 
been efficiently recovered, and photographed. The gel was shaken in alkaline transfer 
buffer for 30 minutes, and blotted onto a nitrocellulose membrane (Hybond-XL) by 
capillary transfer in alkaline transfer buffer for 12-20 hours at room temperature 
(Sambrook & Russell, 2001b). The membrane was washed in 0.5 M Tris pH8 for 15 
minutes and the DNA crosslinked by exposure to 120 mJ/cm of 254 nm UV light. 
The membrane was incubated in a Hybaid rotating oven at 68ºC in Southern pre-
hybridisation buffer for 1-3 hours, followed by blocking of non-specific binding by 
incubation in 20 ml Southern hybridisation buffer for 2-5 hours. Specific fragments were 
detected by addition of 32P labelled probe (section  2.2.6.4) to the hybridisation buffer and 
overnight incubation at 68ºC. The blot was washed once in Southern prehybridisation 
buffer (45 minutes) and twice in membrane wash buffer (one hour each) before being 
rinsed in water and exposed to a phosphorimage screen. The screen was processed using a 
Personal Molecular Imager (BioRad) and analysed using Quantity One software. 
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2.2.6.4 32P labelling of probe by random priming 
The probe for Southern blot hybridisation was labelled using the Roche Random Primed 
DNA Labelling Kit, following the manufacturer’s instructions. The appropriate plasmid to 
be used as a probe was linearised by restriction enzyme digestion and purified using the 
Qiagen QIAquick PCR Purification Kit. Reactions were set up containing approximately 
500 ng denatured linearised DNA (boiled 10 minutes, then incubated on ice 10 minutes), 2 
µl each of dTTP and dATP (0.5 mM), 2 µl hexanucleotide mix, 5 U Klenow enzyme, and 
2 µl each of α-32P dCTP and α-32P dGTP (20 µCi each) in a final volume of 20 µl. The 
reaction was incubated at 37ºC for one hour, and stopped by addition of 5 µl 0.2 M EDTA, 
followed by 25 µl 10 mM Tris-HCl, pH 8.0. The unincorporated nucleotides were removed 
by purification through a G-50 Microspin column and the probe denatured by addition of 
40 µl 10 mM Tris-HCl, pH 8 and 20 µl 1 M NaOH. After 5 minutes, the solution was 
neutralised with 20 µl 1M HCl and the entire probe (110 µl) added to the tube containing 
the hybridisation buffer and membrane (section  2.2.6.3). 
2.2.7 Analysis of proteins 
2.2.7.1 SDS-PAGE 
BHK cells were transfected or infected as previously described (sections  2.2.1.3 and 
 2.2.4.3) or Sf21 cells infected with recombinant baculoviruses at the indicated m.o.i.s. 
Cells were harvested by scraping into 1 ml PBS and pelleted. The pellets were washed 3 
times in PBS and 60 µl 1 x SDS PAGE sample buffer added. The samples were boiled for 
10 minutes in a water bath prior to loading on the gel. 
Gels used were minigels consisting of an 8% running gel (unless otherwise specified) 
made with 39:1 acrylamide:bisacrylamide, and 5% stacking gel with 19:1 
acrylamide:bisacrylamide. 20 µl protein samples were resolved by electrophoresis at 200 V 
for 45 min using a BioRad Mini-protean III kit in 1 x PAGE buffer. 10 µl high-range 
rainbow molecular weight markers were run on the gel as a molecular size marker. 
2.2.7.2 Coomassie staining of proteins 
Proteins were separated by SDS-PAGE as described above and the gel incubated in 0.2% 
Coomassie in destain for 30 min with gentle agitation. The gel was then washed 
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extensively in H20 and boiled in a microwave oven in H20 for 10 min to remove a large 
proportion of the stain. The gel was washed in destain until the protein bands were readily 
visible, and photographed. 
2.2.7.3 Western blotting 
Protein samples were separated by SDS-PAGE as described above and gels blotted onto a 
Hybond-P PVDF membrane using a BioRad transfer kit for 2 hours at 250 mA in Towbin 
buffer.  The membrane was blocked by shaking in 10 ml blocking solution for 2 hours at 
room temperature.  The primary antibody was diluted as indicated in 5% Marvel in TBST 
and shaken with the membrane for 1 hour at room temperature, or overnight at 4°C, 
followed by 3 x 5 min washes in TBST.  The membrane was then incubated in a 1:1000 
dilution of HRP-conjugated secondary antibody in 5% Marvel in TBST for 1 hour at room 
temperature.  Following 3 x 5 min washes in TBST, specific bands were detected by 
addition of 1 ml ECL mix (freshly mixed ECL I and ECL II) for 1 min and exposure of the 
membrane to auto-radiographic film. 
2.2.8 Immunofluorescence of transfected and infected cells 
Glass coverslips within 24 well plates were seeded with 1x105 BHK cells per well and the 
next day transfected for 18 hours with 0.5 µg indicated plasmids by lipofection (section 
 2.2.1.4). Alternatively, coverslips of cells were infected with 5 p.f.u./cell of the indicated 
virus (section  2.2.4.3) for 6 hours.  
Cells were washed twice in PBS and then fixed for 10 minutes in 1 ml formaldehyde fix. 
The monolayers were thoroughly washed in PBS and 1 ml permeabilisation solution added 
for 10 min. The cells were washed again in PBS and coverslips that had been infected with 
HSV-1 blocked for 30 minutes with 10% human serum in PBS (to block IgG binding). 
Coverslips were placed cell-side down on to appropriate primary antibodies, diluted to the 
indicated concentrations in PBS/1% FCS, for one hour at room temperature. The coverslips 
were then washed 3 x 5 min face-down and 3 x 5 min face-up in PBS/1% FCS with very 
gentle agitation. The appropriate FITC- or Cy5- conjugated secondary antibodies were 
added in the same way and the coverslips incubated face-down for one hour at room 
temperature. After 6 further washes in PBS/1%FCS, the coverslips were rinsed in H2O and 
air-dried. Dry coverslips were mounted on glass slides using AF-1 mounting agent and 
examined using a Zeiss LSM 510 confocal microscope. Laser lines with excitation 
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wavelengths of 488 nm, 545 nm and 633 nm were used to detect the FITC, TRITC and 
Cy5 fluors respectively and images were compiled in Adobe Photoshop. 
2.2.9 Purification of the UL32 protein 
2.2.9.1 Infection of Sf21 cells 
175 cm2 flasks of Sf21 cells at approximately 50% confluency were infected at a 
multiplicity of 5 p.f.u./cell in 20 ml Sf21 growth medium and incubated at 28ºC for two 
days. The cells were pelleted at 835 x g for 5 min and then resuspended in 1 ml buffer A 
(containing protease inhibitor tablets) per flask. Insoluble protein was removed by ultra-
centrifugation at 44,000 x g for 20 minutes at 4ºC. The supernatant (soluble protein) was 
collected and stored at -70ºC. 
2.2.9.2  MonoQ ion-exchange chromatography 
All chromatography was carried out using the AKTA 900 purification system. Soluble 
extracts of protein were filtered through a 0.45 µm filter and separated by anion exchange 
chromatography using a 1 ml MonoQ 5/50 GL column (Amersham). The column was 
prepared by equilibration with 5 column volumes buffer A at a flow rate of 1 ml/min. The 
protein was loaded onto the column and washed with 5 column volumes buffer A. Proteins 
were eluted with a salt gradient by gradually increasing the proportion of buffer B applied 
to the column so as to increase the NaCl concentration from 50 mM to 1 M over a 60 ml 
gradient. Fractions of 0.5 ml were collected and stored at -70ºC. 20 µl each fraction was 
added to 10 µl 3 x SDS PAGE sample buffer and the proteins separated on an 8% SDS-
PAGE gel which was stained with Coomassie (sections  2.2.7.1 and  2.2.7.2) or western 
blotted (section  2.2.7.3) to identify peak fractions containing UL32. 
2.2.9.3  Measurement of protein concentration 
The concentration of total protein in the fractions collected from the MonoQ column was 
determined by Bradford assay (Bradford, 1976). 5 µl each sample was mixed with 250 µl 
protein dye (BioRad) in the wells of a 96-well plate and the absorbance measured at 560 
nm. The concentration of protein was calculated from a standard curve for BSA samples of 
known concentration. 
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2.2.9.4  Superose 12 size exclusion column 
A 24 ml Superose 12 HR 10/30 column (Amersham) was used to determine the size of 
UL32. Buffer A was used to equilibrate the column at a flow rate of 0.2 ml/min for 10 
column volumes. IgG (160 kDa), BSA (67 kDa) and ribonucleaseA (13.7 kDa) were used 
as molecular markers, and these were pooled and diluted to a final concentration of 2 
mg/ml each in buffer A and filtered. A further 0.2 column volumes buffer A were added to 
the column, and a 200 µl aliquot of the diluted markers was applied to the column at a flow 
rate of 0.25 ml/min and eluted in 1 column volume buffer A. The elution point of each 
marker was identified from the UV trace. Peak fractions from the MonoQ column were 
then pooled and 200 µl injected onto the Superose 12 column and fractionated using 
identical conditions to the markers. 0.5 ml fractions were collected and stored at -70°C, 
before being analysed by SDS-PAGE and Coomassie staining or western blot as before. 
2.2.10 Generation of UL32 rabbit antisera 
2.2.10.1 Preparation of immunogen and immunisation 
UL32-containing fractions from multiple MonoQ fractionations were pooled and the total 
protein quantified (section  2.2.9.3). The protein used as an immunogen had a concentration 
of approximately 1.5 mg/ml (total protein) in buffer A. The purity of the UL32 protein in 
this sample was estimated as approximately 40% by density analysis of the protein bands 
from a Coomassie stained gel (using BioRad QuantityOne software). The total protein 
sample was emulsified in Freund’s complete adjuvant (FCA) for immunisation by Dr 
Susan Graham (MRC Virology Unit), and two rabbits were immunised and sera collected 
by Colin Hughes (University of Glasgow). A pre-immune bleed was taken from each 
rabbit prior to immunisation. The primary immunisation contained 50-100 µg total soluble 
protein in FCA. This was followed by a boost after four weeks and then two further boosts 
at two week intervals, all containing 50-100 µg protein emulsified in Freund’s incomplete 
adjuvant (FIA). Sera from test bleeds collected one week after the third boost were 
prepared as in section  2.2.10.2 and tested along with the pre-immune sera by western 
blotting for reactivity to the UL32 protein (sections  2.2.7.1 and  2.2.7.3). The rabbits were 
then given a final fourth boost of 100 µg protein in FIA and bled one week later for the 
final antisera. 
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2.2.10.2 Collection and preparation of antisera 
Final bleeds of approximately 50 ml were taken from rabbits R1 and R2 and allowed to 
clot at 4°C overnight. The serum was removed from the clot and centrifuged at 835 x g for 
10 min to remove any remaining red blood cells. The supernatants were kept and used as 
the UL32 antisera, named R1 and R2. These were stored in aliquots at -20°C and were 
tested for reactivity against UL32 by western blot and immunofluorescence.  
2.2.11 Co-immunoprecipitation of baculovirus-expressed 
proteins 
2x106 Sf21 cells were infected with the appropriate baculoviruses at 2.5 p.f.u./cell in 
suspension in a total volume of 2 ml in Sf21 growth medium and plated out into 35 mm 
dishes. After 48 hours at 28°C, cells were scraped into the medium and harvested by 
centrifugation at 835 x g for 5 min. Cells were resuspended in 1 ml PBS, pelleted in a 
microfuge for 10 sec and the supernatant discarded. The pellets were resuspended in 500 µl 
EZ buffer by vortexing and incubated on ice for 20 minutes. Insoluble protein was 
removed by ultra-centrifugation at 44,000 x g for 20 min and the supernatant (soluble 
protein) retained. 40 µl of this supernatant was mixed with 40µl H20 and 40µl 3 x SDS 
PAGE sample buffer (total extracted protein sample). For the immunoprecipitation, 150 µl 
of the soluble supernatant protein was incubated with 2 µl appropriate antibody, rotating 
end-over-end at 4ºC for 2 hours. 50 µl protein-A-sepharose beads (50% slurry in PBS) was 
added and incubated on a rotator at 4ºC for a further hour. Immune complexes were 
collected by centrifugation at 14,100 x g for 30 sec and washed four times with 0.5 ml EZ 
buffer (the final wash being in a fresh tube).The washed beads were resuspended in 60 µl 1 
x SDS PAGE sample buffer and boiled for 10 min in a waterbath. 20 µl each sample (and 
20 µl of each total extracted protein sample) was analysed by SDS-PAGE and western 
blotting (sections  2.2.7.1 and  2.2.7.3 ). 
2.2.12 Generation of HSV-1 recombinant expressing HA-
tagged UL32 
The approach taken involved the rescue of the UL32 null mutant hr64 with a DNA 
fragment encoding UL32 tagged near to its N-terminus with a tag derived from the 
influenza haemagglutinin (HA). 
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2.2.12.1 Preparation of hr64 genomic DNA 
175 cm2 flasks of UL32-5 cells were infected with hr64 at 5 x 105 p.f.u./flask and 
incubated at 31°C for 3 days. The infected cells were tapped into the medium and 
centrifuged at 835 x g for 10 min. The supernatant was centrifuged again at 21,860 x g for 
3 hours and the pellet containing the cell released virus particles was resuspended in 1 ml 
TE+RNase by pipetting and sonication. 40 µl 0.25 M EDTA, 25 µl 20% SDS and 50 µl 20 
mg/ml proteinase K were added and incubated for 30 min at 50°C. DNA was purified 
following the addition of 32 µl 4 M NaCl/0.5 M EDTA by sequential extraction with 
phenol and chloroform:isoamyl alcohol. The aqueous phase containing the viral DNA was 
dialysed once against 1 litre 1 x TE for 16-20 hours at 4°C, followed by further dialysis 
against 1 litre 1 x TE for 2 hours. 
2.2.12.2 Transfection  
The construction of plasmid p33-HA-32 is described in section  5.3.1. p33-HA-32 was 
digested with NdeI and XhoI and the fragment containing 33-HA-32 was gel purified 
(section  2.2.3.6). 35 mm plates of BHK cells were transfected with 0.5 µg hr64 genomic 
DNA and 0.5 µg 33-HA-32 fragment by the calcium phosphate method as described in 
section  2.2.1.3. Cells were incubated in EC5 at 37°C for 3 days to allow recombination and 
replication to occur. Once infection was evident in the plates, cells were scraped into the 
media, sonicated, and the virus progeny titrated on BHK cells as described in section 
 2.2.4.2. 
2.2.12.3 Plaque purification and growth of HA-HSV-1 stock 
Serial two-fold dilutions of the above harvested virus were made and each was used to 
infect 12 wells of a 96-well plate of BHK cells, covering the range 128 p.f.u/well to 
3.9x10-3 p.f.u./well. The plate was incubated at 37°C for 4 days and then the cells from 
four wells each containing a single plaque were scraped into the medium. 50 µl from each 
of these wells was used to infect a 35 mm dish of BHK cells overnight. The infected cells 
were then scraped into the medium and divided into two samples. One sample was lysed, 
separated by SDS-PAGE and checked for expression of HA-tagged UL32 by western 
blotting using mouse anti-HA antibody (sections  2.2.7.1 and  2.2.7.3). Once presence of the 
HA tag had been confirmed for a single plaque, the other half of this sample was used to 
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infect 175 cm2 flasks of BHK cells to generate a virus stock named HA32EP (section 
 2.2.4.1). 
2.2.13 Generation of a HSV-1 UL32 null mutant by 
recombination in E. coli 
The new HSV-1 UL32 null mutant, ∆UL32EP, was generated using the Counter-Selection 
BAC modification kit (GeneBridges), which utilises the Red/ET homologous 
recombination enzymes. The kit was used according to the manufacturer's instructions. 
2.2.13.1 Growth of DH10B E. coli and expression of recombination 
enzymes 
E. coli DH10B cells (GeneHogs) containing the BAC, fHSV-1∆pac, and pSC101-BAD-
gbaAtet (encoding the Red/ET recombination enzymes) were cultured overnight in LB 
containing tetracycline (3 µg/ml) and chloramphenicol (50 µg/ml) at 30°C, 225 rpm and 
used to inoculate 30 ml fresh LB + cam/tet. The culture was incubated at 30°C, 225 rpm 
for approximately two hours until the OD600 reached 0.3. The expression of the genes 
mediating the Red/ET recombination was induced by addition of 3 ml 30% L-arabinose 
and a temperature switch to 37°C. After one hour at 37°C, the cells were made competent 
for transformation as follows. The culture was centrifuged at 835 x g for 15 min at 4°C and 
the pellet resuspended gently in 30 ml ice-cold H20, and centrifuged again. This was 
repeated three times, reducing the volume of ice-cold H20 by half each time. Finally, the 
cells were resuspended in 0.5 ml 10% ice-cold glycerol and used for electroporation of 
rpsL-neo-32, as described below. 
2.2.13.2 Insertion of rpsL-neo-32 PCR cassette into BAC 
The cassette for recombination was the rpsL-neo fragment flanked by homology arms to 
UL32 gene. This cassette was generated by PCR (section 6.12) and was designed so that 
the rpsL-neo sequences replaced nucleotides 202 to 1599 of UL32. 2 µl of the rpsL-neo-32 
PCR product were transformed into 40 µl of the above electrocompetent DH10B cells 
containing fHSV-1∆pac (as in section  2.2.2.1). 1 ml LB was added and the cells incubated 
at 37°C and 225 rpm for 70 min before plating onto a LB-agar plate containing cam (50 
µg/ml) and kan (15µg/ml) overnight at 37°C. 
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The resulting colonies picked were also plated on kan/cam/strep plates for 48 hours to 
confirm they had the strepS phenotype expected from successful insertion of the rpsL-neo 
containing cassette. 
2.2.13.3 Preparation of BAC DNA and confirmation of the disruption of 
the UL32 gene 
BAC DNA for screening was prepared from 5 ml overnight cultures of clones with the 
phenotype camR, kanR and strpS by the alkaline lysis method (Sambrook & Russell, 
2001a). Two aliquots of each DNA sample (approx 1 µg each) were digested with 5 U 
EcoRI each for 6 hours at 37°C. The reactions were stopped by addition of 5 x loading dye 
and the samples were run on duplicate 0.8% agarose gels in 0.5 x Loening's Buffer at 20 V 
overnight. The gels were Southern blotted (sections  2.2.6.3) and probed for the presence of 
either the kanamycin cassette or the UL32 gene using 32P labelled probes generated by 
random priming (section  2.2.6.4). 
One clone with the correct kanamycin positive Southern blot profile (UL32 negative and 
kanamycin positive) was identified and BAC DNA was prepared for transfection into 
mammalian cells using the Qiagen Midi Kit (Tip 100) (section  2.2.3.3). After isopropanol 
precipitation the DNA pellet was resuspended in 200 µl H20. 1/10 volume 3 M NaOAc and 
2 ½ volumes EtOH were added and the DNA was precipitated at -20°C overnight. Finally, 
the DNA was pelleted and resuspended in 50 µl TE+RNase.  
2.2.13.4 Transfection of mutated BACs into UL32-5 cells 
35 mm dishes of UL32-5 cells were set up the day before transfection. 2 µg mutated BAC 
DNA and 2 µg BamHI cleaved pGX2 DNA (containing the HSV-1 BamHI K fragment to 
repair the a sequence deleted from fHSV-1∆pac) were transfected using the calcium 
phosphate method (section  2.2.1.3). The cells were incubated in EC5 for 3 days and then 
scraped into the medium and sonicated. One half of the sonicate was added to a new 35 
mm dish of UL32-5 cells and incubated for 48 hours at 37°C. Once CPE was established, 
after 3 days, the cells and virus from this plate were scraped into the medium and stored at 
-70°C before titration of the viral yield and large scale production of virus stock, named 
∆32EP (sections  2.2.4.1 and  2.2.4.2).  
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2.2.14 Pulsed Field Gel Electrophoresis 
2.2.14.1 Preparation of agarose embedded cell suspensions 
Duplicate 35 mm plates of BHK cells were infected at a multiplicity of 5 p.f.u./cell as 
described in section  2.2.4.3 and harvested after 18 hours by scraping into the medium and 
centrifugation at 835 x g for 5 min. Pelleted cells from each plate were resuspended in 200 
µl PFGE cell suspension buffer, pooled, and equilibrated to 50ºC.  200 µl melted 2% 
CleanCut Agarose was added, mixed well and 4 x 100 µl samples from each infection were 
added to BioRad plug moulds and set at 4º.  
2.2.14.2 Preparation of total DNA and restrictions enzyme digestion in 
agarose blocks 
Agarose blocks were incubated at 50ºC overnight in proteinase K reaction buffer 
containing 1 mg/ml proteinase K. Blocks were then washed 4 x 30 min in 0.5 ml PFGE 
WASH 
The agarose blocks were washed twice in 0.1 x PFGE WASH to reduce the EDTA 
concentration and incubated for 30 min in 200 µl of the appropriate 1 x restriction enzyme 
buffer at 37ºC. The blocks were then digested with 40 U of enzyme in fresh restriction 
buffer overnight, and washed twice in 0.5 ml PFGE WASH. 
2.2.14.3 Electrophoresis and Southern blotting of PFGE samples 
One gram of PFGE certified agarose was melted in 100 ml 0.5 x TBE, allowed to cool and 
poured into the CHEF-DR II casting mould. Each agarose block was placed in one well of 
this gel, ensuring there were no air bubbles. The wells were then sealed by filling with 1% 
CleanCut Agarose. The gel was placed in the CHEF-DR II electrophoresis tank containing 
2 litres of 0.5 x TBE pre-cooled to 14ºC.  DNA was separated using run parameters of 6 
V/cm for 16 hours at 14ºC with a ramped switch time of 1 – 15 sec. After electrophoresis 
the gel was stained in 0.5 µg/ml ethidium bromide in dH20 for 20 min, examined by UV 
light and photographed. 
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The gel was soaked in 0.25 M HCl for 15 min and then the DNA Southern blotted as 
described in section  2.2.6.3. HSV-1 DNA was detected by hybridisation to fHSV-1pac+ 
BAC DNA, 32P labelled by nick-translation (Rigby et al., 1977; Sambrook et al., 1989). 
2.2.15 Electrophoresis Mobility Shift Assay for DNA binding 
Simultaneous large scale infections of Sf21 cells with AcUL32 and pac6 were carried out 
in 175 cm2 flasks and extracts prepared (section  2.2.9.1). Equivalent fractions were 
collected following MonoQ column fractionation of these extracts (section  2.2.9.2) and 
used for the DNA binding experiments described below. A 20 µl sample of each fraction 
was analysed by SDS-PAGE and Coomassie staining to identify fractions containing UL32 
(sections  2.2.7.1 and  2.2.7.2).  
2.2.15.1 3’ end-labelling of double-stranded DNA 
DNA fragments were excised from plasmids by restriction enzyme digestion and purified 
from agarose gels ( 2.2.3.6). The sticky ends of these fragments were filled in using DNA 
pol I Klenow fragment and a radiolabelled nucleotide as follows. Approximately 400 ng 
DNA was incubated in a 30 µl total reaction with 5 U Klenow, 1 x polymerase buffer, 0.3 
ul each of dATP, dTTP, dGTP (1 mM stocks) and 2 µl (20 µCi) α-32P dCTP for 15 min at 
37ºC. The enzyme was inactivated at 75°C for 15 min and the DNA stored at -20°C. 
2.2.15.2 Gel Electrophoresis 
The labelled DNA was diluted in H2O and approximately 4 ng DNA incubated in a total 
reaction volume of 30 µl with 1 x buffer M and 10 µl MonoQ column fraction for 30 min 
at room temperature. 6 µl loading buffer was added and the samples resolved by 
electrophoresis on a large 8% non-denaturing polyacrylamide gel in 0.5 x TBE at 200 V 
for 5 hours. The gel was then dried onto a piece of DE81 for 2 hours at 80ºC. The dried gel 
was exposed to a phosphorimage screen which was processed using a Personal Molecular 
Imager (BioRad) and analysed using Quantity One software. 
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2.2.16  Zinc binding assay 
2.2.16.1 Preparation of protein samples 
Simultaneous large scale infections of Sf21 cells with AcUL32 and pac6 were carried out 
in 175 cm2 flasks with the addition of 10 µM zinc acetate to the growth medium, and 
harvested after 48 hours (section  2.2.9.1). Soluble protein extracts were prepared and 
dialysed 4 times for one hour each against buffer A at 4°C to remove unbound zinc. These 
samples were fractionated through the MonoQ column and equivalent fractions from the 
two infections collected (section  2.2.9.2). A 20 µl sample of each fraction was analysed by 
SDS-PAGE and Coomassie staining to identify those containing UL32 (sections  2.2.7.1 
and  2.2.7.2). Protein concentrations of the fractions were determined using the Bradford 
assay (section  2.2.9.3). 
2.2.16.2 Zinc binding 
Zinc binding was measured by release of bound zinc into solution upon addition of p-
chloromercuribenzoic acid (PCMB) as follows. Duplicate 200 µl protein fractions were 
mixed with 100 µM 4-(2-pyridylazo) resorcinol (PAR), with and without 2 mM (PCMB) 
in a total volume of 300 µl. These were transferred to the wells of a 94-well microtitre 
plate and absorbance measured at 492 nm using a Titertek Multiskan Plus plate reader. The 
difference in absorbance between the samples with and without PCMB is indicative of the 
amount of zinc released by each protein sample. The zinc released was determined by 
comparison with a standard curve for known zinc concentrations processed in the same 
way. 
2.2.17 Computer software 
PSIpred (Jones, 1999)    - http://bioinf.cs.ucl.ac.uk/psipred/ 
Expasy Translate (Gasteiger et al., 2003)  - http://www.expasy.org/tools/dna.html 
PSORT (Nakai & Horton, 1999)  - http://psort.ims.u-tokyo.ac.jp/
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3 Generation of rabbit antisera reactive with the 
UL32 protein 
 
3.1 Introduction 
The planned experiments for the initial characterisation of UL32 had a requirement for a 
UL32 antiserum, particularly one which could detect UL32 from samples of HSV-1 
infected and transfected BHK cells on western blot. This chapter describes the testing of 
four already available sera and subsequent partial purification of the UL32 protein and 
generation of new polyclonal rabbit antisera. These antisera were then employed in many 
of the experiments described later in this thesis 
3.2 Testing of UL32 anti-peptide antibodies 
Four UL32 anti-peptide sera already available in the laboratory were first tested for their 
ability to recognise UL32. These had been generated by Dr. Arvind Patel (MRC Virology 
Unit), from rabbits immunised with branched peptides from either the N- or C- terminus of 
UL32. The sequences of these peptides are listed below. 
Antibodies N9 and N10: peptide 1025B – MATSPPGVLASVAV (residues 1-14 of UL32) 
Antibodies C11 and C12: peptide 1017D – RHSISLLSLEHTL (residues 580-592 of UL32) 
The ability of the anti-peptide antibodies to recognise UL32 was examined by western 
blotting. Firstly, UL32 expressed from recombinant baculovirus-infected cells was 
analysed to confirm the size and expression of the UL32 protein. A recombinant 
baculovirus expressing the UL32 protein (AcUL32) was provided by Dr. Patel. AcUL32 
contains the UL32 ORF (HSV-1 nucleotides 69159 to 67201) and expressed under the 
control of the polyhedrin promoter.   
Sf21 cells were infected with 5.p.f.u/cell AcUL32 or the parental baculovirus pac6, which 
is identical to AcUL32 except that it expresses the lacZ protein rather than UL32. The cells 
were harvested after 48 hours and lysed by boiling in the presence of SDS (1 x SDS PAGE 
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sample buffer). Samples were separated by electrophoresis on 8% polyacrylamide gels and 
proteins detected by staining with Coomassie ( 2.2.7.1 and  2.2.7.2). The resultant gel is 
shown in figure 3.1A.  
A strong band of slightly larger than 66 kDa was present in the AcUL32 infected lane (lane 
2) which was absent from the pac6 infected sample (lane 1). This band represents the 
UL32 protein, as the reported size of UL32 is 67 kDa (Chang et al., 1996). The pac6 
infected sample in contrast, showed a strong staining band corresponding to the lacZ 
protein expressed by the pac6 baculovirus (which has a reported size of 116 kDa). 
To examine whether UL32 could be detected by western blotting using the anti-peptide 
antisera, BHK cells were transfected with 1 µg pUL32 using the calcium phosphate 
method (section  2.2.1.3) or infected with 5 p.f.u./cell wt HSV-1 or hr64 (section  2.2.4.3) 
for 18 hours. Sf21 cells were infected at a multiplicity of 5 p.f.u./cell with AcUL32 or the 
parental baculovirus pac6 as described above. The cells were harvested and lysed and 
samples were separated by electrophoresis on duplicate 8% polyacrylamide gels before 
being transferred onto PVDF membranes and blocked using blocking solution (section 
 2.2.7.1). The membranes were incubated with the anti-peptide antibodies (diluted 1:500). 
This was followed by incubation with HRP-conjugated protein-A (1:1000) and the proteins 
detected using an ECL substrate (section  2.2.7.3). 
Representative membranes of samples immunoblotted with antibodies C12 and C11 are 
shown in figure 3.1, panel B. Both C12 and C11 recognised a protein in the lysate from 
AcUL32 infected Sf21 cells (lane 1), which was absent from pac6 infected cells (lane 2). 
This band corresponded in size to the UL32 band in the Coomassie stained gel in figure 3.1 
A. Thus both antibodies are capable of specifically recognising UL32. Although UL32 was 
readily apparent in AcUL32-infected cells it could not be detected in transfected BHK cells 
(lane 3). This is likely to result from a combination of the lower efficiency of transfection 
compared to infection, and that the polyhedrin promoter drives higher level expression 
than the HCMV major immediate early promoter. The transfection efficiency in these 
experiments was approximately 20% as determined by transfection with pElacZ and 
counting blue-stained cells, expressing β-galactosidase (section  2.2.1.5).  In addition, 
neither C11 nor C12 could detect the UL32 expressed from wt HSV-1 infected cells (lane 
4). Similarly both N9 and N10 specifically detected UL32 from Sf21 but not transfected or 
HSV-1 infected BHK cells (data not shown). 
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Figure 3.1: Testing UL32 anti-peptide antibodies in western blot.
A. Sf21 cells were infected with 5 p.f.u./cell AcUL32 or pac6 and harvested at 48 
hours post infection. Cell lysates were prepared and separated by electrophoresis 
on 8% polyacrylamide gels and stained with Coomassie.
B. BHK cells were transfected with 1 µg pUL32 by the calcium phosphate 
procedure (lane 3), or infected with 5 p.f.u./cell wt HSV-1 or hr64 (lanes 4 and 
5) and harvested after 18 hours. Sf21 cells were infected with 5 p.f.u./cell 
AcUL32 or pac6 and harvested at 48 h.p.i. (lanes 1 and 2). Cell lysates were 
prepared and separated on polyacrylamide gels and transferred to a PVDF 
membrane. The membranes were probed with either C12 or C11 antibodies at 
1:500 followed by HRP-conjugated protein-A (1:1000), and developed with 
ECL. The positions of markers are indicated (kDa).
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I therefore concluded that the anti-peptide antisera were probably insufficiently potent to 
be useful in further experiments and decided to generate an antiserum against the full-
length native protein. 
 
3.3 Expression of UL32 protein from baculovirus 
The expression levels and solubility of UL32 in AcUL32-infected Sf21 cells were analysed 
at different time points to optimise infection conditions for the production of protein for 
use as an immunogen. Sf21 cells were infected with 5 p.f.u./cell AcUL32, for 24, 48 or 72 
hours. After the specified time, the cells were harvested and resuspended in buffer A. An 
aliquot of the resuspended cells was retained as the total protein sample. The remainder 
was centrifuged to obtain a soluble extract (supernatant fraction). Samples of the total 
proteins and soluble extracts were analysed by SDS-PAGE and the gel stained with 
Coomassie. 
Figure 3.2 shows that UL32 was undetectable as 24 hours post infection (lane 2) but a 
strong band corresponding to UL32 was detected in large amounts at 48 and 72 hours post 
infection (lanes 3 and 4). In addition, UL32 was efficiently recovered in the soluble 
extracts at these later times (lanes 6 and 7). The slightly greater amount of soluble UL32 at 
72 hours post infection was not reproducibly observed, and it was decided to use a 48 hour 
infection to minimise problems with possible protein breakdown products. 
3.4 Partial purification of UL32 using anion exchange 
chromatography 
Anion exchange chromatography was used in an attempt to enrich the extract from 
AcUL32-infected cells for the UL32 protein prior to immunisation. This procedure 
separates proteins based upon their charge and so should allow partial purification of UL32 
from a number of other baculovirus-expressed and cellular proteins with different 
properties. 
Five 175 cm2 flasks of Sf21 cells were infected with 5 p.f.u. per cell AcUL32 and 
harvested 48 hours post infection into 5 ml total buffer A (containing protease inhibitors)  
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Figure 3.2: Expression of UL32 protein from AcUL32-infected Sf21 cells at 24-72 
hours post infection.
Sf21 cells were infected with 5 p.f.u./cell AcUL32 and harvested at 24, 48 and 72 hours 
post infection. Total proteins were harvested and soluble extracts prepared by 
centrifugation. The samples were separated on an 8% acrylamide gel and stained with 
Coomassie. The position of the UL32 protein is indicated. Lane 1 contains marker 
proteins of the indicated sizes (kDa).
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(section  2.2.9.1). Insoluble proteins were removed by ultra-centrifugation and the samples 
filtered through 0.45 µm filter. 20 µl soluble protein extract was analysed by SDS-PAGE 
followed by Coomassie staining to confirm good expression of the UL32 protein (data not 
shown).  
The chromatography was carried out using the AKTA 900 purification system and a 1 ml 
MonoQ 5/50 GL column (Amersham). The column was equilibrated with buffer A and the 
filtered protein sample applied to the column. The column was washed and the protein 
eluted with a salt gradient from 50 mM NaCl to 1 M NaCl over 60 ml (section  2.2.9.2). 0.5 
ml fractions were collected throughout the gradient. 
Figure 3.3 shows a representative trace of the UV absorbance, corresponding to protein 
concentration, for the purification. The large peak between 0-10 ml contains the flow-
through proteins that did not bind to the MonoQ column. SDS-PAGE analysis and 
Coomassie staining showed no detectable UL32 in these fractions (data not shown), 
confirming that UL32 protein bound efficiently to the MonoQ column. Various peaks can 
be seen as proteins are eluted at different salt concentrations. All fractions were analysed 
by SDS-PAGE and Coomassie staining, which demonstrated that the UL32 peak was 
eluted over fractions B13-C6, at approximately 0.3 M NaCl. Figure 3.4A shows the 
Coomassie stained gel of these peak fractions, demonstrating the presence of UL32 in 
these fractions. The identity of UL32 was confirmed by western blotting using the C12 
antibody (figure 3.4B). Inspection of figures 3.4A and B revealed that fractions B15-C2 
were most highly enriched for the UL32 protein. An equivalent MonoQ fractionation of 
soluble proteins expressed from the pac6 baculovirus showed an almost identical elution 
profile with the exception that the peak corresponding to UL32 at 27 ml was absent (data 
not shown). 
This experiment confirmed that UL32 could be successfully enriched using anion 
exchange chromatography. However, as the UL32 was to be injected into rabbits, any toxic 
compounds needed to be removed. Therefore, the purification was repeated in the absence 
of the detergent, NP40. Soluble protein from AcUL32-infected Sf21 cells was prepared and 
applied to the MonoQ column as before, but NP40 was omitted from the buffers used for 
washing and elution. Examination of the resulting fractions yielded results essentially 
indistinguishable from those obtained in the presence of NP40 (data not shown). 
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Figure 3.4: Confirmation of the presence of UL32 in peak fractions from anion 
exchange purification.
Sf21 cells were infected with AcUL32 and the cell extract purified through a MonoQ
column (see figure 3.3). Fractions were collected and analysed by SDS- PAGE and 
either Coomassie staining (A) or western blotting with anti- peptide antibody C12 
(1:500) followed by HRP- conjugated protein- A (1:1000) (B). Only fractions B13- C6, 
corresponding to the UL32 peak, are shown. Positions of size marker proteins are 
indicated (kDa).
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3.5 Production of UL32 antisera  
Three separate samples of protein were applied to the MonoQ column in the absence of 
NP40 and the peak fractions from each (seven fractions in total) pooled for use as 
immunogen. The total protein concentration was determined by Bradford assay as 
approximately 1.5 mg/ml (section  2.2.9.3). The purity of UL32 in this sample was 
estimated following SDS-PAGE analysis and Coomassie staining. Analysis of the gel 
using the "lane" function (Bio-Rad Quantity One) indicated that the UL32 peak 
corresponded to approximately 40% of the protein present in the whole lane. 
The protein sample was emulsified in adjuvant by Dr. Susan Graham (MRC Virology 
Unit) and two rabbits immunised and sera collected by Colin Hughes (University of 
Glasgow). The immunisation schedule is described in methods, section  2.2.10.1.  
 
3.6 Testing pre-immune and test-bleed sera 
A pre-immune bleed was taken from each rabbit prior to immunisation to confirm that the 
rabbits had no pre-existing antibodies that reacted against proteins of a similar size to 
UL32 that may interfere with the recognition of UL32, and also to act as a negative control 
for the recognition of UL32 by the immune sera. 
A test bleed of 5ml was taken from each rabbit one week after the third UL32 protein boost 
to ensure that the antisera produced after immunisation was able to recognise UL32. 
Both the pre-immune and test-bleed sera were harvested by clotting overnight at 4°C, 
removing the serum and then separating this from any remaining red blood cells by 
centrifugation (section  2.2.10.2). These sera were split into small aliquots and stored at -
20°C, and the pre-immune named R1-PI and R2-PI, with the test bleeds named R1-TB and 
R2-TB. All of these were then examined for reactivity against UL32 in western blots. The 
pre-immune sera were used at a much higher concentration (1:6) than the antisera to ensure 
that even low levels of pre-existing reactivity were detected. 
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3.6.1 Western blot using R1 and R2 
BHK cells were transfected with 1 µg pUL32 or pCMV10 using the calcium phosphate 
method and harvested after 18 hours. Alternatively BHK cells were infected with wt HSV-
1 or hr64 at a multiplicity of 5 p.f.u. per cell or mock infected for 18 hours. For further 
testing of the pre-immune sera, Sf21 cells were also infected with 5 p.f.u. per cell AcUL32 
and harvested 48 hours post infection. 20 µl samples of each were separated by 
electrophoresis on an 8% acrylamide gel and transferred to PVDF membranes. The 
membranes were immunoblotted with either R1-PI or R2-PI pre-immune sera at a 1:6 
dilution, or R1-TB or R2-TB antisera at a 1:500 dilution. This was followed by incubation 
with HRP-conjugated protein-A and detection using the ECL substrate. The results are 
shown in figure 3.5.  
The pre-immune serum R1-PI (panel A) recognised two protein bands of between 45 and 
66 kDa in all lanes. However, these proteins are both smaller than UL32, which migrates at 
67 kDa, and so should not interfere with the recognition of UL32 by the final antisera. 
Furthermore, there are no extra bands seen in the samples containing UL32 (lanes 3, 4 and 
6), confirming that R1-PI doesn't react against UL32. In contrast, antiserum R1-TB (shown 
in figure 3.5, panel B) clearly reacts against a protein corresponding to the reported size of 
UL32 of 67 kDa in the sample from cells transfected with pUL32 (lane 11), but not in cells 
transfected with pCMV10 (lane 12). R1-TB also detects a specific band of the same size in 
wt HSV-1 infected cells (lane 9), that is not present in cells that are infected with UL32 
null mutant hr64 (lane 8) or mock infected (lane 7). This confirms that antiserum R1 reacts 
specifically against the UL32 protein in western blots.  
Pre-immune serum R2-PI (figure 3.5C) again showed two bands between 45 and 66 kDa in 
all lanes, but showed no reaction against the UL32 protein in lanes 14 and 15. R2-PI did 
however, react against a number of extra proteins in the baculovirus-infected sample (lane 
17) at least one of which was a similar size to UL32. Antiserum R2-TB (figure 3.5D) 
reacted similarly to R1-TB, recognising UL32 protein from cells transfected with pUL32 
(lane 22) and infected with wt HSV-1 (lane 20) but showing no reaction to the samples not 
containing UL32. However, the recognition of the UL32-containing samples by R2-TB 
was somewhat weaker than that of R1-TB. These results show that both antisera can 
specifically recognise the UL32 protein in western blot. 
Chapter 3   100 
 
 
A. R1-PI
66>
97>
45>
m
o
ck
hr
64
pC
M
V1
0
pU
L3
2
w
t H
SV
-
1 
infected transfected
Ac
UL
32
1 2 3 4 5 6
pU
L3
2
pC
M
V1
0
UL32
w
t H
SV
-
1 
hr
64
m
o
ck
 
infected
66>
97>
45>
7 8 9 10 11
transfected
B. R1-TB
66>
97>
45>
12 13 14 15 16 17
m
o
ck
hr
64
pC
M
V1
0
pU
L3
2
w
t H
SV
-
1 
infected transfected
Ac
UL
32
18 19 20 21 22
66>
97>
45>
pU
L3
2
pC
M
V1
0
w
t H
SV
-
1 
hr
64
m
o
ck
 
infected transfected
C. R2-PI D. R2-TB
Figure 3.5: Testing pre-immune sera and test-bleed antisera for reaction against 
UL32.
BHK cells were infected with 5 p.f.u./cell wt HSV- 1 or hr64 or mock infected, or 
transfected with 1 µg pUL32 or pCMV10 and harvested after 18 hours. Sf21 cells were 
infected with AcUL32 at 5 p.f.u./cell for 48 hours. All samples were separated by SDS-
PAGE and immunoblotted using a 1:6 dilution of R1- PI (A) or R2- PI (C), or a 1:500 
dilution of R1- TB (B) or R2- TB (D) as indicated. This was followed by incubation 
with HRP- conjugated protein- A (1:1000) and detection using ECL. Positions of size 
markers are indicated (kDa)
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3.6.2 Immunofluorescence using R1 and R2 
The two antisera were next tested for their ability to recognise UL32 by 
immunofluorescence in transfected cells. Duplicate glass coverslips of BHK cells were 
transfected with 0.5 µg pUL32 or pCMV10 using Lipofectamine 2000 (section  2.2.1.4). 18 
hours post transfection the coverslips were treated with formaldehyde fix and 
permeabilisation solution (section  2.2.8). The cells were incubated with antibodies R1-TB 
or R2-TB (1:500 dilution) followed by r-FITC (FITC-conjugated goat anti-rabbit IgG) 
(1:200) and examined by confocal microscopy. Representative images are shown in figure 
3.6.  
Both R1-TB and R2-TB antisera showed bright fluorescence in the cytoplasm of cells 
transfected with pUL32. In contrast, when the cells were transfected with the vector 
control pCMV10, no fluorescence was seen in any cells within a whole field of view, even 
though β-galactosidase expression from cells transfected with pELacZ confirmed a high 
transfection efficiency. This indicates that both antisera can specifically detect UL32 in an 
immunofluorescence assay. 
As the test bleeds showed good reactivity to UL32, both rabbits were given one final boost 
before final bleeds of approximately 50 ml were taken. These were harvested as previously 
described and named R1 and R2. These antisera were analysed for reactivity against UL32 
in the same assays as the test bleeds. Both final bleeds reacted in an identical way to the 
test bleeds, specifically recognising the UL32 protein in both western blot and 
immunofluorescence. Again, R1 showed a stronger reaction against UL32 than R2 in the 
western blots. The antisera were stored in aliquots at -20°C. 
 
3.7 Titration of R1 antiserum in western blot 
Since R1 appeared to give a stronger UL32 signal and lower background than R2 it was 
chosen as the main antiserum against UL32, and titrated to find the optimum concentration 
for use in western blots. 
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Figure 3.6: Testing R1 and R2 antisera for their ability to recognise UL32 by 
immunofluorescence.
0.5 µg pUL32 or pCMV10 was transfected into BHK cells on glass coverslips using 
Lipofectamine 2000. 18 hours post transfection, cells were fixed with formaldehyde 
and permeabilised with NP40. Coverslips were then probed with R1 (A) or R2 (B) at 
1:500 dilution followed by r- FITC (1:200) and examined by confocal microscopy. All 
images represent the same exposure.
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Figure 3.7: Titration of R1 antibody in western blot.
A. BHK cells were transfected with 1 µg pUL32 or pCMV10 using the calcium 
phosphate method. 18 hours post transfection, cells were harvested and lysed 
and samples separated by SDS- PAGE and western blotted. Membranes were 
incubated with R1 at the indicted dilutions, followed by HRP- conjugated 
protein- A- sepharose. The positions of size markers are indicated and UL32 is 
denoted with an arrow.
B. Sf21 cells were infected with 5 p.f.u./cell pac6 or AcUL32 recombinant 
baculoviruses for 48 hours. Soluble protein extracts were prepared and 
separated by electrophoresis on an SDS- PAGE gel and immunoblotted with R1 
at the indicated dilutions. The positions of size markers are indicated and UL32 
is denoted with an arrow.
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BHK cells were transfected with 1 µg pUL32 or pCMV10 and harvested after 18 hours. 
Samples were separated by SDS-PAGE and western blotted and the membranes 
immunoblotted using R1 at the concentrations indicated in figure 3.7A. A band 
corresponding to UL32 was detected at all four antibody concentrations. This band was 
most prominent at the 1:250 and 1:500 dilutions, and much weaker when the antiserum 
was diluted to 1:1000 and 1:2000. However, a slightly higher background signal was 
present at the 1:250 dilution (as seen in the samples transfected with pCMV10). It was 
therefore decided to use R1 at a 1:500 dilution in western blots of transfected cells for the 
remainder of this work. 
The reactivity of R1 with extracts of baculovirus-infected insect cells was also examined. 
Sf21 cells were infected with 5 p.f.u. per cell AcUL32 or pac6 for 48 hours. Soluble 
extracts were prepared as previously described and duplicate samples separated by SDS-
PAGE and western blotted. Membranes were then immunoblotted with R1 at the 
concentrations indicated in figure 3.7B. The R1 antibody recognised a number of bands in 
the AcUL32 sample, many of which were also present in the pac6 samples. This is not 
surprising since the UL32 preparation used for immunisation was known to contain many 
other proteins of cellular and/or baculovirus origin, a proportion of which were likely to 
have been recognised as foreign antigens by the rabbits. These additional proteins were 
most prominent at the higher concentrations of R1 (1:500 and 1:100 dilution). The UL32 
protein is the largest band unique to the AcUL32 sample, corresponding to the reported 
size of 67 kDa. A number of smaller bands can also be seen between the sizes of 30-50 
kDa in the UL32 samples that are not present in the pac6 samples. These are likely to be 
breakdown products of the UL32 protein, which are also recognised by the R1 antiserum. 
At the 1:2000 dilution, full-length UL32 was readily detected, with a reduction in the 
intensity of some of the other bands, and therefore this dilution was chosen for western 
blots of baculovirus-expressed UL32. 
 
3.8 Discussion  
This chapter described the partial purification of UL32 and the production of two new 
antisera raised against UL32. 
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These new antisera were required because the anti-peptide antibodies against UL32 
available in the laboratory were very weak, and large amounts of protein were required for 
detection on western blot. Thus baculovirus-expressed protein but not UL32 from 
transfected or HSV-1 infected cells could be detected. 
Anion exchange chromatography provided a convenient method for the partial purification 
of UL32 from other baculovirus-expressed and cellular proteins on the basis of charge. 
This method did not completely remove other proteins, but resulted in a protein preparation 
that was approximately 40% pure, with UL32 as the predominant protein, which was 
suitable for use as an immunogen. 
Two antisera were produced, both of which specifically reacted against UL32 in western 
blots and were potent enough to achieve the initial aim of detecting UL32 in transfected 
and HSV-1 infected cells. The R1 antibody was selected for main use due to its stronger 
reactivity against UL32 relative to background signal. When used in western blots of 
baculovirus-expressed UL32, the antibodies showed reactivity against many other proteins, 
although this may be expected as other proteins were present in the immunogen sample 
injected into the rabbit. However, by using the parental control baculovirus, pac6, it was 
easy to identify bands corresponding to full-length UL32 and its breakdown products in a 
western blot. 
The new antisera also recognised UL32 in immunofluorescence assays and showed that 
UL32 localises to the cytoplasm of transfected cells. This is not surprising since HSV-1 
UL32 lacks any obvious nuclear localisation sequence (NLS) and is too large to be able to 
diffuse through the nuclear pore. A putative NLS has been identified within HCMV UL52 
which does localise to the nucleus of transfected cells (Borst et al., 2008), and the PSORT 
II sub-cellular localisation prediction program identifies a putative NLS in a number of 
other UL32 homologues within the Betaherpesvirinae (Nakai & Horton, 1999). However, 
such a sequence is absent from HSV-1 UL32 and known homologues within the 
Alphaherpesvirinae.  
The recognition of UL32 in immunofluorescence of transfected cells by the new antisera 
confirms that these polyclonal antisera can recognise the native form of UL32 as well as 
the denatured form in western blots. These antisera may therefore be useful for other 
techniques using native proteins, such as immunoprecipitation (IP). 
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4 Mutagenesis of UL32 
 
4.1 Introduction 
Although previous work has identified UL32 as a protein essential for genomic DNA 
packaging, its precise role within this pathway is still unclear. Furthermore, no large-scale 
mutagenic analysis of the protein has been carried out to identify essential regions. Thus 
far, bioinformatic analysis of the UL32 sequence has not yielded any information about the 
potential function of UL32 based on sequence similarity to other known proteins, whether 
viral or non-viral. 
This chapter describes the generation and characterisation of a panel of insertional mutants 
throughout the length of the UL32 protein. The ability of each mutant to support the 
growth and DNA packaging of a virus lacking UL32 (hr64) was investigated in order to 
identify regions of the UL32 protein essential for function. 
Further data presented in this chapter describe site-directed mutagenesis of conserved 
amino acids within UL32 and a similar analysis of the mutated proteins. 
 
 
4.2 Generation of UL32 insertional mutants 
4.2.1 Transposon-mediated mutagenesis 
Random transposon-mediated insertional mutagenesis is an extremely useful tool for 
studying relatively uncharacterised proteins. It enables rapid generation of a panel of 
mutants with insertions scattered throughout the protein to allow identification of regions 
essential for growth and function.  
The mutagenesis of UL32 was carried out using the Mutation Generation System kit from 
Finnzymes. This kit employs the transposition machinery of the bacteriophage Mu to insert 
a 1,131 bp artificial transposon (Entransposon) encoding a kanamycin resistance (kanR) 
gene into the target plasmid at random sites in a cell-free reaction (figure 4.1). The DNA is  
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MuA transposase
In vitro transposition
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Figure 4.1: Principles of the Mutation Generation System.
An in vitro reaction catalysed by the MuA transposase results in the insertion of a 
1,131 bp Entransposon (encoding kanR and containing NotI sites at either end) into the 
ampR target plasmid. This insertion may be within the target gene (as indicated here) 
or the plasmid backbone. Colonies are selected by resistance to kanamycin and 
ampicillin and plasmid DNA isolated from individual colonies. This DNA is digested 
with NotI and re- ligated to remove the bulk of the transposon leaving a 15 bp insertion. 
The plasmid DNA is retransformed back into E. coli and ampR colonies selected. 
Plasmid DNA from individual colonies is analysed by restriction digest and DNA 
sequencing to determine the position and nature of the insertions.
ampR
ampR
ampR
kanR
kanR
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then transformed into bacteria and those plasmids that have the Entransposon selected by 
growth in the presence of kanamycin. The DNA is isolated and the kanamycin resistance 
gene excised using NotI sites situated at each end of the Entransposon. The DNA is 
recircularised resulting in a 15 bp insert consisting of 10 bp derived from the Entransposon 
(encoding a novel NotI site) and a 5 bp duplication of the target site (figure 4.2).  
Insertions of 15 bp will not disrupt the reading frame of the protein and the resultant 
product should be identical to the wildtype protein except for the insertion of 5 amino 
acids. The inserted sequences do not encode a stop codon in any of the three frames, 
ensuring that none of the mutated proteins will be truncated. 
 
4.2.2 Mutagenesis of UL32 protein 
Plasmid pUL32 was generated by Arvind Patel (MRC Virology Unit). It contains an HSV-
1 fragment comprising nucleotides 69159 to 67201 cloned as an NcoI to Eco47III fragment 
into the SmaI site of pCMV10. Within pUL32, the UL32 ORF is encoded by 1791 
nucleotides (69162 – 67372 of HSV-1) and is under the control of the HCMV major 
immediate-early promoter. 
 
pUL32 was incubated in a cell-free transposase reaction for one hour as described in 
section  2.2.3.10 and the reaction transformed into electrocompetent E. coli DH10 cells 
(GeneHogs; Invitrogen Ltd.). Plasmids containing the transposon were selected by growth 
in the presence of ampicillin and kanamycin. 293 colonies were picked and DNA prepared 
by the boiling lysis method (section  2.2.3.2).  
As the inserted Entransposon is 1,131 bp, digestion with XbaI and KpnI, which cleave near 
to either end of the UL32 gene, was used to screen whether the insert was within the UL32 
gene or the plasmid backbone. Figure 4.3A shows the positions of the KpnI and XbaI sites 
in pUL32. Integration of the Entransposon into the backbone should generate fragments of 
4954 and 1973 bp, whereas integration into the UL32 containing fragment should result in 
fragments of 3823 and 3104 bp.  
Figure 4.3B is a representative gel of this screen and the different restriction profiles 
obtained upon insertion of the Entransposon into either the plasmid backbone or the UL32 
gene. Of these nine plasmids, the two marked with asterisks (lanes 3 and 9) generated  
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5’ NNNVWXYZNNN 3’
3’ NNNVWXYZNNN 5’
5’ NNNVWXYZTGCGGCCGCAVWXYZNNN 3’
3’ NNNVWXYZACGCCGGCGAVWXYZNNN 5’
A = Ile, Met, Thr, Asn, Lys, Ser, Arg
X = any amino acid
X* = any amino acid except Gln, Glu, Lys, Met, Trp
A.
B.
Figure 4.2: Sequence of insertions generated by the MGS.
A. The randomly selected 5 bp target site is shown in orange and is duplicated 
during the transposition reaction. After NotI digestion, 10 bp of the 
Entransposon remains forming the short insert (blue). The box indicates the 
inserted NotI site, with the arrows indicating where the enzyme cleaves and the 
DNA is re- ligated.
B. The frame in which the Entransposon is inserted and the sequence of the target 
DNA will determine the precise sequence of amino acids inserted. This table 
shows the 15 bp insert and translation of this in all three frames. 
Duplication of target site
10 bp remains of Entransposon
Randomly selected target site
XXAlaAlaAlaX*XX
YZNVWXGCAGCCGCGYZTVWXNNNFrame 3:
XXHisGlnProArg
Leu
Met
Val
XX
ZNNWXYCAVCCGCGGZTGWXYNNVFrame 2:
XXAArgGlyCysXX
NNNXYZAVWCGCGGCTGCXYZNVWFrame1:
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Figure 4.3 : Screening for transposon insertions within pUL32.
A. Plasmid map of pUL32, showing the positions of XbaI and KpnI sites and the sizes 
of fragments generated in a double digest with these enzymes.
B. A representative 0.8% agarose gel of transposon-containing plasmid DNAs
digested with KpnI and XbaI, showing two populations, in agreement with the 
fragments predicted above. The size and identity of each fragment is indicated and 
the positions of DNA markers are shown.
UL32
pUL32
5796 bp
KpnI
XbaI
KpnI-XbaI = 1973bp
Remainder of vector = 3823bp
A.
UL32 + t (3104bp)
vector (3823bp)
UL32 
(1973bp)
pCMV10 + t 
(4954bp)
* *
B.
1 2 3 4 5 6 7 8 9
1000bp>
6000bp>
2000bp>
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fragments consistent with the predicted of sizes 3823bp and 3104bp, for the 1131bp 
transposon inserted within the UL32 gene. The remaining seven plasmids generated 
fragments consistent with the transposon inserted within the vector. In total 39 plasmids 
were identified with the Entransposon inserted within the UL32 fragment. An aliquot of 
each of these 39 plasmids was digested with NotI to excise the Entransposon and then re-
ligated before being transformed into E. coli DH10 cells. Colonies were selected with 
ampicillin, picked and final DNA plasmid preparations made by boiling the lysis method 
as before. 
4.2.3 Position of insertions within UL32 
The approximate positions of insertions within the UL32 gene were first determined by 
digestion of the transposon-containing plasmids with NotI and XbaI. The XbaI site is 176 
bp downstream from the 3' end of the UL32 ORF. This digest should generate 3 fragments; 
the 1,131 bp transposon, a fragment of up to 2 kb indicating the distance of the insertion 
from the XbaI site near the 3' end of the UL32 fragment, and a third fragment of between 
3.8 and 5.8 kb containing the vector backbone. Figure 4.4 shows a representative gel of 15 
mutants digested with XbaI and NotI. Lane 1 shows pUL32 which is linearised with XbaI 
but not cleaved by NotI. The Entransposon can be seen in all other lanes and the location 
of the transposon relative to the 3' end of the UL32 gene is shown by the smaller of the two 
other fragments, with the larger being the vector backbone. This enabled the approximate 
position of all 39 inserts to be determined. 
Six primers (5240, UL32F1, UL32F2, UL32F3, UL32F4, and UL32R1) were designed to 
span the entire length of the UL32 gene and the positions and sequences of these primers 
are shown in figure 4.5. The appropriate primer was used to sequence the region of each 
final mutant plasmid from which the Entransposon had been excised. Once it had been 
established that each mutant contained the expected 15 bp insertion, the full UL32 
sequence of each mutant was determined using all six sequencing primers. 
In each case a 15 bp insertion was present consisting of a duplication of the target sequence 
and the 10 bp sequence TGCGGCCGCA derived from the Entransposon. The position and 
sequence of each insert within the UL32 gene is shown in figure 4.6. For consistency the 
first nucleotide of the 15 bp insertion is considered as the T residue of the sequence 
TGCGGCCGCA with the target sequence duplication being at the 3' end of the insert.  
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Figure 4.4: Mapping the position of insertion of transposon into pUL32 mutants.
Plasmid DNA of pUL32 and all mutants prior to excision of the transposon was 
digested with XbaI and NotI and fragments separated on a 0.8% agarose gel and 
visualised under UV light. This is a representative gel showing the position of the 
transposon within a selection of clones. The positions of the transposon is shown and 
positions of size markers are indicated.
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A.
B.
CACCACAGAAGTAAGGTTCCUL32R1
GTTTGTGAGCCTGCTTCGUL32F4
GCTGATGAACTGGAAGGATTGCUL32F3
TCTCTGTGCCAAATGCCTGGUL32FR
CGTATGTGGCCTTCGATCCUL32F1
CCATTGACGCAAATGGGC5240
5' - 3' sequence
Figure 4.5: Position and sequence of primers used for sequencing of UL32 mutants.
A. Plasmid map of pUL32 showing the positions of the six primers used to sequence 
the whole of the UL32 gene for all of the UL32 transposon mutants
B. 5’ – 3’ sequences of these sequencing primers. All primers give reads 
corresponding to the sense strand except UL32R1, which is complementary.
pUL32
5240
UL32F1
UL32F2
UL32F3
UL32F4
UL32R1
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Apart from the 15 bp insert, the full DNA sequence of each clone was identical to that of 
the wt UL32 gene of pUL32. 
Each DNA sequence was next translated using the Expasy Translate program and 
compared to the wt UL32 protein sequence using the ClustalX alignment programme to 
identify the position and sequence of each 5 amino acid insertion. As the insertion can be 
in any of the three frames and also involves the duplication of part of the target sequence, 
there is variation between the inserted amino acids in different mutants. The sequence of 
the amino acid insertion within each mutant protein is shown in table 4.1. Each mutant was 
named according to the last unaltered amino acid before the insertion and will be referred 
to as such for the remainder of this thesis. Clones 17 and 77, and 117 and 277 had identical 
insertions at the same points in the protein and only one clone of each pair (17 and 277 
respectively) was selected for further characterisation. The positions of each insertion 
within the UL32 protein are shown in figure 4.7. 
After sequencing of all of the mutants, 1 µg of each was again digested with NotI and XbaI 
and separated on a gel to confirm that the inserted NotI site was in the expected position 
and that the transposon had been excised. Figure 4.8 shows the digest patterns for a 
selection of clones with inserts between amino acids 378 and 485. As expected, the nearer 
the insertion to the C-terminus of UL32 the smaller the NotI-XbaI fragment.  
4.2.4 Expression of UL32 mutant proteins 
Having verified the DNA sequences of the insertional mutants, it was important to check 
that the encoded proteins were of a similar size to wt UL32 and expressed at similar levels. 
1 µg each plasmid was transfected into BHK cells by the calcium phosphate method as 
described in section  2.2.1.3. 18 hours post transfection, cells were harvested and lysed and 
the proteins separated on an 8% polyacrylamide gel. These were transferred to PVDF 
membranes which were reacted with R1 antibody against UL32, followed by HRP-coupled 
protein-A and developed using ECL as previously described. To verify similar amounts of 
sample were loaded in each well, the membranes were stripped and reprobed with a 
monoclonal antibody recognising actin (AC-40), followed by HRP-conjugated goat anti-
mouse IgG. 
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Table 4.1: Position of each insertion and sequence of amino acid insertion.
The position of the inserted DNA sequence for each clone was determined by sequencing 
and compared to the sequence of the UL32 gene in pUL32 (figure 4.6). The full DNA 
sequences for each clone were then translated to the protein sequence using Expasy
Translate program. The inserted amino acids for each clone are listed. Each protein mutant 
was renamed  according to the last unaltered amino acid. Those shown in red contained 
exactly the same insertion in the same position as another mutant.
Clone number Inserted amino acids Mutant designation
21 PAAAP in5
163 AAAAV in12
131 CGRIL in40
81 VAAAH in55
56 CGRNE in67
121 GAAAR in93
256 CGRRG in95
123 CGRKL in136
166 VRPHC in155
113 CGRMY in177
281 NAAAK in187
20 AAAAF in198
288 VAAAG in220
130 LRPQP in232
249 VRPQR in302
248 MRPHC in309
174 DAAAP in328
45 VRPQP in332
274 CGRNA in338
116 GAAAR in376
11 CGRSG in377
17 CGRSG in378
77 CGRSG NONE
34 DAAAP in398
140 TAAAA in407
206 CGRSR in414
19 LRPHW in435
182 DAAAS in449
49 CGRTG in475
102 AAAAA in486
8 CGRTE in490
138 CGRIK in494
253 CGRIC in498
33 VRPHW in512
277 VRPHQ in558
117 VRPHQ NONE
95 CGRIR in572
238 HAAAR in580
292 CGRTL in592
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Figure 4.8:  Position of insertions within UL32 mutant plasmids.
A representative gel showing the positions of the insertion in mutant plasmids in378 to 
in485. 1 µg each plasmid was digested with XbaI and NotI and separated on a 0.8% 
agarose gel. The small fragment liberated in each lane indicates the distance between the 
insert and the end of the UL32 gene, with decreasing size showing the insertion lies further 
towards the 3’ end of the gene. Positions of size markers are indicated.
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Figure 4.9 shows the western blots of cells transfected with each of the 37 mutants. As 
previously seen, R1 reacts with a protein of approximately 67 kDa, which is not seen in the 
cells transfected with pCMV10 empty vector. All of the insertional mutants produced a 
protein of the expected size and accumulated to similar levels to wt UL32 in transfected 
cells, indicating that their stability is not significantly affected. The actin staining confirms 
that similar amounts of protein were loaded in each well. 
4.2.5 Localisation of UL32 mutant proteins 
The localisation of transfected wt UL32 and all of the mutants was examined by 
immunofluorescence to determine whether any of the mutants differed in their localisation 
compared to wt UL32. BHK cells on coverslips were transfected with 0.5 µg pUL32, 
pCMV10 or each mutant plasmid using Lipofectamine 2000 (section  2.2.1.4). 18 hours 
post transfection the coverslips were fixed and permeablilised with formaldehyde and 
NP40 as previously described. The cells were incubated with antibody R1 followed by r-
FITC (FITC-conjugated goat anti-rabbit IgG) and examined by confocal microscopy. 
Images are shown in figure 4.10. As previously shown, wt UL32 localises to the cytoplasm 
of transfected cells. No fluorescence was seen in the cells transfected with the empty 
vector, pCMV10 (figure 4.10A). Again, each of the mutant plasmids clearly expressed 
protein and all of these showed similar cytoplasmic localisation to wt UL32 (figure 4.10B). 
 
4.3 Ability of mutants to complement growth of hr64 
The functionality of the mutated proteins was first assessed by analysis of their ability to 
complement the growth of the mutant virus hr64 in a transient complementation assay 
(section  2.2.5). BHK cells were transfected with 1µg of plasmids pUL32, pCMV10 or the 
insertional mutants using the calcium phosphate method. Six hours post transfection, the 
cells were superinfected with 5 p.f.u. per cell hr64. After one hour, the virus that had not 
penetrated the cells was neutralised with an acid glycine wash. 18 hours post infection, the 
cells and media were harvested and sonicated. The viral progeny were titrated on the 
complementing cell line, UL32-5. The plates were incubated for 4 days at 37°C, stained 
and plaques counted. This assay was repeated for each mutant and the ability of each to 
complement the growth of hr64 determined by comparison of the yields obtained to that  
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Figure 4.9: Expression of insertion mutants.
BHK cells were transfected with 1 µg pUL32, pCMV10 or plasmids encoding the insertional 
mutants by the calcium phosphate method. 18 hours post transfection cells were harvested and 
the lysates resolved by electrophoresis on 8% polyacrylamide gels. Samples were transferred 
to PVDF membranes and blotted with antibody R1 (1:500) followed by HRP-couple protein-
A (1:1000), and developed with ECL. Membranes were then stripped and reprobed with a 
monoclonal antibody recognising actin (AC-40; 1:500) and HRP-conjugated goat anti-mouse 
IgG (1:1000) to confirm equal loading in each lane.
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in414
Figure 4.10: Localisation of UL32 insertion mutants within transfected cells.
0.5 µg the indicated plasmid DNA was transfected into BHK cells using Lipofectamine 2000. 
18 hours post transfection, cells were fixed with formaldehyde and permeabilised with NP40. 
Coverslips were then probed with antibody R1 (1:500) followed by r-FITC (1:200) and were 
then examined by confocal microscopy. Scale bar = 20 µm.
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obtained with pUL32. The mean value for each mutant is shown in figure 4.11, expressed 
as a percentage of the mean yield obtained with pUL32. 
The empty vector pCMV10 was not able to support growth of hr64 on BHK cells, giving 
very low background titres of virus. Plasmid pUL32 complemented the growth of hr64 
efficiently, giving titres ranging from 1.3 x 104 to 9.2 x 104 p.f.u., which were over 100 
fold greater than those with pCMV10. 15 of the 37 mutants showed clear complementation 
of hr64, all giving yields of over 10% compared to pUL32. Nine of these, mutants in5, 
in12, in93, in95, in302, in328, in376, in377 and in378 gave values between 20-100% of wt 
UL32. Six of the mutants (in67, in187, in220, in232, in332 and in475) gave titres that were 
above those seen with pUL32, but none of these differences were greater than two-fold and 
are probably insignificant. The remaining 22 mutants did not complement the growth of 
hr64, having titres of less than 10% of that of pUL32. These were mutants in40, in55, 
in136, in155, in177, in198, in309, in338, in398, in407, in414, in435, in449, in486, in490, 
in494, in498, in512, in558, in572, in580 and in592. This lack of complementation was 
unlikely to be due to low levels of UL32 expression as the repeat experiments were 
performed on different occasions with different batches of cells, which should rule out any 
differences in expression levels. 
These results show, that there is variation in the ability of the mutants to complement the 
growth of hr64 and identify essential regions throughout the protein. Of the 10 insertions 
within the N-terminal portion of the protein (residues 1-177), 5 generated functional 
proteins. 9 of the 12 insertions in the central portion (residues 187 – 378) were tolerated. In 
contrast, only 1 of 15 mutations (in475) in the C-terminal portion (residues 398 – 592) was 
functional in this assay. This suggests that the C-terminal third of the protein is particularly 
critical for its function, although mutants that disrupted function were present in other parts 
of the molecule. 
 
4.4 Ability of mutants to complement DNA packaging  
4.4.1 Amplicon packaging assay 
The ability of each mutant UL32 protein to support DNA encapsidation was next tested 
using an amplicon packaging assay. This assay makes use of an amplicon plasmid (pSA1) 
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containing a minimal packaging signal (Uc-DR1-Ub) and HSV-1 origin of replication oriS 
(Stow et al., 1983). These features allow the amplicon to be replicated as a concatemer and 
packaged in the presence of wt HSV-1 helper virus. The amplicon plasmid is transfected 
into cells, and wt or mutant HSV-1 superinfected to provide the helper functions. Total and 
DNase resistant DNA samples are harvested from these cells, digested, Southern blotted 
and probed for the presence of the amplicon using 32P labelled DNA. All of the replicated 
amplicon DNA will be detected in the total DNA samples, whereas only packaged 
amplicon DNA, which is protected from DNase treatment by the viral capsid and so will be 
present in the DNase-treated samples.  
In addition, unreplicated input pSA1 can be cleaved into small fragments by DpnI since the 
plasmid DNA is fully dam methylated. Following replication in mammalian cells this 
methylation is lost and the DNA becomes resistant to DpnI thereby allows essentially zero 
background signal levels from input molecules to be obtained (Hodge & Stow, 2001; 
Nasseri & Mocarski, 1988).  
Figure 4.12 shows the result of a packaging assay confirming that provision of wt UL32 is 
required for packaging of amplicon DNA by hr64. BHK monolayers were transfected with 
1 µg pUL32 or pCMV10 along with 0.5 µg pSA1 using the calcium phosphate method as 
described. Six hours post transfection the cells were infected with 5 p.f.u./cell hr64 or wt 
HSV-1. Total and DNase resistant DNA were harvested as described in section  2.2.6.2. 
These samples were digested with EcoRI and DpnI and separated on a 0.8% agarose gel. 
The gel was Southern blotted and probed using 32P labelled pAT153, which is the parental 
vector for pSA1. The EcoRI digestion linearises pSA1, producing a band of approximately 
4.4 kbp. 
Lane 1 shows cells that were transfected with pUL32 but not superinfected, and therefore 
neither replication nor packaging of pSA1 is seen. Infection with wt HSV-1 allowed both 
replication and packaging of the amplicon DNA (lane 2).  As expected, pSA1 was 
replicated to equivalent levels in the hr64 infection in the presence of either the empty 
vector or pUL32, confirming that hr64 does not have a defect in DNA replication (lanes 3 
and 4). In contrast, packaged amplicon DNA was detected in the cells that received pUL32 
but not the empty vector pCMV10. 
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Figure 4.12: Packaging of amplicon DNA in the presence of hr64.
BHK cells were transfected with 0.5 µg pSA1 along with 1 µg either pUL32 or pCMV10 
using the calcium phosphate method. The cells were superinfected with 5.p.f.u./cell wt 
HSV-1 or hr64, harvested 18 h.p.i., and total and packaged DNA prepared. DNA was 
digested with EcoRI and DpnI and separated by agarose gel electrophoresis before being 
Southern blotted. pSA1 was detected by probing with 32P labelled pAT153.
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4.4.2 Ability of mutants to support amplicon DNA packaging in 
hr64 infected cells 
The ability of the mutants to support packaging of amplicon DNA was tested as above and 
the results are shown in figure 4.13. The amount of pSA1 packaged by each mutant was 
determined by densitometric analysis of the bands on the phosphorimage and compared to 
that packaged in the presence of wt UL32, and the values of repeated experiments are 
shown in table 4.2.  
As before, packaged amplicon DNA was detected in hr64 infected cells transfected with 
pUL32 but not pCMV10 in each experiment. DNA replication was not affected in cells 
transfected with any of the UL32 mutants. 15 of the mutants supported packaging of the 
amplicon DNA, with values of packaged pSA1 over 50% of that shown with pUL32. 
These were the mutants in5, in12, in67, in93, in95, in187, in220, in232, in302, in328, 
in332, in376, in377, in378 and in475. The remaining 22 mutants did not support DNA 
packaging (values of less than 10% of wt UL32). Some mutants showed a faint band of 
DNase resistant DNA, for example mutant in309 and in407, due to the long 
phosphorimage. However, when quantified, these values were very low (less than 10% of 
that seen with pUL32) and repeated experiments with these mutants showed no significant 
packaging of DNA. 
These results show there is complete correlation between the ability of mutants to support 
viral growth and their ability to package amplicon DNA. 
4.4.3 Dominant negative inhibition of packaging in wt HSV-1 
infected cells 
It was possible that one or more of the mutants that were unable to package amplicon DNA 
or complement viral growth might act as a dominant-negative inhibitor of the DNA 
packaging pathway.  
To investigate this possibility, BHK cells were transfected with 1 µg each UL32 plasmid 
and 0.5 µg pSA1 as before, but superinfected at 5 p.f.u. per cell with wt HSV-1. Total and  
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Figure 4.13: Ability of insertional mutants to package amplicon DNA.
BHK cells were transfected with 0.5 µg pSA1 and 1 µg of the indicated plasmid using the 
calcium phosphate procedure. Cells were superinfected with 5p.f.u./cell hr64, harvested 18 
h.p.i. and total and packaged DNA prepared. DNA was digested with EcoRI and DpnI and 
separated by agarose gel eletrophoresis before being Southern blotted. pSA1 was detected by 
probing with 32P labelled pAT153.
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Table 4.2: Quantification of the ability of mutants to package amplicon DNA.
Phosphorimages from 2 separate amplicon packaging experiments were quantified using 
Quantity One software. The amount of pSA1 packaged in each experiment was quantified 
according to total counts/mm2 in each band of DNase resistant DNA. Each of these was 
expressed as a percentage of the values obtained when pUL32 was used to support DNA 
packaging.
mutants Experiment 1 Experiment 2 Mean
pUL32 100 100 100.00
pCMV10 1.14
in5 99.3 109 104.15
in12 168 184.6 176.30
in40 6.9 6.6 6.75
in55 0.5 1.41 0.96
in67 45.2 100 72.60
in93 55.1 82 68.55
in95 56.4 136.6 96.50
in136 9.5 0.8 5.15
in155 1.1 0.2 0.65
in177 3.7 3.9 3.80
in187 183.3 189.3 186.30
in198 4.67 0 2.34
in220 187 80 133.50
in232 103 83.8 93.40
in302 51.5 108 79.75
in309 8.1 0 4.05
in328 56.9 59.7 58.30
in332 96 83.8 89.90
in338 7.5 0.8 4.15
in376 87 120 103.50
in377 110.4 85.6 98.00
in378 248.6 78.1 163.35
in398 4.95 2.05 3.50
in407 9.6 0.6 5.10
in414 8.3 2.4 5.35
in435 6.7 4 5.35
in449 2.3 8.4 5.35
in475 85.5 51.7 68.60
in486 0 4.55 2.28
in490 0.8 8.7 4.75
in494 1.15 0 0.58
in498 3.8 2.5 3.15
in512 1.45 0 0.73
in558 0.1 0 0.05
in572 0.4 0.8 0.60
in580 6.9 4.8 5.85
in592 0 0 0.00
% packaged compared to pUL32
0.28 2.0
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DNase resistant DNA was prepared and the samples processed, Southern blotted and 
probed with 32P-labelled pAT153 as above. 
As shown in figure 4.14, transfection of the UL32 mutants did not greatly affect the 
replication levels of pSA1. Amplicon packaging was seen in cells infected with wt HSV-1, 
and addition of the plasmid encoding wt UL32 had no effect on packaging of pSA1. 
Although there was some variation in the levels of total and packaged amplicon it is clear 
that none of the mutant proteins is a potent inhibitor of the function of wt UL32 expressed 
by the superinfecting virus. 
 
4.5 Site specific mutagenesis of conserved CxxC/CxxxC 
motifs 
4.5.1 CxxC/CxxxC motifs 
As discussed in the introduction, HSV-1 UL32 is a very cysteine rich protein with 22 Cys 
residues throughout its length. Many of these are highly conserved within the 
Herpesviridae (with seven being completely conserved), including three CxxC/CxxxC 
motifs which are present in almost all currently known herpesvirus UL32 sequences. The 
first of these motifs has the sequence CLVC in HSV-1 UL32 and corresponds to amino 
acids 127-130. The two cysteine residues are completely conserved in all herpesvirus 
sequences, and the residue at position three is always valine, leucine or isoleucine. The 
second CxxC motif has the sequence CLLC at amino acids 422-425 in HSV-1 UL32, and 
the cysteines and second leucine are completely conserved. The final motif is found at 
amino acids 497-501 in HSV-1 and has the sequence CDPMC. The first cysteine is 
conserved with the exception of murid herpesviruses 1 and 2. The aspartic acid and second 
cysteine are completely conserved, as is the proline, with the exception of the VZV 
homologue in which it is a leucine. The high degree of conservation of all of these residues 
suggests an important role in the function of the UL32 protein. 
This section describes the site-specific mutagenesis of each of these conserved 
CxxC/CxxxC motifs in turn and the functional analysis of these mutants. 
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Figure 4.14: Ability of insertion mutants to act as dominant-negative packaging 
inhibitors.
BHK cells were transfected with pSA1 along with each indicated plasmid using the calcium 
phosphate method. Cells were superinfected with 5 p.f.u./cell wt HSV-1, harvested 18 h.p.i., 
and total and DNase resistant DNA prepared. Samples were digested, separated on an agarose 
gel and Southern blotted as described previously. pSA1 was detected by hybridisation to 32P 
labelled pAT153 probe. 
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4.5.2 Construction of CxxC/CxxxC mutants 
In order to easily create specific mutations in each of the CxxC/CxxxC motifs, a PCR-
based approach was used, summarised in figure 4.15.  
 Two pairs of primers were designed for each motif, which encoded serines in place of the 
cysteines (SxxS/SxxxS), and introduced a novel restriction enzyme site to facilitate 
screening. These primers also spanned unique restriction sites at either end of the fragment 
for use in subsequent cloning steps (UL32CxxC1: PmlI and NheI, UL32CxxC2: XhoI and 
NheI, UL32CxxxC3: XhoI and PstI). The sequences of these primers are shown in table 4.3 
below. First round PCRs using primer pairs F1-R1 and F2-R2 generated two fragments for 
each motif which overlapped at the mutated sequences. These fragments were annealed 
and amplified using the outside primers (F1 and R2) to generate a large fragment 
containing the mutated sequences. The large PCR products were inserted into pGEM T 
sub-cloning vector to facilitate further cloning, and white colonies (containing the PCR 
product) selected (section  2.2.3.9). These colonies were screened for the presence of the 
inserted novel restriction site. The fragments were then excised from the sub-cloning 
vector by cleavage with the appropriate restriction enzymes and ligated into pUL32 
digested with the same enzymes. Plasmid DNA was prepared using a Qiagen QIAprep 
Spin Miniprep kit, screened for presence of the novel restriction enzyme site and 
sequenced to confirm that only the desired nucleotide substitutions were present.  
Chapter 4   136 
 
 
SxxS
SxxS
X
Y
Z
R2
F1
SxxSX Y
Z
SxxS
SxxS
CxxCX Y
Z
Z
F1
F2
R1
R2
X
Z
Y
pGEM
T vec
β-galactosidase
First round PCRs, denaturation
and annealing of products
Second round of PCR
Ligation into pGEM T vector,  
selection of white colonies
 
Chapter 4   137 
 
 
Figure 4.15: Generation of site-specific CxxC/CxxxC mutants.
Site specific mutations were introduced into the CxxC/CxxxC motifs by a two-step PCR 
approach. The first round of PCR used primer pairs F1-R1 and F2-R2. Primers F2 and R1 
specified the mutated sequence to be inserted (SxxS/SxxxS), and a novel restriction site (Z). 
Primers F1 and R2 incorporated unique restriction sites at each end (X and Y). Two PCR 
products were generated which overlapped at the mutated sequences. These were dentaured
and reannealed and amplified by PCR using the outside primers (F1 and R2) to produce a 
complete fragment with the mutated site. The PCR product was inserted into a sub-cloning 
vector (pGEM T vector) which was transformed into E. coli and colonies with the PCR insert 
distinguished by blue-white screening. The PCR product was then excised from the T vector 
by digestion with enzymes X and Y and ligated into pUL32 digested with the same enzymes. 
This was transformed back into E. coli and plasmid DNA from individual colonies prepared, 
screened for presence of the novel restriction site and sequenced.
X
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  5' - 3' sequence   
UL32CxxC1 
  
inserted 
site 
CxxC1F1 CACGTGATAGGTGTGCCGCCCGTC   
CxxC1R1 GGTGCGGGAGACCAGGGAGGGCCGGTCTAGAGCGAAGGTGTCGA TGGCCGC XbaI 
CxxC1F2 GCTCTAGACCGGCCCTCCCTGGTCTCCGGCACCATCGAGCTGTAC AAGCAAACC XbaI 
CxxC1R2 CACGAAGATGCTAGCGGCGCAGTG   
UL32CxxC2 
  
  
CxxC2F1 CCCACTGCGCCGCTAGCATCTTCGTGGCC   
CxxC2R1 CAGGTTGGACAGCAGGGATTCTCCGCCGCTGCGCCCGCG HinfI 
CxxC2F2 GGAGAATCCCTGCTGTCCAACCTGTTACTGGTGCGTGCTTAC TGGCTGGCCC HinfI 
CxxC2R2 GGGTCAGCCTCGAGCTGGTCGACGACGGG   
UL32CxxxC3 
  
  
CxxxC3F1 CGACCAGCTCGAGGCTGACCCCGA   
CxxxC3R1 AATGGCGGACATGGGATCCGAGAACATGTGCTTAAAGATGGCC TCGGGCCC BamHI 
CxxxC3F2 ATGTTCTCGGATCCCATGTCCGCCATTACGGAGATGGAGGTT GACCCCTGG BamHI 
CxxxC3R2 GATCCCAAGCTTGCATGCCTGCAGGTCGAC   
 
Table 4.3: Sequences of primers used for generating CxxC/CxxxC mutants.  
5’-3’ sequences of the primers designed for generation of CxxC/CxxxC mutants. The 
sequences encoding the mutated serine residues are shown highlighted in red. The novel 
restriction sites used for screening of the products are underlined and denoted in the right 
hand column. The unique restriction sites near the end of the PCR fragments used for 
further cloning are indicated in blue. 
 
 
4.5.3 Expression and localisation of CxxC/CxxxC mutants 
As with the transposon mutants, the expression level of each CxxC/CxxxC mutant was 
compared to wt UL32 in a transfection assay. BHK cells were transfected with 1 µg each 
plasmid by the calcium phosphate method and harvested at 18 hours. The samples were 
analysed by western blotting with antibody R1 and HRP-conjugated protein-A as before 
and the results shown in figure 4.16A. All three of the CxxC/CxxxC mutants express 
similar levels of polypeptides that are recognised by R1. Re-probing the blot with the actin 
antibody confirmed that similar levels of protein were loaded in each case. 
The localisation of these mutant proteins in transfected cells was also examined compared 
to wt UL32. Coverslips of BHK cells were transfected with 0.5 µg each plasmid and  
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Figure 4.16: Transfection of CxxC/CxxxC mutants.
A. BHK cells were transfected with 1 µg pCMV10, pUL32 or mutant plasmid DNA 
using the calcium phosphate method. 18 hours post transfection, cell lysates were 
prepared and samples were separated by SDS-PAGE then western blotted as 
previously described. Membranes were probed with antibody R1 (1:500) followed by 
HRP-conjugated protein-A (1:1000). Blots were then stripped and reprobed for actin 
as a loading control. 
B. 0.5 µg plasmid DNA was transfected into BHK cells using Lipofectamine 2000. 18 
hours post transfection, cells were fixed with formaldehyde and permeabilised with 
NP40. Coverslips were then probed with R1 (1:500) followed by r-FITC (1:200) and 
examined by confocal microscopy. Scale bar = 20 µm.
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processed at 18 hours post transfection as described previously. The coverslips were 
incubated with R1 followed by r-FITC, and analysed by confocal microscopy. The results 
are shown in figure 4.16B. Again, there seems to be no difference in the localisation of any 
of the CxxC/CxxxC mutants compared to wt UL32, with all four proteins localising 
throughout the cytoplasm. 
4.5.4 Ability of CxxC/CxxxC mutants to complement growth of 
hr64 
The ability of the CxxC/CxxxC mutants to support the growth of hr64 virus was examined 
using the complementation yield assay as previously described in section  4.3.  
The results of duplicate experiments are shown in figure 4.17A. The values for each 
mutant are a mean of the duplicate experiments and are expressed as a percentage of that 
obtained with pUL32. 
pUL32 complemented the growth of hr64, giving a mean titre of 6 x 105 p.f.u., compared 
to a value of 7x102 with the empty vector pCMV10. Mutants UL32CxxC1 and 
UL32CxxxC3 were not able to support viral growth significantly better than the empty 
vector, resulting in yields that were 1.1% and 1.9% of that obtained with pUL32, 
respectively. Interestingly, mutant UL32CxxC2 retained some function in this assay, 
giving titres of almost 18% of that obtained with pUL32.  
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Figure 4.17: Function of CxxC/CxxxC mutants.
A. Complementation yield assay. BHK cells were transfected and superinfected as 
described in the legend to figure 4.11. 18 h.p.i., progeny was harvested and titrated 
on UL32-5 cells for 4 days. Plaques were counted and titres expressed as a 
percentage of those obtained with wt UL32. The red squares and blue triangles show 
the results from duplicate independent experiments, and the light blue bars show the 
mean values.
B. Amplicon packaging assay. Cells were transfected with the indicated plasmids and 
superinfected as described in the legend to figure 4.12. Total and DNase resistant 
DNA were prepared and processed as described in section 2.2.6.2 and pSA1 was 
detected by hybridisation to 32P labelled pAT153.
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4.5.5 Ability of CxxC/CxxxC mutants to support amplicon DNA 
packaging in hr64 infected cells 
The three cysteine mutants were also tested for their functionality in the amplicon DNA 
packaging assay as previously described. The phosphorimage results are shown in figure 
4.17B, and the mean values for two replicate packaging assays expressed as a percentage 
of the packaging in the presence of pUL32 are shown below: 
 
% packaged compared to wt UL32  
  Experiment 1 Experiment 2 Mean  
pUL32 100 100 100 
pCMV10 0.2 1.5 0.85 
UL32CxxC1 0 11.5 5.75 
UL32CxxC2 12.5 35.8 24.15 
UL32CxxxC3 0 0.3 0.15 
 
Table 4.4: Quantification of the ability of CxxC/CxxxC mutants to package amplicon 
DNA. 
The amounts of packaged DNA from two separate experiments were quantified according 
to total counts/mm2 in each DNA band from the phosphorimage. Each was expressed as a 
percentage of the values of packaged DNA seen in the cells where pUL32 was used to 
support DNA packaging. 
 
 
As expected, DNA packaging occurred following infection with wt HSV-1 or hr64 
infection in the presence of pUL32 but not pCMV10. Consistent with the complementation 
yield assay results, neither UL32CxxC1 nor UL32CxxxC3 supported DNA packaging. In 
contrast some packaged DNA was observed with UL32CxxC2. Quantitation of these 
results showed that UL32CxxC2 packaged pSA1 to a level of approximately 25% of that 
obtained with pUL32. This is consistent with the complementation yield results indicating 
that a protein mutated in the central CxxC motif retains limited function, suggesting that 
these highly conserved cysteine residues are not absolutely essential for UL32 function.   
 
4.6 Deletion of the C-terminus of UL32 – UL32∆C 
One further site specific mutant was created, which contained a deletion of the C-terminal 
four amino acids of UL32. The extreme C-terminus has previously been implicated as 
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essential for the function of the homologous HCMV protein UL52 (Borst et al., 2008). 
These workers constructed a BAC genome with an HA tag inserted immediately following 
the last codon of UL52 and found that the resulting DNA was non-infectious. In addition, 
this tagged UL52 protein had an altered localisation upon transfection of the BAC DNA 
into cells. Whilst wt UL52 was found to localise predominantly to the nucleus, the 
disruption of the C-terminus resulted in localisation throughout the cell, leading the authors 
to hypothesise that the C-terminus of HCMV UL52 is required for its correct sub-cellular 
localisation. I therefore wanted to examine whether the extreme C-terminus of HSV-1 
UL32 was essential for its function.  
4.6.1 Construction of UL32∆C  
The UL32∆C mutant was constructed by a two-step PCR mutagenesis, using a similar 
method to that used for the CxxC/CxxxC mutants, summarised in figure 4.18. Primer pairs 
were designed that were complementary to the UL32 sequence except with deletion of the 
12 nucleotides that encode the final four amino acids of the protein (CTYV). These 
primers also introduced a novel restriction enzyme site (HinfI) for ease of screening. The 
sequences of the two primer pairs are shown in table 4.18C. The first round PCR used 
primer pairs F1-R1 and F2-R2 to generate two small fragments containing the mutated 
sequence in the overlap region. These were annealed and amplified in a second round of 
PCR using the outside primers (F1 and R2). The product was a 600 bp fragment flanked 
with HindIII and XhoI sites which had a deletion of the final four codons but retained the 
TGA stop codon. This PCR product was inserted into the pGEM T sub-cloning vector and 
screened for the presence of the novel HinfI restriction site. The fragment containing the 
HinfI site was excised by digestion with HindIII and XhoI, gel purified and inserted into 
pUL32 digested with the same enzymes. This plasmid, UL32∆C was sequenced to confirm 
deletion of the final four codons. 
4.6.2 Expression and localisation of UL32∆C 
The expression and localisation of UL32∆C was compared to wt UL32 in transfected cells 
(figure 4.19). The western blot shows that UL32∆C produced a polypeptide recognised by 
antibody R1 that was expressed at similar levels to wt UL32 protein. There was no visible 
size difference between wt UL32 and UL32∆C, but this is not surprising, as the deletion of 
four amino acids is predicted to only reduce the molecular weight from 63.9 kDa to 63.6 
kDa (figure 4.16A). In the immunofluorescence studies of transfected BHK cells, the  
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GAGCACACCCTGTGACACCGACTCCCATCGCCGCGGCTCCCC∆CR2
TCGCTCCTGTCCCTGGAGCACACCCTGTGACACCGACTCCCA∆CF2
TGGGAGTCGGTGTCACAGGGTGTGCTCCAGGGACAGGAGCGA∆CR1
CGACCAGCTCGAGGCTGACCCCGA∆CF1
5' - 3' sequence
Figure 4.18: Primers used for generation of UL32∆C.
A. The positions of primer pairs ∆CF1- ∆CR1 and ∆CF2- ∆CR2 relative to the 3’
end of UL32, showing the nucleotides deleted in the primer sequences. The 
positions of the introduced HinfI sites are indicated in red.
B. The product generated by the PCR mutagenesis, with 12 nucleotides (coding 
for amino acids CTYV) deleted.
C. 5’- 3’sequences of primers designed for generation of UL32∆C. The 
nucleotides complementary to the UL32 sequence are shown in blue and the 
introduced HinfI sequences underlined.
ACC CTG TGT ACC TAT GTA TGA CAC CGA CTC CCA
∆CR2
∆CF1
T    L    C    T   Y   V    -
TGG GAC ACA TGG ATA CAT ACT GTG GCT GAG GGT
∆CF2
∆CR1
HinfI
HinfI
A.
TGG GAC ACT GTG GCT GAG GGT
T    L     -
ACC CTG TGA CAC CGA CTC CCA
B.
C.
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Figure 4.19: Expression and localisation of UL32∆C in transfected cells.
A. BHK cells were transfected with 1 µg pCMV10, pUL32 or UL32∆C plasmid DNA 
using the calcium phosphate method. 18 hours post transfection, cell lysates were 
prepared and samples were separated by SDS-PAGE then western blotted as 
previously described. Membranes were probed with antibody R1 (1:500). Blots were 
then stripped and reprobed for actin as a loading control. 
B. 0.5 µg plasmid DNA was transfected into BHK cells using Lipofectamine 2000. 18 
hours post transfection, cells were fixed with formaldehyde and permeabilised with 
NP40. Coverslips were then probed with antibody R1 (1:500) followed by r-FITC 
(1:200). These were then examined by confocal microscopy. Scale bar = 20 µm.
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localisation of UL32∆C was indistinguishable from that of wt UL32, both being 
distributed throughout the cytoplasm (figure 4.16B). 
4.6.3 Ability of UL32∆C to complement the growth and DNA 
packaging defects of hr64 
UL32∆C was then tested for functionality in the two assays examining the 
complementation of growth and DNA packaging of hr64.  
Figure 4.20A shows that UL32∆C was incapable of supporting virus growth in hr64 
infected BHK cells. Furthermore, UL32∆C did not support DNA packaging, and 
quantitation of duplicate experiments showed that UL32∆C packaged DNA to a level of 
4.78% of that obtained with wt UL32, not significantly more than the value of 3.15% 
obtained with the empty vector pCMV10 (figure 4.20B). 
These results indicate that the C-terminal four amino acids of UL32 are essential for DNA 
packaging and virus replication.  
 
4.7 Discussion 
4.7.1 Creation of UL32 insertional mutants 
Firstly, a panel of 37 insertional mutants was created using a random transposon based 
mutagenesis system. This approach was selected for the initial studies of UL32 because no 
previous work has been attempted to identify regions of the protein essential for its 
function. The identity of the mutants was confirmed by DNA sequencing and each 
expressed a full-length protein at similar levels to wt UL32. Like wt UL32, each protein 
localised to the cytoplasm of transfected cells. The insertions are generally well-spaced 
giving good coverage throughout the UL32 protein, except for a relatively small region 
between amino acids 232 and 301 with no insertions. 
A further set of site specific mutants were created – UL32CxxC1, UL32CxxC2 and 
UL32CxxxC3. These substituted the highly conserved cysteine residues in each of these  
Chapter 4   147 
 
 
UL
32
∆
C
pU
L3
2
pC
M
V1
0
virus
w
t H
SV
-
1
pC
M
V1
0
hr
64
plasmid
Total
Packaged
A.
Figure 4.20: Functional analysis of ∆C mutant.
A. Complementation yield assay. BHK cells were transfected and superinfected as 
previously described. 18 h.p.i., viral yields were collected and titrated on UL32-5 
cells for 4 days. Plaques were counted and titres expressed as a percentage of those 
obtained with wt UL32. The red squares and blue triangles represent duplicate 
independent experiments and the light blue bars show the mean values.
B. Amplicon packaging assay. Cells were co-transfected with pSA1 and either 
pCMV10, pUL32 or UL32∆C and superinfected  with wt HSV-1 or hr64 as 
previously described. Total DNAse resistant DNA were prepared and processed as 
described in section 2.2.6.2 and pSA1 was detected by hybridisation to 32P labelled 
pAT153.
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CxxC/CxxxC motifs with serines. Finally, the extreme C-terminus of UL32 (final four 
amino acids) was deleted, generating the UL32∆C mutant.  
4.7.2 Analysis of functionality of the UL32 mutants 
The mutants were examined in two functional assays – their ability to complement the 
growth of the UL32 mutant virus hr64 and their ability to support DNA packaging by 
hr64. 
An exact correlation was found between the ability of mutants to support viral growth and 
their ability to package DNA, both for the insertional mutants and the site-specific 
CxxC/CxxxC and UL32∆C mutants. This suggests that the key function of UL32 in the 
viral life cycle is in initiation of DNA packaging. Were UL32 required at a later stage of 
the viral life cycle, another class of mutants might be expected that support DNA 
packaging but fail to complement growth of the mutant virus. This phenotype has been 
reported during mutational analysis of the UL25 protein, which is not required for the 
initiation of packaging, but is important for the termination of packaging and nuclear 
egress (O'Hara et al.). 
4.7.3 Correlation between functionality of the mutant protein and 
conservation of the UL32 protein 
Figure 4.21 shows a similarity plot (generated by Nigel Stow) constructed by extracting the 
UL32 protein sequences for the Alphaherpesvirinae from the RefSeq database. These were 
aligned with ClustalW and analysed using PlotSimilarity (GCG). The graph shows 
similarity plotted against amino acid number, with the peaks indicating regions of high 
conservation throughout these sequences and the troughs indicating poor conservation. 
Differences between the lengths of the proteins and the introduction of padding characters 
results in the alignment length being 720 amino acids compared to the 596 aa length of 
HSV-1 UL32. The positions of all of the insertional mutants are indicated on this 
alignment with the functional mutants (those giving over 10% packaging or growth 
complementation compared to wt UL32) shown in green and the non-functional (less than 
10% of the values of wt UL32) in red. From the data, broad regions of the UL32 protein 
can be identified which have differing susceptibilities to disruption, which correlate with 
their conservation. The C-terminal portion of the protein shows a high degree of similarity 
and contains many highly conserved residues (C-terminal third). This region is intolerant  
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of disruption, with all but one of the insertions after amino acid 398 generating a non-
functional protein. The central portion (central region) of the protein is less well conserved 
and is much more tolerant of insertions, with 9 out the 12 mutants between amino acids 
187 and 378 retaining functionality. The N-terminal third has two distinct regions of highly 
conserved residues and again, these correlate with the functionality of the mutants, with the 
mutants between amino acids 40 and 55 (N term A) and 136-177 (N term B) not 
supporting virus growth or DNA packaging of hr64. 
Figure 4.22 shows another alignment of UL32 protein sequences from the 
Alphaherpesvirinae, this one created by aligning the same sequences using ClustalX. This 
gives a more detailed view of the conservation of individual amino acids within UL32 and 
also indicates completely conserved residues with an asterisk (*).  
Again, the positions of all insertional mutants are indicated on this alignment with the 
functional mutants shown in green and the non-functional in red. A number of mutants 
have the insertion directly preceding or following a residue that is completely conserved 
within the Alphaherpesvirinae (mutants in40, in136, in155, in398, in435, in494, in498 
in558, in580 and in592) or that is conservatively substituted (mutants in55, in177, in407 
and in572). Furthermore, mutant in498 has the 5aa insertion within the third conserved 
CxxxC motif immediately after the first cysteine. All of these mutations render the protein 
non-functional, consistent with the completely conserved residues being essential for UL32 
activity.  
In contrast, mutant in475, which has an insertion directly before an aspartic acid (D) that is 
almost completely conserved within these sequences (with the exception of Suid 
herpesvirus 1), is fully functional. It is interesting to note that this aspartic acid is not well 
conserved in the UL32 sequences of the Beta- and Gamma- herpesvirinae. With the 
exception of mutant in475, the remaining mutants that retained function in the packaging 
and growth assays are all found within less conserved regions of UL32.  
In general, insertions within those regions of UL32 that are the most highly conserved 
were non-functional, whereas the regions of lower conservation were more tolerant to the 
insertion of 5 amino acids. When looking at the similarity plot, 20 out of the 22 non-
functional insertions were in regions above the mean similarity level of the UL32 protein, 
with 13 of the 15 functional insertions in regions of lower than average similarity. 
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4.7.4 Correlation between function and predicted secondary 
structure 
As there is no crystal structure of HSV-1 UL32 available, the position of mutants was 
compared to the secondary structure of UL32 predicted by the PSIPRED program 
(McGuffin et al., 2000). The predicted secondary structure of UL32 is shown in figure 
4.23, with positions of the functional mutants denoted in green and non-functional in red. 
The majority of mutants with insertions within predicted helices are non-functional, 
probably because they disrupt the structure of the helix. Conversely, most of the functional 
mutants lie within predicted unstructured regions of the protein. However, there are some 
mutants that do not follow this pattern, and mutants in12, in376, in377 and in378 all lie 
within helical regions but are able to complement the growth and packaging of hr64.  
4.7.5 Site-specific mutants 
Four further mutants were created to analyse highly conserved regions of the UL32 
protein. The first set comprised three independent substitution mutations of the 
CxxC/CxxxC motifs replacing the cysteines with serines. Serine was chosen as the 
replacement amino acid because it has the same structure as cysteine apart from 
replacement of the –SH group with an –OH. This should however abolish the ability of the 
mutated residue to participate in disulphide bond formation and to coordinate zinc ions. 
Mutation of the first and third CxxC/CxxxC motifs (CLVC and CDMPC) completely 
abrogated protein function, but substitution of the central pair of cysteines with serines 
resulted in a protein that retained partial ability to support growth and DNA packaging in 
cells infected with hr64. This was an unexpected result, as the CxLC sequence of this 
motif is completely conserved throughout all herpesvirus sequences. 
CxxC motifs have been identified in a wide range of proteins, both viral and non-viral, 
which perform a variety of different functions. These motifs are found in proteins involved 
in formation and isomerisation of disulphide bonds, for example the thioredoxin 
superfamily, some of which can act as chaperones to aid folding of other proteins (Berndt 
et al., 2008). It has previously been suggested that UL32 acts a redox chaperone, being 
involved in the correct folding and localisation of the VP19C capsid protein (S. Weller, 
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presented at International Herpesvirus Workshop, 2005), although these data have not been 
published. CxxC/CxxxC motifs are also important in zinc binding proteins and C-X(2-4)-C 
sequences are found in many zinc finger (ZnF) containing proteins. ZnFs also often contain 
conserved histidines, and are divided into different classes based upon the organisation of 
the Cys and His residues and the secondary structure of these motifs. Many zinc binding 
proteins contain multiple zinc fingers throughout their length. Herpesvirus UL32 
sequences do not contain these conserved histidine residues in the characteristic ZnF 
arrangement, but HSV-1 UL32 has previously been reported to bind zinc (Chang et al., 
1996) and this is likely to be through the CxxC/CxxxC motifs. Zinc binding proteins are 
implicated in a wide range of functions, including interactions with other proteins, 
folding/assembly of other proteins and interactions with nucleic acids. None of these 
functions has yet been assigned to UL32, but its role in DNA packaging could involve 
interactions with other capsid or packaging proteins. 
The results presented here indicate that the central CxxC motif is not as critical for protein 
function as the first and third motifs. It is possible that the outer motifs function in zinc 
binding activity and the central motif is not involved in this activity. It could be envisaged 
that the first and third motifs, although far apart in the primary sequence of the protein, are 
in close proximity in the native protein, where they might be involved in zinc co-
ordination. Alternatively, there may be a degree of redundancy, so that when the central 
CxxC is mutated, one of the other conserved motifs could partially overcome this 
mutation. However, this does not seem to be the case for the other CxxC/CxxxC motifs 
which are completely essential, and would presumably require changes to the overall 
conformation of the protein. 
The other site specifically targeted was the extreme C-terminus of UL32 with a deletion of 
the C-terminal four amino acids (UL32∆C). This deletion includes the C-terminal 2 amino 
acids which are completely conserved within the Alphaherpesvirinae, and not surprisingly, 
the mutation destroyed protein function. This is consistent with previous data showing that 
the extreme C-terminus is essential for protein function and correct localisation in UL52 of 
HCMV (Borst et al., 2008). This is also in agreement with the phenotype of the insertional 
mutant in592, which has the insertion directly preceeding these four amino acids, and is 
non-functional. The final four amino acids of HSV-1 UL32 (CTYV) are found to fit the 
consensus for PDZ domain-binding sites (X-S/T-X-V). PDZ domains are among the most 
common domains found in proteins are involved in protein-protein interactions and the 
clustering and localisation of proteins, commonly binding consensus sequences at the C-
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terminus of proteins (van Ham & Hendriks, 2003) . It remains to be determined whether 
the C-terminus of UL32 is involved in PDZ domain binding within the context of HSV-1 
infection. 
4.7.6 Inhibition of wt UL32 function  
Each of the non-functional mutants was also tested in a transient packaging assay to 
determine whether they inhibited the function of wt UL32. A dominant negative phenotype 
is often seen if a mutated protein can still perform part of its function, for example binding 
to an interaction partner, but cannot carry out other functions. In this way, the mutated 
protein can sterically or otherwise inhibit the function of the wildtype protein. This 
property has been demonstrated with the HSV-1 DNA replication proteins, where mutant 
forms of the origin binding protein, ICP8 and UL8 all inhibit wt HSV-1 infection (Barnard 
et al., 1997; Chen & Knipe, 1996; Stow et al., 1993). Recently, it was also demonstrated 
that deletion of a NLS from the packaging protein UL15 created a dominant mutant able to 
inhibit HSV-1 replication (Yang et al., 2007). 
None of the UL32 mutants tested showed potent dominant negative inhibition of the 
packaging of wt HSV-1 in these assays. There may be a number of possible reasons for 
this. The UL32 protein may act as a monomer in HSV-1 packaging, for example having an 
enzymatic activity, so that as long as a wildtype form is present in cells, the mutant form 
has no effect. Alternatively the wt form of the protein may compete for binding of any 
potential partners more efficiently than the mutant proteins, or any interaction may be 
transient enough that the wt UL32 is still able to interact with its binding partners briefly 
even in the presence of the mutant protein. 
One further possible reason why none of the mutants showed dominant-negative activity in 
this assay is that for some reason mutant UL32 expressed from a plasmid was unable to 
compete effectively with the wt protein expressed by wt HSV-1. An alternative approach 
to this assay might be to transfect three plasmids – the amplicon, pUL32 and the insertional 
mutant - and superinfect with hr64, to ensure that wt and mutant UL32 are similarly 
expressed in cells. A subset of the mutants have been tested again using this method and no 
dominant-inhibitory activity was seen, confirming the previous results (Dr Nigel Stow; 
data not shown). 
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4.7.7 Conclusions 
This chapter describes the generation of a large panel of mutants within UL32, allowing 
functional characterisation of a substantial portion of the protein.  Thus far, the precise role 
of UL32 within the DNA packaging pathway is not known, so the explanation for some of 
these mutants being non-functional remains unclear. Nevertheless, once specific functions 
for UL32 begin to emerge, these mutants should prove invaluable in identifying regions of 
the protein that contribute to such activities. 
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5 Investigation of potential interactions of UL32 
with other HSV-1 proteins 
 
5.1 Investigating the effect of UL32 on the localisation of 
HSV-1 capsids and capsid proteins in infected cells 
HSV-1 DNA cleavage and packaging occurs in replication compartments (RCs) within 
infected cells, and many proteins involved in cleavage and packaging have been shown to 
localise to these sites. Lamberti and Weller (1998) reported that UL32 was required for the 
correct localisation of capsids to RCs in HSV-1 infected cells. They found that capsids 
were mis-localised throughout the nuclei (excluding the RCs) in cells infected with the 
HSV-1 UL32 mutant, hr64. However, these results have not been subsequently confirmed, 
and UL32 appears to be absent from B capsids or virions (Lamberti & Weller, 1998). I 
therefore decided to repeat these experiments to examine whether UL32 does have an 
affect on the localisation of capsids or capsid proteins. 
5.1.1 The effect of UL32 on capsid localisation  
Firstly the localisation of capsids was investigated using a rabbit anti-capsid antibody 
kindly provided by Dr David Pasdeloup (MRC Virology Unit). This antibody was raised 
against cytoplasmic capsids and as such recognises capsid and some tegument proteins (Dr 
Pasdeloup, personal communication). The presence of RCs were visualised with an 
antibody recognising ICP8, the HSV-1 single stranded DNA-binding protein. 
 BHK cells on coverslips were infected with 5 p.f.u. per cell wt HSV-1 or hr64 for six 
hours. Cells were then fixed and permeablilised using formaldehyde and NP40 and 
blocked with human serum (section  2.2.8). Coverslips were incubated with the anti-capsid 
antibody (1:1000) and M7381 (mouse-anti ICP8 IgG ;1:200). The cells were washed and 
then incubated with r-FITC (FITC-conjugated goat anti-rabbit IgG; 1:200) and m-Cy5 
(Cy5-conjugated goat anti-mouse IgG; 1:500), to allow simultaneous detection of both 
ICP8 and capsids within infected cells. The coverslips were examined by confocal 
microscopy using lasers with excitation lines at 488 nm and 633 nm, corresponding to the 
excitation wavelengths of the FITC and Cy5 fluors respectively. The two channels were 
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scanned separately and the same settings maintained throughout. The results are shown in 
figure 5.1.  
In both infections, the replication compartments are evident, as indicated by the staining of 
ICP8 within the nucleus (images B and E). As has been previously reported, capsids in wt 
HSV-1 infected cells localised predominantly to the RCs where they co-localised with 
ICP8 (images A and C). In contrast to the data from Lamberti and Weller, there was no 
significant difference in capsid localisation in the hr64 infected cells, with the majority of 
the capsids again colocalising with ICP8 in the RCs (images E and F). In both infections, a 
small portion of capsid staining can be seen at the outer edge of the cell, which may 
represent input capsids or cross-reactivity of the antibody with HSV-1 glycoproteins on the 
surface of the cell. 
5.1.2 The effect of UL32 on the localisation of VP5 and VP19C  
These results were furthered by examining the localisation of two specific capsid proteins, 
VP5 and VP19C, in the presence and absence of UL32. VP5 is the major capsid protein 
making up the hexons and pentons. VP19C is a triplex protein which has also been 
reported to be partially mis-localised and aggregated in the cytoplasm of cells infected with 
hr64 (S. Weller, presented at International Herpesvirus Workshop, 2005), although these 
results have not been published  
BHK cells were infected and coverslips fixed and permeabilised as above. Coverslips were 
incubated with R515 (rabbit anti-ICP8 IgG; 1:500) together with either DM165 (mouse 
anti-VP5 IgG; 1:500) or M2040 (mouse anti-VP19C IgG; 1:500) antibodies. This was 
followed by incubation with r-FITC and m-Cy5 antibodies and examination of the 
coverslips by confocal microscopy. Resultant images are shown in figure 5.2. In all 
infections, ICP8 staining could be clearly seen in the nucleus, indicating that RCs had 
formed (images A, D, G and J). In agreement with the previous results using the anti-
capsid antibody, VP5 showed the same localisation in cells infected with wt HSV-1 (image 
B) and hr64 (image E), colocalising with ICP8 in both instances (images C and F). VP19C 
also co-localised with ICP8 within RCs in cells infected with both wt HSV-1 (images H 
and I) and hr64 (images K and L). 
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wt HSV-1 
hr64 HSV-1 
FITC Cy5 merge
Figure 5.1: UL32 does not affect the localisation of capsids in HSV-1 infected cells.
BHK cells on coverslips were infected with 5 p.f.u./cell wt HSV-1 or hr64. 6 h.p.i. cells 
were fixed with formaldehyde and permeablilised with NP40, followed by blocking with 
human serum. Coverslips were incubated with M7381(mouse anti-ICP8; 1:200) and 
rabbit anti-capsid (1:1000) antibodies. This was followed by incubation with m-Cy5 
(Cy5-conjugated anti-mouse; 1:500) and r-FITC (FITC-conjugated anti-rabbit; 1:200) 
and the examination of cells by confocal microscopy. Scale bar = 20 µm.
capsidA ICP8B C
capsidD ICP8E F
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Figure 5.2: UL32 does not affect the localisation of capsids proteins in HSV-1 
infected cells.
BHK cells on coverslips were infected with 5 p.f.u./cell wt HSV-1 or hr64. 6 h.p.i., 
cells were fixed, permeabilised and blocked. Coverslips were incubated with R515 
(rabbit anti-ICP8 IgG; 1:500) and either DM165 (mouse anti-VP5 IgG; 1:500,  panel 
A) or M2040(mouse anti-VP19C IgG; 1:500,  panel B). These were then incubated 
with r-FITC and m-Cy5 and examined by confocal microscopy. Scale bar = 20 µm.
FITC Cy5 merge
VP19CICP8
wt HSV-1
ICP8 VP19C
hr64 HSV-1 
G H I
J K L
A.
B.
wt HSV-1
hr64 HSV-1
ICP8 VP5
VP5ICP8
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Together, these data suggest that UL32 is not required for the correct recruitment of 
capsids or the individual capsid proteins VP5 or VP19C to replication compartments prior 
to DNA packaging.  
 
5.2 Generation of an HA-tagged UL32 construct 
To further aid the studies examining the potential interactions of UL32 with other HSV-1 
proteins, a plasmid expressing a tagged version of UL32 was generated. The tag used was 
the HA tag, which is a nine amino acid peptide derived from the haemagglutinin protein of 
influenza virus. High quality mouse monoclonal antibodies are available for the HA tag, 
which would allow this tagged version of UL32 to be visualised in immunofluorescence 
assays along with other HSV-1 proteins for which rabbit antisera are available in the 
laboratory. 
5.2.1 Generation of plasmid pHA-UL32 
It was decided to clone the HA-tag at the N-terminus of UL32 to avoid disruption of the 
very highly conserved extreme C-terminus. Furthermore, attempts by another group to add 
an HA tag to the C-terminus of the HCMV UL32 homologue, UL52, resulted in a non-
functional protein. These authors were able to successfully introduce the tag at the N-
terminus of the protein and generate a functional construct (Borst et al., 2008). Another 
important factor to be considered when designing the tagged construct was the 
arrangement of UL32 and surrounding genes within the HSV-1 genome. The start codon 
(ATG) of UL32 overlaps in the opposite orientation with the start codon of the UL33 gene, 
as shown in figure 5.3A. UL32 is encoded by HSV-1 nucleotides 69162 to 67372 with 
UL33 encoded on the opposite strand from nucleotides 69161 to 69553. Therefore, if the 
tag was placed at the extreme N-terminus of UL32, this would interrupt the first codon of 
the UL33 gene. Instead, the tag was inserted between the second and third codons of 
UL32. This also ensured the Kozak consensus sequence for the initiation of translation of 
UL33 was not disrupted, and that the NcoI site was conserved, which could then be used 
for further cloning steps (section  5.3.1). In addition, the positioning of the tag would allow 
this construct to be used to introduce a tagged version of UL32 into the HSV-1 genome 
without disrupting the UL33 gene.  
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Figure 5.3: Primers used to generate pHA-UL32.
A. HSV-1 nucleotides 69175 to 69133 showing the overlap of the 5’ termini of 
the UL32 and UL33 genes. The N terminal amino acids of UL32 are shown in 
blue and UL33 in green.
B. Plasmid map of pUL32 indicating the positions of the primers HA-F and HA-
R used to generate the HA-UL32 construct.
C. 5’-3’ sequences of primers used to generate pHA-UL32. The blue nucleotides 
show those that are complementary to the UL32 gene and the red nucleotides 
show those encoding the HA tag. The black nucleotides are complimentary to 
the plasmid backbone. The KpnI and PmlI restriction endonuclease sites used 
for the cloning are underlined.
D. The nucleotide sequence of the 5’ end of the HA-tagged UL32 gene in 
plasmid pHA-UL32 and the corresponding protein sequence. Amino acids are 
shown in blue for the UL32 sequence and red for the HA tag. The KpnI
restriction endonuclease site is underlined.
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A.
CTCCCGCCCAGCCATGGCAACTTCGCCCCCCGGGGTCCTGGCG 
M  A    T    S    P   P   G    V    L   A
GAGGGCGGGTCGGTACCGTTGAAGCGGGGGGCCCCAGGACCGC
G   G   W   P   M
nt 69161
nt 69162 UL32
UL33
B.
5’ ACCTATCACGTGACTGGCCGTCAGGAGCTCGGC 3’HA-R:
5’ GCTCGGTACCCCATGGCATACCCTT
ACGACGTGCCTGACTACGCTACTTCGCCCCCCGGGGTCCTGGCG 3’HA-F:
C.
GG TAC CCC ATG GCA TAC CCT TAC GAC GTG CCT GAC TAC GCT ACT TCG CCC CCC GGG GTC CTG GCG 
M   A   Y    P   Y   D    V    P   D   Y    A   T    S    P    P    G    V    L     A
D.
pUL32
UL32
KpnI
PmlI
HA-F
HA-R
NcoI
NcoI
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The tag was introduced into pUL32 using a PCR approach. Two primers were designed as 
shown in figure 5.3B and C. Primer HA-F encoded the first two codons of UL32, followed 
by the HA tag and then eight more UL32 codons (amino acids 3-11). This primer also 
included a KpnI restriction endonuclease site that was used for further cloning. Primer HA-
R was completely complimentary to the UL32 sequence approximately 150 nucleotides 
downstream from HA-F, and included a PmlI restriction site for further cloning. PCR using 
primers HA-F and HA-R generated a product of approximately 150 bp, flanked by PmlI 
and KpnI restriction sites. The pUL32 plasmid was digested with these enzymes and the 
large fragment purified following gel electrophoresis. This was then ligated to the PCR 
fragment (also digested with PmlI and KpnI) to generate plasmid pHA-UL32. 
5.2.2 Expression and localisation of HA-UL32 protein in 
transfected cells 
It was essential to verify that the plasmid pHA-UL32 did indeed express the HA-tag fused 
to the UL32 protein and that HA-UL32 could be detected using a commercial anti-HA 
antibody. This was done using western blots and immunofluorescence of cells transfected 
with pHA-UL32.  
BHK cells were transfected with 1 µg pUL32 or pHA-UL32 using the calcium phosphate 
method. Cells were harvested 18 hours post infection, boiled in the presence of SDS and 
separated by electrophoresis on an 8% polyacrylamide gel. Samples were transferred to 
PVDF membranes and immunoblotted using a mouse anti-HA antibody (F-7; 1:500) 
followed by HRP-conjugated goat anti-mouse IgG (1:1000) and developed using ECL 
substrate. The resultant gel is shown in figure 5.4A. Lane 1 shows a band of the expected 
size for HA-UL32, indicating that the tag is able to be recognised by this antibody. A 
corresponding band was not present in the cells transfected with the untagged pUL32 (lane 
2) confirming that this recognition is specific to the HA tag. The membrane was stripped 
and re-probed using R1 (anti-UL32) to confirm that a UL32 reactive protein migrated at 
the same position as the product recognised by the anti-HA antibody (lanes 3 and 4).  
To investigate the localisation of HA-UL32 in transfected cells, BHK cells on coverslips 
were transfected with 0.5 µg pUL32 or pHA-UL32 using Lipofectamine 2000. 18 hours 
post transfection, cells were fixed and permeablilised with formaldehyde and NP40 and  
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Figure 5.4: Expression and localisation of HA-UL32.
A. BHK cells were transfected with 1 µg pHA-UL32 or pUL32 using the calcium 
phosphate method. 18 hours post transfection, cell lysates were prepared and 
samples were separated by SDS-PAGE then western blotted as previously 
described. Membranes were probed with F-7 (mouse anti-HA; 1:500),  followed 
by HRP-conjugated goat anti-mouse IgG (1:1000). The membranes were then 
stripped and re-probed with R1, followed by HRP-coupled protein-A.
B. 0.5 µg plasmid DNA was transfected into BHK cells using Lipofectamine 2000. 
18 hours post transfection, cells were fixed and permeabilised. Coverslips were 
then probed with F-7 (mouse anti-HA; 1:500) followed by m-Cy5 (1:500) and 
examined by confocal microscopy. Scale bar = 20 µm.
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incubated with F-7 (1:500) followed by m-Cy5. The coverslips were analysed by confocal 
microscopy and the images are shown in figure 5.4B. The anti-HA antibody shows bright 
fluorescence in the cytoplasm of those cells transfected with pHA-UL32 (image A) but no 
fluorescence was seen in the cells transfected with pUL32 (image B), again confirming the 
specificity of the antibody. HA-UL32 has the same localisation as untagged wtUL32 
(figure 3.6), indicating that the addition of a small tag does not affect the localisation of the 
UL32 protein. 
5.2.3 Functional analysis of pHA-UL32 
It was also necessary to confirm that the tagged protein expressed from pHA-UL32 
retained functionality. This was done by testing pHA-UL32 in the two assays already 
described in chapter 4 examining the complementation of growth and DNA packaging of 
the hr64 virus.  
5.2.3.1 Complementation yield analysis 
BHK cells were transfected with 1 µg pUL32, pCMV10 or pHA-UL32 and superinfected 
with hr64 as previously described (section  4.3). 18 hours post infection, the cells and 
media were harvested and viral progeny were titrated on the complementing cell line, 
UL32-5. Cells were stained and plaques counted, and the yields are shown in figure 5.5A. 
The value for pHA-UL32 is a mean of duplicate experiments and is expressed as a 
percentage of that obtained with pUL32. 
As in previous experiments, pUL32 successfully complemented the growth defect of hr64, 
giving a mean titre of 6 x 105 p.f.u., compared to a value of 4.6x102 with the empty vector 
pCMV10. pHA-UL32 supported viral growth as efficiently as the untagged protein, with a 
mean titre of 6.6x105 p.f.u., 110% of that obtained with pUL32. 
5.2.3.2 The ability of pHA-UL32 to support amplicon DNA packaging by hr64 
The HA-tagged UL32 construct was also tested for its ability to support the DNA 
packaging of hr64 in the amplicon packaging assay. BHK cells were transfected with 1 µg 
pUL32, pCMV10 or pHA-UL32 along with 0.5 µg pSA1 and superinfected with wt HSV-1 
or hr64 as described in section  2.2.6. Cells were harvested at 18 hours post infection and 
total and DNase resistant DNA samples prepared. The DNA samples were separated by 
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electrophoresis, Southern blotted and pSA1 was detected by hybridisation to 32P-labelled 
pAT153 probe as described previously.  
Figure 5.5B shows that pSA1 replication occurred in all samples. As expected, DNA 
packaging occurred following infection with wt HSV-1 (lane 1) or hr64 infection in the 
presence of pUL32 (lane 2) but not pCMV10 (lane 3). Consistent with the 
complementation yield assay results, pHA-UL32 was able to support DNA packaging of 
hr64 (lane 4). Quantification of the data from this and a repeat experiment revealed that 
pHA-UL32 supported pSA1 packaging to 80% and 105% of the levels observed with 
pUL32. 
These results together confirm that a construct was successfully created that expressed the 
UL32 protein containing an HA tag and that this protein was indistinguishable from wt 
UL32 in assays examining its ability to support viral growth and DNA packaging of hr64. 
 
5.3 Generation of an HSV-1 recombinant virus 
expressing HA-tagged UL32  
An HSV-1 recombinant virus expressing the same HA-UL32 was then generated. The 
method used for this is described in section  2.2.12. 
The approach taken was to rescue the hr64 mutation with a fragment containing the HA-
UL32 gene. Since the HA tag lies very close to the end of the UL32-containing fragment in 
pHA-UL32, a plasmid, p33-HA-UL32, containing additional sequences from the UL33 
gene to facilitate homologous recombination, was first constructed. 
5.3.1 Generation of plasmid p33-HA-32 
Figure 5.6 shows the cloning strategy used to generate plasmid p33-HA-32. Since the 
UL32 and UL33 initiation codons overlap within an NcoI restriction site (recognition 
sequence CCATGG) (figure 5.3A), this NcoI site can be used for convenient linking of the 
UL33 gene and the HA-tagged UL32 gene. Firstly, pHA-UL32 was digested using NcoI 
and NdeI, the fragments separated by agarose gel electrophoresis and the large fragment 
(containing HA-UL32 and a large section of the plasmid backbone) purified from the gel.  
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Figure 5.5: Functional analysis of pHA-UL32.
A. Complementation yield assay. BHK cells were transfected and superinfected as 
previously described in figure 4.11. 18 h.p.i., viral yields were collected and titrated 
on UL32-5 cells for 4 days. Plaques were counted and titres expressed as a 
percentage of those obtained with pUL32.
B. Amplicon packaging assay. Cells were co-transfected with pSA1 and either 
pCMV10, pUL32 or pHA-UL32 and superinfected  with wt HSV-1 or hr64 as 
previously described in figure 4.12. Total and DNase resistant DNA were prepared 
and samples digested with EcoRI and DpnI. DNA was separated by agarose gel 
electrophoresis and Southern blotted, and pSA1 was detected by hybridisation to 32P 
labelled pAT153.
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Figure 5.6: Generation of p33-HA-32.
A. pHA-UL32 was digested with NcoI and NdeI and the fragments separated by 
agarose gel electrophoresis. The large fragment containing the plasmid 
backbone and HA-UL32 was purified.
B. pUL33 was digested with HindIII and blunt-ended. An NdeI linker was added 
this was re-digested with NcoI and NdeI. The fragment containing UL33 was 
purified to yield a fragment containing the UL33 gene flanked by NcoI at its 5’
end and NdeI downstream of the 3’ end
C. The UL33 and pHA-UL32 fragments were ligated via the NdeI and NcoI
restriction enzyme sites to generate plasmid p33-HA-32, containing HA-UL32 
(blue) and UL33 (green) encoded in the opposite orientation to one another.
D. The nucleotide sequence of the 5’ termini of UL33 and HA-UL32 within 
plasmid p33-HA-32. The start codon of each gene and the orientation are 
indicated by arrows. The amino acids of the UL33 protein are shown in green 
and UL32 in blue, with the HA tag shown in red. The shared NcoI restriction 
site is underlined
CTCCCGCCCAGCCATGGCATACCCTTACGACGTGCCTGACTACGCTACTTCGCCCCCCGGGGTCCTGGCG 
M  A   Y    P    Y   D   V    P    D   Y   A   T   S    P    P    G   V   L   A
GAGGGCGGGTCGGTACCGTATGGGAATGCTGCACGGACTGATGCGATGAAGCGGGGGGCCCCAGGACCGC
G   G   W   P  M
UL33
UL32
D.
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As pUL33 does not contain an NdeI site, the cloning strategy used to excise UL33 was 
slightly different. pUL33 was digested with HindIII and blunt-ended. An NdeI linker was 
added, the product re-digested with NdeI and NcoI and the UL33-containing fragment 
purified. This generated a fragment encoding UL33 with the NcoI site at the 5' end of the 
gene, and an NdeI site downstream of the 3' end of the gene. The two fragments (the UL33 
fragment and the plasmid backbone containing HA-UL32) were then ligated and 
transformed into XL-1 blue cells. DNA of a resulting plasmid, p33-HA-32, was prepared 
using a Qiagen QIAquick Spin Miniprep kit and the sequence of the junction between 
UL33 and HA-UL32 confirmed by sequencing. The sequence was identical to that of wt 
HSV-1 except for the 45 nucleotide insertion coding for the HA tag. The insertion does not 
place any additional ATG codons upstream of the UL33 start codon and so should not 
affect the UL33 protein. The 33-HA-32 fragment was then excised from the plasmid by 
restriction digest using NdeI and XhoI to promote recombination with hr64 DNA in the 
marker rescue. 
5.3.2 Marker rescue of hr64 
For the marker rescue, hr64 genomic DNA was first prepared from infected UL32-5 cells 
as described in section  2.2.12.1. 0.5 µg hr64 DNA and 0.5 µg gel-purified 33-HA-32 
fragment were co-transfected into duplicate 35 mm plates of non-complementing BHK 
cells, as described in section  2.2.12.2. One plate showed evidence of infection after 
incubation at 37°C for 3 days, and the cells and media were harvested. The progeny were 
titrated onto BHK cells to confirm that the virus could successfully replicate on non-
complementing cells and to obtain a titre of this initial harvest. 
Plaque purification of the initial harvested virus was performed, as described in section 
 2.2.12.3. Samples of two-fold serial dilutions covering the range 128 p.f.u/well to 3.9x10-3 
p.f.u./well and used to infect microtitre wells of BHK cells. After 4 days incubation at 
37°C, four wells were chosen containing single plaques were used to infect 35 mm dishes 
of BHK cells overnight. These virus-infected cells were harvested, the proteins separated 
by SDS-PAGE and the membranes were screened by western blotting using F-7 (anti-HA) 
to confirm that they expressed HA-UL32. Figure 5.7 shows that each harvested viral 
progeny produced a protein of the correct size that was recognised by the anti-HA 
antibody. Clone G7 was selected for use and the harvested cells used to infect 175 mm2 
flasks of BHK cells and generate a stock of virus, which was named HA32EP. This stock 
was also tested for the absence of the original hr64 virus by staining of infected cells for  
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Figure 5.7: Screening of marker rescuants for the expression of HA-UL32.
Single wells from the serial dilution of marker-rescuant virus progeny were chosen 
and used to infect 35 mm dishes of BHK cells overnight. Cells were harvested and 
protein separated by electrophoresis on 8% polyacrylamide gels and western blotted. 
The membranes were probed with F-7 (mouse anti-HA), followed by HRP-coupled 
goat anti-mouse IgG. The positions of size markers are indicated (kDa).
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β-galactosidase expression (from the lacZ cassette inserted into hr64). No β-galactosidase 
activity was seen, confirming that the virus stock contained only HA32EP HSV-1. 
5.3.3 Growth curve of HA32EP on BHK cells 
The above isolation of HA32EP confirmed that this virus was able to replicate in non-
complementing BHK cells, and its growth was next compared to wt HSV-1 and hr64. 35 
mm dishes of BHK cells were infected with 10 p.f.u. per cell wt HSV-1, hr64 or HA32EP. 
One hour after infection the cells were washed once with 0.14 M NaCl, exposed to acid 
glycine wash for one minute, then washed with EC5, followed by continued incubation in 
EC5 at 37°C. Cells were harvested at 4, 8, 12, 16, 20 and 24 hours post infection and the 
cells and media sonicated before being titrated onto BHK cells for 3 days (section  2.2.4.2). 
Plaques were counted and virus yields determined. This single-step growth analysis (figure 
5.8) demonstrates that HA32EP replicates with similar kinetics to wt HSV-1, in contrast to 
hr64, which did not show any growth in BHK cells. 
5.3.4 Investigating the ability of HA32EP to package HSV-1 DNA 
The DNA packaging ability of HA32EP was investigated by using a viral DNA packaging 
assay. Duplicate monolayers of BHK cells were infected with 5 p.f.u. per cell wt HSV-1 or 
HA32EP. After one hour, cells were washed once with 0.14 M NaCl, exposed to acid 
glycine wash for one minute, then washed with EC5. One of each sample was harvested 
after this acid glycine wash and the cells pelleted and stored at -20°C (input). The other 
sample was incubated in EC5 at 37°C and harvested after 18 hours (18 hour). Total and 
DNase resistant DNAs were prepared from both input and 18 hour samples as described in 
section  2.2.6.2. These samples were digested with EcoRI and separated by electrophoresis 
on a 0.8% agarose gel. The gel was Southern blotted and hybridised to 32P labelled 
pGX153, which contains the BamHI P fragment of HSV-1 inserted into pAT153. Probing 
with pGX153 should detect 2 bands corresponding to the HSV-1 EcoRI N (2.4 kbp) and G 
and F fragments (16.1 and 16.2 kbp respectively, which migrate as one band).  
Figure 5.9 shows that the amount of viral DNA in the input samples was insufficient to be 
detected in a short exposure (lanes 1, 3, 5 and 7). In contrast, wt HSV-1 and HA32EP 
DNA was readily detected at 18 hours post infection (lanes 2 and 4). Furthermore, both wt 
HSV-1 and HA32EP packaged the replicated viral DNA to a similar level (lanes 6 and 8). 
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< N
Figure 5.9: Packaging of viral DNA by wt HSV-1 and HA32EP.
BHK cells were infected with 5 p.f.u./cell wt HSV-1 or HA32EP and harvested at 
either 1 h.p.i. (input) or 18 h.p.i (18 hour). Total and packaged DNA were prepared 
and digested with EcoRI. DNA was separated by agarose gel electrophoresis, 
Southern blotted, and the membrane probed with 32P labelled pGX153.The positions 
of the EcoRI F, G and N fragments are indicated.
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The above assays confirmed that HA32EP replicates and packages DNA with similar 
efficiency to wt HSV-1 in BHK cells.    
5.4 Localisation of HA-UL32 in HA32EP infected cells 
Previous work concerning the localisation of UL32 within HSV-1 infected cells has 
yielded conflicting results. Chang et al (1996) reported that UL32 localised predominantly 
to the cytoplasm of infected cells in infection, using a rabbit antisera directed against 
UL32. Lamberti and Weller (1998) examined the localisation of UL32 by transfection of 
an epitope-tagged UL32 construct and superinfection using hr64. They found that although 
UL32 was predominantly cytoplasmic, there was a portion that localised to the replication 
compartments in the nucleus, colocalising with ICP8. The R1 antisera generated earlier in 
this work (see section 3) was incapable of specifically detecting UL32 in HSV-1 infected 
cells by immunofluorescence and gave very high levels of background staining throughout 
cells infected with hr64 (data not shown). Therefore HA32EP was used to investigate the 
localisation of HA-UL32 in HSV-1 infected cells. 
BHK cells on coverslips were infected with 5 p.f.u. per cell HA32EP or wt HSV-1 for 6 
hours. Cells were fixed and permeablilised and blocked using human serum, and the 
coverslips were incubated with F-7 (anti-HA) and R515 (rabbit anti-ICP8; 1:500) 
antibodies, followed by r-FITC and m-Cy5. The coverslips were examined by confocal 
microscopy and the images are shown in figure 5.10. 
In the HA32EP infected cells, ICP8 staining was clearly visualised within the nucleus 
(image A). The HA-UL32 staining co-localised with ICP8 (images B and C). No HA 
staining was seen in cells infected with wt HSV-1 (image E), even though the ICP8 
staining showed that the cells were efficiently infected (image D), confirming the 
specificity of the anti-HA antibody. Therefore, in contrast to other reports, this study shows 
that the UL32 protein localises entirely to the replication compartments within the nucleus 
of HSV-1 infected BHK cells.  
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Figure 5.10: Localisation of HA-UL32 in HSV-1 infected cells.
Coverslips of BHK cells were infected with 5 p.f.u./cell HA32EP (A-C) or wt 
HSV-1 (D-E) for 6 hours. Cells were fixed and permeabilised using 
formaldehyde and NP40 and blocked with human serum. Coverslips were 
incubated with F-7 (mouse anti-HA; 1:500) and R515 (rabbit anti-ICP8; 1:500), 
followed by r-FITC (1:200) and m-Cy5 (1:500). Coverslips were mounted and 
examined by confocal microscopy. Scale bar = 20 µm.
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5.5 Investigation of the interaction of UL32 with HSV-1 
packaging proteins UL6, UL17 and UL25 
No direct interactions have yet been reported between UL32 and any other HSV-1 protein, 
although it has recently been reported that UL32 may affect the localisation of UL25 in 
HSV-1 infected cells (Scholtes & Baines, 2009). It was therefore decided to analyse 
whether UL32 could interact with any other HSV-1 DNA cleavage/packaging protein. This 
section describes results obtained for UL6, UL17 and UL25. The analysis of possible 
interactions with the three components of the terminase is described in the following 
section ( 5.6). 
5.5.1 Localisation of UL6, UL17 and UL25 in HSV-1 infected cells 
in the absence of UL32 
As UL32 and all other packaging proteins localise to replication compartments in infected 
cells (along with the capsid proteins), I first examined whether UL32 plays a role in the 
correct localisation of UL6, UL17 and UL25 in HSV-1 infection .  
BHK cells were infected with 5 p.f.u. per cell wt HSV-1 or hr64 and fixed at 6 hours post 
infection. Cells were processed as before and incubated with R335 (rabbit anti-UL25; 
1:500), R992 (rabbit anti-UL6; 1:500) or R1218 (rabbit anti-UL17; 1:500), together with 
M7381 (mouse anti-ICP8). This was followed by incubation with m-Cy5 and r-FITC and 
examination by confocal microscopy. Representative images are shown in figure 5.11. 
All cells infected with wt HSV-1 showed clear ICP8 staining in the nucleus, indicating that 
replication compartments had been formed (images B, H and N). As previously reported, 
all three proteins UL6, UL17 and UL25 were seen predominantly within the nucleus in 
these cells (images A, G and M) (Scholtes & Baines, 2009; Taus et al., 1998) and co-
localised with ICP8, confirming that they localise to replication compartments during 
wildtype infection (images C, I and O). In the hr64 infected cells, ICP8-stained replication 
compartments could again be visualised within the nucleus (images E, K and Q). UL6 and 
UL17 co-localised with the ICP8 foci, as in wt HSV-1 infection (images D and F; J and L). 
In contrast to the report from Scholtes and Baines, the localisation of UL25 in hr64  
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Figure 5.11: UL32 does not affect the localisation of packaging proteins UL6, UL17 
or UL25 in HSV-1 infected cells.
Coverslips of BHK cells were infected with wt HSV-1 or hr64 at 5 p.f.u./cell for 6 hours. 
Cells were fixed and permeabilised and incubated with M7381 (mouse anti-ICP8) along 
with either R992 (rabbit anti-UL6; 1:500), R1218 (rabbit anti-UL17; 1:500) or R335 
(rabbit anti-UL25; 1:500). This was followed by r-FITC and m-Cy5. The cells were 
examined by confocal microscopy. Scale bar = 10µm.
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infected cells was also indistinguishable from cells infected with wt HSV-1, with UL25 
again colocalising with ICP8 (images P and R). 
These results suggest that UL32 is not required for the localisation of UL6, UL17 or UL25 
to the replication compartments in infected cells. 
5.5.2 Co-localisation analysis of UL32 with UL6, UL17 or UL25 in 
transfected cells 
To analyse whether UL32 might interact with UL6, UL17 or UL25 in the absence of other 
viral proteins, a co-transfection assay was used. For this assay, plasmids pAS30, pMH19 
and pIM96 were used, encoding UL6, UL17 and UL25 respectively, each under the control 
of the HCMV IE promoter. 
BHK cells were transfected with 0.5 µg pAS30, pMH19 or pIM96, either alone or in 
combination with 0.5 µg pHA-UL32, using Lipofectamine 2000. Cells were fixed and 
permeabilised 18 hours post transfection. Coverslips were reacted with F-7 and either 
R992, R1218 or R335, followed by staining with r-FITC and m-Cy5, as described above. 
Cells were examined by confocal microscopy and representative results are shown in 
figure 5.12. 
As previously observed, HA-UL32 localised to the cytoplasm of transfected cells when 
expressed alone and no background signal was apparent in the FITC channel (images A-
C). When expressed alone, UL6 was present solely in the nuclei of cells (images D-F), 
consistent with published results (White et al., 2003).  In cells co-expressing both proteins, 
UL6 remained in the nucleus while HA-UL32 remained cytoplasmic (images G-I). UL25 
was present throughout the cell when expressed alone, predominantly in the cytoplasm, but 
also with a portion entering to the nucleus (images J-L). In co-transfected cells, neither 
UL25 or HA-UL32 was altered in its localisation (images M-O). The failure of UL25 to 
transport UL32 into the nucleus suggests the lack of a strong interaction between these 
proteins. Like HA-UL32, UL17 was found to localise exclusively to the cytoplasm when 
expressed alone (images P-R). In the co-transfected cells, both proteins remained diffusely 
distributed throughout the cytoplasm, and it is difficult to interpret whether any observed 
co-localisation is indicative of an interaction (images S-U). 
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Figure 5.12: Interaction of HA-UL32 with packaging proteins UL6, UL25 and 
UL17 in transfected cells.
BHK cells on coverslips were transfected with 0.5 µg  of the indicated plasmids 
using Lipofectamine 2000. 18 hours post transfection, cells were fixed and 
permeabilised with formaldehyde and NP40 and incubated with either R992, R335 
or R1218 (all at 1:500) along with F-7. This was followed by incubation with r-
FITC and m-Cy5. Coverslips were mounted onto slides and examined by confocal 
microscopy. Scale bar = 20 µm
 
Chapter 5   
 
183
UL6 HA-UL32
UL6
UL6
HA-UL32
HA-UL32
HA-UL32
UL25
UL25
pHA-UL32
pAS30 + 
pHA-UL32
pAS30
pIM96 + 
pHA-UL32
pIM96
FITC Cy5 merge
A B C
FED
G H I
J K L
ONM
HA-UL32B
pMH19
pMH19 + 
pHA-UL32
HA-UL32UL17 RQP
HA-UL32UL17 UTS
Chapter 5   
 
184
These results suggest that UL32 does not interact with packaging proteins UL6 or UL25 in 
the absence of other HSV-1 proteins in transfected mammalian cells, although it remains 
possible that an interaction with UL17 may occur. 
5.5.3 Co-immunoprecipitation analysis of UL32 with UL6, UL17 or 
UL25 
Possible interactions of UL32 with these three proteins were also examined using co-
immunoprecipitation (co-IP) of recombinant baculovirus-expressed proteins.  
5.5.3.1 Immunoprecipitation from baculovirus-infected cells 
As no interactions have previously been reported for UL32, I first carried out a co-IP using 
two DNA packaging proteins with a well-established interaction as a positive control for 
the assay. For this, baculoviruses AcUL28 and AcUL15 (expressing proteins UL28 and 
UL15 respectively) were used. Sf21 cells were mock infected or infected with 2.5 p.f.u. per 
cell of each baculovirus alone, or together. Forty-eight hours post-infection cells were 
harvested and lysed, and insoluble proteins removed by centrifugation (section  2.2.11). An 
aliquot of each soluble extract was incubated with a rabbit antibody specific to UL28 
(R123). Immune complexes were collected by further incubation with protein-A-sepharose 
followed by centrifugation and extensive washing. Soluble and immunoprecipitated 
samples were boiled in the presence of SDS and separated on an 8% polyacrylamide gel. 
The proteins were transferred to PDVF membranes reacted with antibodies specific to 
UL28 (R123) or UL15 (R605) followed by HRP-conjugated protein-A and detected using 
the ECL substrate. The resultant blots are shown in figure 5.13. 
UL28 was not detected in mock infected cells or those infected with AcUL15 alone, but 
was expressed in cells receiving either AcUL28 alone, or together with AcUL15 (panel A; 
lanes 1-4). Similarly, UL15 was absent from cells that were mock infected or infected with 
only AcUL28, but could be detected in cells receiving AcUL15 both in the presence and 
absence of UL28 (panel A; lanes 5-8). UL28 was efficiently precipitated from cells 
infected with AcUL28 by its appropriate antibody (R123) (panel B; lanes 11 and 12). 
Furthermore, UL15 was co-immunoprecipitated by R123 in cells infected with both 
baculoviruses (panel B; lane 16). This was dependent on the presence of UL28, as no 
UL15 was precipitated in cells infected with AcUL15 alone (panel B; lane 14). These 
results confirm previous published reports that UL15 and UL28 interact in the absence of  
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A. Soluble protein extracts
B. Immunoprecipitation with R123
Figure 5.13: Immunoprecipitation of UL28 and UL15 from recombinant baculovirus-
infected cells.
A. Sf21 cells were mock infected or infected with 2.5 p.f.u./cell of the indicated 
recombinant baculoviruses. 48 h.p.i., soluble protein extracts were prepared. 
Samples of these extracts were separated on an 8 % polyacrylamide gel and 
western blotted. The membranes were incubated with either R123 (anti-UL28; 
1:500) (lanes 1-4) or R605 (anti-UL15; 1:500) (lanes 5-8). This was followed by 
incubation with HRP-conjugate protein-A and detection using (ECL substrate. The 
positions of size marker proteins are indicated (kDa).
B. Samples of the soluble protein extract were immunoprecipitated with R123 and the 
immune complexes harvested by incubation with protein-A-sepharose. These 
immunoprecipitated samples were separated by SDS PAGE and immunoblotted as 
above with either R123 (lanes 9-12) or R605 (lanes 13-16). The positions of size 
marker proteins are indicated (kDa).
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other proteins (Abbotts et al., 2000) and indicate that this protocol is appropriate for the 
detection of interaction between baculovirus-expressed proteins. 
5.5.3.2 Co-immunoprecipitation of UL32 with UL25, UL17 or UL6 
The above assay was then used to investigate whether UL32 interacts with UL25, UL17 or 
UL6, using the recombinant baculoviruses AcUL17, AcUL25 and AcUL6. 
Sf21 cells were mock infected or infected with AcUL6, AcUL25 or AcUL17, either alone 
in the presence of AcUL32. Soluble extracts were prepared 48 h.p.i and an aliquot of each 
incubated with the appropriate antibody R335, R1218 or R992. The immune complexes 
were harvested and soluble extracts and immunoprecipitated samples separated by SDS-
PAGE and western blotted as above. Membranes were incubated with either R1 (anti-
UL32) or R335, R1218 or R992, followed by HRP-conjugated protein-A, and the resultant 
blots are shown in figure 5.14.  
As shown in figure 5.14A, UL25 was expressed in cells infected with AcUL25 alone or in 
combination with AcUL32 (panel A; lanes 3 and 4). The anti-UL25 antibody R335 
successfully precipitated UL25 from these cells (panel A; lanes 7 and 8). UL32 was 
detected in cells infected with AcUL32 alone, or co-infected with AcUL25 (panel A; lanes 
10 and 12). However, UL32 did not co-precipitate with UL25 from cells that were dually 
infected with AcUL32 and AcUL25 (panel A; lane 16).  
Similarly, both UL17 and UL6 could be specifically precipitated from baculovirus infected 
cells using their cognate antibodies, but not from mock infected cells or those receiving 
UL32 alone (panels B and C; lanes 1-4). Again, UL32 was not co-precipitated from the 
dually infected cells (panels B and C; lane 16), although probing of the soluble extracts 
confirmed that UL32 was efficiently expressed in these cells (panels B and C; lane 12). 
In summary, the results of the co-localisation and co-immunoprecipitation experiments 
provide no evidence for an interaction between UL32 and UL25, UL6 or UL17. 
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Figure 5.14: Immunoprecipitation of UL32 and UL25, UL17 or UL6 from 
recombinant baculovirus-infected cells.
Sf21 cells were mock infected or infected with 2.5 p.f.u./cell of the indicated 
recombinant baculoviruses. 48 h.p.i., soluble protein extracts were prepared. 
Immunoprecipitations were carried out with R335 (A), R1218 (B) or R992 (C) and 
the immune complexes harvested by incubation with protein-A-sepharose. The 
soluble extracts and immunoprecipitated samples were separated by electrophoresis 
on 8 % polyacrylamide gels and western blotted. The membranes were 
immunoblotted using the antibodies indicated below each filter (all at 1:500 dilution), 
followed by HRP-conjugated protein-A and detected using ECL substrate. The 
positions of size marker proteins are indicated (kDa).
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B. AcUL32 and AcUL17 – immunoprecipitated with R1218
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C. AcUL32 and AcUL6 – immunoprecipitated with R992
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5.6 Investigation of the interaction of UL32 with the 
terminase components 
Similar experiments were next performed to examine whether UL32 could interact with the 
components of the HSV-1 terminase UL15, UL28 and UL33. 
5.6.1 Localisation of the terminase components in infected cells 
in the absence of UL32 
Like the other packaging proteins, the terminase components localise to the replication 
compartments of infected cells. It has been reported UL15 is essential for the recruitment 
of UL33 and UL28 to RCs (Higgs et al., 2008; Yang et al., 2007). Firstly, it was 
investigated whether UL32 might also have any role to play in the correct localisation of 
these proteins during HSV-1 infection.  
Coverslips of BHK cells were infected with 5 p.f.u. per cell wt HSV-1 or hr64. Six hours 
post infection, cells were fixed, permeabilised and blocked. Coverslips were incubated 
with M7381 to detect ICP8 along with R605 (anti-UL15), R123 (anti-UL28) or R148 (anti-
UL33) rabbit antibodies. This was followed by incubation with r-FITC and m-Cy5 and 
examination of the cells by confocal microscopy. Images are shown in figure 5.15. 
In each infection with either wt HSV-1 or hr64, ICP8 staining was visible in the nucleus, 
confirming efficient infection and that replication compartments had formed (images B, E, 
H, K, N and Q). In agreement with published results, UL15, UL33 and UL28 all 
predominantly localised to the nuclei of wt HSV-1 infected cells (images A, G and M). In 
all instances, this staining co-localised with ICP8 (images C, I and O). In the hr64 infected 
cells, the localisation of UL15, UL33 and UL28 was essentially unchanged, colocalising 
with ICP8 in RCs within the nuclei (images D and F; J and L; P and R). This suggests that 
UL32 is not involved in the localisation of the terminase components UL15, UL33 and 
UL28 in infected cells. 
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Figure 5.15: UL32 does not affect the localisation of terminase subunits UL15, 
UL33 or UL28 in HSV-1 infected cells.
Coverslips of BHK cells were infected with 5 p.f.u./cell wt HSV-1 or hr64 for 6 
hours. Cells were fixed and permeabilised and incubated with anti-ICP8 (M7381) 
along with either R605 (anti-UL15; 1:500), R148 (anti-UL33; 1:200) or R123 
(anti-UL28; 1:500) antibodies. This was followed by r-FITC and m-Cy5 
antibodies. The cells were examined by confocal microscopy. Scale bar = 20 µm.
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5.6.2 Co-immunoprecipitation analysis of UL32 and the terminase 
components 
To investigate whether UL32 could interact with any of the terminase components in the 
absence of other proteins, immunoprecipitations from baculovirus infected cells were 
carried out.  
Sf21 cells were co-infected with AcUL32 and baculoviruses expressing UL15 (AcUL15), 
UL33 (AcUL33) or UL28 (AcUL28). Forty-eight hours post infection, cells were lysed and 
soluble protein extracts prepared. Extracts were immunoprecipitated using the appropriate 
rabbit antibody recognising UL28 (R123), UL15 (R605) or UL33 (R148). Immune 
complexes were collected by incubation with protein-A-sepharose and the soluble extracts 
and immunoprecipitated proteins separated by electrophoresis on 8% polyacrylamide gels 
(or 15% gels for the UL33 samples) and western blotted. Duplicate membranes were 
probed with anti-UL32 antibody (R1) and R123, R605 or R148 as appropriate. 
As shown in figure 5.16, UL33 was expressed in cells infected with AcUL33 alone or 
dually infected with AcUL32, but could not be detected in cells that were mock infected or 
infected with only AcUL32 (panel A; lanes 1-4). UL32 was detected only in cells infected 
with AcUL32 alone or in combination with AcUL33 (panel A; lanes 10-12). The anti-
UL33 antibody R148 successfully precipitated UL33 from cells in which this protein was 
expressed (panel A; lanes 7 and 8). However, UL32 was not co-precipitated from the cells 
that were dually infected with AcUL32 and AcUL33 (panel A; lane 16).  
Similarly, both UL15 and UL28 could be specifically precipitated from baculovirus 
infected cells using their cognate antibodies, but not from mock infected cells or those 
receiving UL32 alone (panels B and C; lanes 5-8). Again, UL32 was not co-precipitated 
from the dually infected cells (panels B and C; lane 16), even though the soluble extracts 
confirm that UL32 was efficiently expressed in these cells (panels B and C; lane 12). 
These results suggest that UL32 does not interact with the indicated proteins of the 
terminase complex in recombinant baculovirus-infected cells. 
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Figure 5.16: Immunoprecipitation of UL32 and UL33, UL15 or UL28 from 
baculovirus-infected cells.
Sf21 cells were mock infected or infected with 2.5 p.f.u./cell of the indicated 
recombinant baculoviruses. 48 h.p.i., soluble protein extracts were prepared. 
Immunoprecipitations were carried out by incubation with R148 (A), R605 (B) or 
R123 (C) and the immune complexes harvested by incubation with protein-A-
sepharose. The soluble extracts and immunoprecipitated samples were separated on 
8% or 15% polyacrylamide gels and western blotted. The membranes were 
immunoblotted using the antibodies indicated below each filter (all at 1:500 dilution), 
followed by HRP-conjugate protein-A and detected using ECL substrate. The 
positions of size marker proteins are indicated (kDa).
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5.6.3 Immunofluorescence analysis of the interaction of wt UL32 
and the terminase components in transfected cells 
Finally the ability of UL32 to interact with the terminase components both individually and 
together was analysed by immunofluorescence using co-transfection assays. 
5.6.3.1 Co-transfections with single terminase components 
Coverslips of BHK cells were transfected as described in section  5.5.2 with pUL33 or 
pUL28 (encoding the UL33 and UL28 proteins respectively) either alone or in conjunction 
with pHA-UL32. Coverslips were fixed and permeabilised and incubated with F-7 along 
with R148 or R123, followed by FITC and Cy5-coupled secondary antibodies as before. 
The images from confocal microscopy are shown in figure 5.17. 
As previously noted, HA-UL32 localised entirely to the cytoplasm of cells when 
transfected alone (images A-C). In contrast, UL33 was localised throughout the cell, both 
in the cytoplasm and nucleus when expressed alone (images D-F). In cells transfected with 
plasmids expressing both proteins, UL33 was again detected throughout the cell, whereas 
HA-UL32 remained within the cytoplasm (images G-I). Therefore, UL33 does not appear 
able to transport UL32 into the nucleus; however, this may not be significant if the 
presence of UL33 in the nucleus is simply a result of its ability to diffuse into the nucleus 
due to its small size. 
UL28 showed a cytoplasmic localisation when transfected alone, similar to that seen with 
HA-UL32 alone (images J-L). It is difficult to interpret the result from the co-transfected 
cells, as both proteins remained in the cytoplasm (images M, N and O).   
To investigate the interaction of UL32 with UL15, BHK coverslips were similarly 
transfected with pJM9 (encoding UL15) along with pHA-UL32 and processed as above. 
Coverslips were incubated with F-7 and R605, followed by r-FITC and m-Cy5 secondary 
antibodies. The images are shown in figure 5.18.  
As in previous experiments, when expressed alone HA-UL32 localised in the cytoplasm of 
transfected cells (images A-C). UL15 was detected exclusively in the nuclei of cells when  
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Figure 5.17: Interaction of HA-UL32 with terminase proteins UL33 and UL28 in 
transfected cells.
BHK cells on coverslips were transfected with 0.5 µg of the indicated plasmids using 
Lipofectamine 2000. 18 hours post transfection, cells were fixed and permeabilised 
and incubated with either R148 (anti-UL33) or R123 (anti-UL28) along F-7 (anti-HA) 
antibodies. This was followed by incubation with r-FITC and m-Cy5. Cells were 
mounted onto slides and examined by confocal microscopy. Scale bar = 20 µm.
Chapter 5   
 
197
transfected alone, in agreement with published data (Koslowski et al., 1999). When the 
two proteins were expressed together, the results varied considerably. A small proportion 
of the cells (approximately 10%) showed the staining pattern seen in figure 5.18 panel 2, 
where UL15 remained in the nucleus (image G) and HA-UL32 was predominantly in the 
cytoplasm (image H). However the majority of the cells (approximately 60%) showed 
patterns similar to panel 3. In these cells, the UL15 staining remained within the nucleus 
(image J), whereas HA-UL32 was partially relocalised into the nucleus where it appeared 
to co-localise with UL15 (images K and L).  Approximately 20% of cells showed complete 
recruitment of HA-UL32 to the nucleus, where it co-stained with the UL15 signal as 
shown in figure 5.18 panel 4 (images M-O). Figure 5.18 panel 5 shows the staining pattern 
seen in the small remainder of the cells, where HA-UL32 remained throughout the 
cytoplasm (image Q), while UL15 also appeared to be retained in the cytoplasm where it 
extensively co-localised with the HA-UL32 protein (images P and R).  
To exclude the possibility that the partial colocalisation seen between HA-UL32 and UL15 
might be due to some unexpected effect of the HA tag, the co-transfections were repeated 
using a tagged form of UL15 and untagged pUL32. The plasmid pJM19 encodes UL15 
tagged with the pp65 epitope at the C-terminus, allowing the localisation of UL15 to be 
detected using an anti-pp65 antibody. Coverslips of BHK cells were transfected with 
pUL32 and pJM19 and processed as before. Coverslips were incubated with R1 and a 
mouse anti-pp65 antibody (1:500) followed by FITC and Cy5 conjugated secondary 
antibodies. The results are shown in figure 5.19. 
As can be seen in panel 1, the pp65 tag did not affect the localisation of UL15, as UL15-
pp65 was still detected solely in the nuclei of cells when transfected alone (images A-C). 
UL32 was detected in the cytoplasm of cells, as previously noted (images D-F). When cells 
were co-transfected with both plasmids, there was again a variation seen in the localisation 
of the proteins. In a small proportion of cells, no interaction was apparent between the two 
proteins with UL32 remaining in the cytoplasm and UL15-pp65 in the nucleus, as shown 
in figure 5.19 panel 2 (images G-I). Approximately 20-30% of cells showed the pattern 
represented in figure 5.19 panel 3, where UL15-pp65 remained in the nucleus, whereas 
UL32 was distributed throughout the cell. As with the previous transfections using HA-
UL32 and UL15, the majority of the cells showed some degree of nuclear colocalisation of 
the two proteins. Approximately 70% of cells showed patterns similar to panels 4 and 5. In 
these cases, UL15-pp65 was localised in the nuclei of cells (images N and Q) with UL32  
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Figure 5.18: Interaction of HA-UL32 with UL15 in transfected cells.
BHK cells on coverslips were transfected with 0.5 µg  of either pHA-UL32 or pJM9 or the 
two plasmids together using Lipofectamine 2000. 18 hours post transfection, cells were 
fixed and permeabilised and incubated with R605 (rabbit anti-UL15; 1:500) along with F-
7 (mouse anti-HA; 1:500). This was followed by incubation with r-FITC and m-Cy5. Cells 
were mounted onto slides and examined by confocal microscopy. Scale bar = 20 µm.
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Figure 5.19: Interaction of UL32 with UL15-pp65 in transfected cells.
BHK cells on coverslips were transfected with 0.5 µg of either pUL32 or pJM19 (1) or 
the two plasmids together (2-5) using Lipofectamine 2000. 18 hours post transfection, 
cells were fixed and permeabilised and incubated with R1 (1:500) along with mouse 
anti-pp65 antibody (1:500). This was followed by incubation with r-FITC and m-Cy5. 
Scale bar = 20 µm.
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either predominantly or completely relocalised to the nuclei (images M and P). When in 
the nucleus, UL32 co-localised extensively with the UL15-pp65 signal (images O and R). 
These data confirm that the colocalisation of HA-UL32 and UL15 was not an artefact of 
the tags added to the proteins and suggest that there is some form of interaction between 
UL32 and UL15 in co-transfected cells. This interaction was not seen in all cells, and so it 
could be that other proteins are required to strengthen or stabilise the interaction between 
the two proteins. 
5.6.3.2 Colocalisation of UL32 with the terminase in transfected cells 
As UL15 is already known to be a component of the terminase along with UL28 and 
UL33, it was next examined whether UL32 could interact with the terminase complex and 
whether the presence of the other terminase proteins might influence its localisation. 
Firstly, BHK cells were co-transfected with pUL33, pJM19 and pUL28-GFP (encoding the 
UL28 protein with a GFP tag inserted at the N-terminus) in the absence of UL32, to 
confirm that these proteins did indeed form a complex within the nucleus. Cells were 
processed as above and coverslips incubated with R148 (anti-UL33) and anti-pp65. This 
was followed by incubation with AlexaFluor antibodies A21428 (555-goat anti rabbit IgG; 
1:1000) and A21050 (633-goat anti-mouse IgG; 1:1000). These were analysed by confocal 
microscopy using the laser wavelengths FITC (to detect UL28-GFP), Cy5 (to detect 633) 
and TRITC (to detect 555). A representative image is shown in figure 5.20 panel A.  
UL28-GFP, UL15-pp65 and UL33 all completely co-localised in the nuclei of co-
transfected cells (images A-D). This was observed consistently and it should be noted that 
in every cell where UL28 was relocalised to the nucleus by UL15, UL33 was also found in 
the nucleus. This confirms that the three proteins successfully form a complex which 
localises to the nuclei of cells. In the following experiments, four plasmids were co-
transfected but only three of the proteins could be detected at any one time. Therefore, the 
localisation of UL33 was not examined, and the presence of both UL15-pp65 and UL28-
GFP in the nucleus was taken to indicate that the terminase complex had been correctly 
formed and translocated to the nucleus of these cells. 
The effect of all three terminase components together on the localisation of UL32 was then 
examined. Cells were transfected as above with pUL28-GFP, pJM19 and pUL33 along  
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Figure 5.20: Interaction of UL32 with the putative terminase in transfected cells.
A. Coverslips of BHK cells were transfected with 0.5 µg pUL28-GFP, pJM19 and 
pUL33 using Lipofectamine 2000. Cells were fixed and permeabilised and 
incubated with mouse anti-pp65 and R148 (anti-UL33) antibodies followed by 
A21428 (AlexaFluor 555 goat anti-rabbit IgG; 1:1000) and A21050 (AlexaFluor
633 goat anti-mouse 633; 1:1000). Note the different colour for the Cy5 channel 
to that used in previous figures
B. BHK cells were transfected with 0.5 µg pUL28-GFP, pJM19 and pUL33 along 
with pUL32. Cells were fixed and permeabilised and incubated with anti-pp65 
and R1 (anti-UL32) antibodies, followed by the secondary antibodies specified
above. Scale bar = 10 µm.
FITC Cy5 (633nm) mergeTRITC (555nm)
UL28-GFPA B UL15-pp65 C UL33 D
A. pUL28-GFP, pJM19 (UL15-pp65), pUL33
UL28-GFPE F UL15-pp65 G UL32 H
B. pUL28-GFP, pJM19 (UL15-pp65), pUL33, pUL32
FITC Cy5 (633nm) mergeTRITC (555nm)
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with pUL32. They were incubated with anti-pp65 and R1, followed by A21428 and 
A21050 secondary antibodies. A representative result typical of virtually every cell 
expressing these proteins is shown in figure 5.20 panel B. In these cells, UL32 was 
completely relocalised to the nucleus (image G) where it co-localised with the UL28-GFP 
and UL15-pp65 staining (image H).  This result suggests that UL32 can interact with the 
terminase complex resulting in its direction to the nucleus of transfected cells. 
5.6.3.3 Which components of the terminase are essential for this 
interaction? 
As the co-transfection of UL32 with all three terminase components resulted in the 
complete relocalisation of UL32 to the nucleus but co-transfection with UL15 alone 
resulting in only partial re-localisation of UL32, I next decided to determine which of the 
terminase components are essential for the complete nuclear relocalisation of UL32. These 
experiments were carried out by transfecting BHK cells with 0.5 µg each of plasmids 
pUL28-GFP, pUL33, pHA-UL32 and pJM19 in various combinations. Cells were 
processed as above and incubated with rabbit antibodies either recognising UL33 (R148) 
or UL32 (R1) along with either F-7 (mouse anti-HA) or mouse anti-pp65 antibodies as 
appropriate. This was followed by incubation with A21428 and A21050.  
As seen in figure 5.21, transfection of pUL28-GFP, pJM19 and pUL32 resulted in all three 
of these proteins colocalising in the nucleus of cells (images A-D). This pattern was 
observed in all cells. In the absence of UL15, both UL28-GFP and UL33 were distributed 
throughout the cell (images E and G). This is consistent with UL33 and UL28 interacting 
directly, with UL15 required for the complete relocalisation of the proteins to the nucleus 
(Beard et al., 2002; Koslowski et al., 1999; Yang et al., 2007). UL32 was found solely in 
the cytoplasm of these cells (image F). In cells co-transfected with pUL33-GFP, pJM19 
and pHA-UL32, UL15 was entirely nuclear and UL33 was largely localised in the nucleus, 
probably by virtue of its interaction with UL15 (images I and J). In addition, UL32 was 
partially relocalised to the nucleus, with a small portion remaining in the cytoplasm (image 
K), similar to the predominant phenotype observed upon co-transfection of just UL15 and 
UL32 (figure 5.18).  
Together these results confirm the observations made in section  5.6.3.1 that UL15 can 
influence the localisation of UL32, and indicate that UL15 is essential for the partial re-
localisation to the nucleus. UL28 also plays an important role since its inclusion increases  
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Figure 5.21: Localisation of the terminase proteins and UL32 in transfected 
cells.
BHK cells were transfected with the indicated plasmids using Lipofectamine 2000. 
18 hours post transfection cells were fixed and permeabilised and incubated with 
primary antibodies anti-pp65, R1, F-7 (anti-HA) and R148 (anti-UL33) as 
appropriate. This was followed by incubation with AlexaFluor antibodies A21428 
and A21050. Scale bar = 20 µm.
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the efficiency of nuclear uptake of UL32. UL33 appears to have little effect on this 
process. 
5.6.4 Interaction of mutated UL32 proteins with the terminase in 
transfected cells 
The experiment described in section  5.6.3.2 was next used to investigate whether the 
insertional or site-specific mutants generated in section 4 interacted with the terminase in 
transfected cells. To do this, cells were transfected as above with 0.5 µg each of pUL28-
GFP, pJM19 and pUL33 along with one of the UL32 mutants. Cells were processed and 
incubated with antibodies as in section  5.6.3.2 to detect the localisation of UL15-pp65 and 
the mutated UL32 proteins along with UL28-GFP. Images showing a selection of the 
UL32 mutants are presented in figure 5.22. When transfected alone each of these 
insertional mutants showed a cytoplasmic localisation, as reported in section 4.2.5 and 
figure 4.10. In the text below, those mutants that showed a positive result in the 
complementation yield and packaging assays in section 4 have been underlined. 
Fifteen of the mutant UL32 proteins exhibited a phenotype similar to that of wt UL32, as 
represented by in302 and in95, with UL32 almost completely relocalised to the nucleus 
along with the terminase components. These were mutants in5, in12, in67, in93, in95, 
in187, in220, in232, in302, in332, in377, in378 and in475. This group also included the 
non-functional mutants in338 and in398 (also shown in figure 5.22). Eleven mutants 
showed an intermediate phenotype, with some UL32 detected in the nucleus but a portion 
remaining in the cytoplasm, as represented by in136, in155 and in558. These also included 
mutant proteins in55, in309, in328, in376, in414, in449, in494 and in498. Eleven 
insertional mutants were not affected by co-transfection with the terminase proteins and 
remained entirely cytoplasmic, suggesting that they did not interact with the terminase 
proteins. This phenotype is represented by in40 and in177 in figure 5.22, and also included 
mutants in198, in407, in435, in486, in490, in512, in572, in580 and in592. 
The site-specific mutants were similarly analysed for their ability to interact with the 
terminase components in this assay. As can be seen in figure 5.22, UL32CxxC1 largely 
remained within the cytoplasm, whereas both UL32CxxC2 and UL32CxxxC3 were almost 
completely and partially relocalised to the nucleus, respectively. The mutant deleted at the 
extreme C-terminus, UL32∆C, also showed partial nuclear co-localisation with the 
terminase.
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Figure 5.22: Interaction of UL32 mutants with the putative terminase in 
transfected cells.
BHK cells on coverslips were transfected with 0.5 µg pUL28-GFP, pJM19, pUL33 
and the indicated UL32 mutant plasmids using Lipofectamine 2000 and processed as 
in the legend to figure 5.19 B. Scale bar = 20 µm.
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Comparison of these results with the functional characterisation of these proteins carried 
out in sections 4.3 and 4.4 revealed that each of the mutants that could support the growth 
and DNA packaging of hr64 co-localised either partially or completely with the terminase 
components in this assay. However, there was variation in the localisation of the non-
functional mutant proteins, with two still showing significant colocalisation with the 
terminase, nine showing partial colocalisation and the remaining eleven being unaffected 
in their localisation. 
 
5.7 Discussion 
This chapter describes the investigation of potential interactions between UL32 and 
various other HSV-1 DNA packaging proteins.  
Many HSV-1 processes occur within replication compartments (RCs) in the cell nucleus, 
including DNA replication, late gene transcription and the cleavage and packaging of viral 
DNA. Many of the HSV-1 cleavage and packaging proteins, as well as HSV-1 capsids 
have previously been reported to localise to the RCs during HSV-1 infection. A single 
report had additionally proposed that UL32 is essential for the correct localisation of 
capsids to RCs (Lamberti & Weller, 1998). I therefore attempted to repeat these 
experiments but found that the presence or absence of UL32 had no effect on the 
localisation of capsids or capsid proteins VP19C or VP5. 
To further investigate the localisation and interactions of UL32, an HA-tagged UL32 gene 
was constructed allowing expression both from a transfected plasmid and a recombinant 
HSV-1 virus. The HA tag, consisting of nine amino acids from influenza haemagglutinin, 
was added near to the N-terminus of UL32 to avoid disruption of the highly conserved C-
terminus. Due to the overlapping arrangement of the UL32 and UL33 genes in HSV-1, the 
HA tag was inserted between the second and third codons of UL32 so that UL33 would 
also remain intact and its translation should be unaffected when the tag was introduced into 
virus. Functional analysis of both the plasmid, pHA-UL32, and the virus, HA32EP, 
confirmed that addition of the HA tag at the N-terminus of UL32 did not affect the ability 
of the protein to support viral growth and DNA packaging. 
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As previously discussed, there have been conflicting reports of the localisation of UL32 in 
infected cells, with different groups finding UL32 localised either entirely within the 
cytoplasm (Chang et al., 1996) or predominantly cytoplasmic with a portion localising to 
RCs within the nucleus (Lamberti & Weller, 1998). This reported localisation is somewhat 
surprising given the known role of UL32 in DNA packaging and led Lamberti and Weller 
to suggest that UL32 may have an alternative/additional function. The UL32 homologue in 
HCMV, UL52, has been found to have a exhibit yet another pattern, being present within 
the nuclei of infected cells, but surrounding the replication compartments and not co-
localising with them (Borst et al., 2008). 
My analysis using the HA-tagged UL32 protein expressed by the virus HA32EP 
demonstrated that HA-UL32 was localised entirely in the nuclei of infected cells at 6 hours 
post infection, where it co-localised with ICP8 in RCs. UL32 therefore shows the same 
sub-cellular localisation as all other packaging and capsid proteins. These results differ to 
those previously published, but there may be a number of explanations for this. Firstly, in 
contrast to Chang et al., my work used an epitope-tagged UL32, and it is possible that the 
reactivity of the anti-HA antibody to its epitope is much stronger than that of their 
polyclonal antiserum to the UL32 protein. This might allow nuclear UL32 to be more 
readily detected (as reported by Lamberti and Weller, 1998) whilst decreasing the 
background signal. However, unlike Lamberti and Weller's studies, I introduced the HA-
tagged protein into virus and employed a normal infection, rather than a transfection-
superinfection assay. Therefore, the levels of HA-UL32 expressed in my experiment 
should be comparable to the normal levels of UL32 during HSV-1 infection, rather than 
expression driven from the strong ICP8 promoter in a plasmid. Furthermore, the other 
groups both examined the localisation of UL32 at very late times (18 hours and 20 hours) 
post infection, considerably after peak titres have been reached and when the cells exhibit 
considerable cytopathic effect. However, DNA packaging is readily detected much earlier, 
with DNase resistant DNA present, and the putative terminase subunits localised to RCs, at 
6 hours post infection (Higgs et al., 2008; Lamberti & Weller, 1998). My experiments 
were therefore carried out at early times (6 hours) post-infection to examine the 
localisation of UL32 while DNA packaging was occurring, and this may also account for 
some of the observed differences. 
It is unlikely that the HA-epitope tag affected the localisation of UL32 since both the HA-
UL32 plasmid and HA32EP virus behaved indistinguishably from corresponding 
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constructs expressing wt UL32 in functional assays. Furthermore, the proteins expressed 
from pHA-UL32 and pUL32 showed the same localisation in transfection assays. 
My observations that UL32 is localised to the RCs within infected cells but is found solely 
within the cytoplasm when transfected alone, suggested that other HSV-1 proteins are 
involved in the correct localisation of UL32 during infection. The most obvious candidates 
for this were the other cleavage/packaging proteins. The potential interactions between 
UL32 and these proteins were therefore investigated. 
At the commencement of my studies, no data indicative of an interaction between UL32 
and any other HSV-1 protein had been published. However, a recent paper suggests that 
UL32 affects the localisation of UL25 during infection (Scholtes & Baines, 2009). These 
authors found that during infection in the absence of UL32, although UL25 was 
predominantly nuclear, significant levels were detected in the cytoplasm. They also noted 
that the ratio of soluble UL25 to UL17 was increased in lysates from these cells, but did 
not examine whether UL25 and UL32 might co-localise or physically interact. However, 
the data presented in this chapter fail to provide evidence that UL32 interacts with the 
packaging proteins UL6, UL17 or UL25. In contrast to Scholtes, I found that UL32 had no 
discernable effect on the localisation of UL25 in infected cells (figure 5.11). It is not clear 
why these results should differ, but my conclusion was supported by the failure to detect an 
interaction between UL32 and UL25 using either a co-transfection or co-
immunoprecipitation assay. Similarly, UL32 did not show any interaction with either 
UL17 or UL6 in these assays. 
Experiments with hr64 also showed that UL32 is dispensable for the correct localisation of 
the putative terminase components UL15, UL28 and UL33 during infection. UL32 showed 
no evidence of an interaction with either UL28 or UL33 alone, however, UL32 and UL15 
influenced each others’ localisation in co-transfected cells in the absence of other viral 
proteins. This is the first evidence indicative of an interaction between UL32 and a 
member of the putative terminase complex. As the effect was not seen in every cell, and 
many cells showed only a partial colocalisation of UL15 and UL32, it may represent a 
weak or transient interaction between the two proteins. The interaction could not be 
confirmed by co-immunoprecipitation of baculovirus-expressed proteins, which again 
suggests that it may be an indirect, weak or transient interaction. The UL15-UL32 
interaction appears to be stabilised or strengthened by the addition of the other two putative 
terminase subunits, UL28 and UL33, as co-transfection of all four proteins consistently 
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caused almost complete relocalisation of UL32 to the nucleus. Co-transfection of UL32 
with all possible combinations of the terminase components suggested that UL28 and 
UL15 were essential for maximum relocalisation of UL32 to the nucleus. These data also 
indicated that UL33 is probably not involved in any interaction between UL32 and the 
terminase complex. 
The interactions between the putative terminase components are now well-established and 
it has been shown previously that UL15 is necessary for localisation of UL28 and UL33 to 
replication compartments during infection (Higgs et al., 2008). It has also been shown that 
these three proteins first form a complex in the cytoplasm and then the nuclear localisation 
signal (NLS) within UL15 directs their localisation to the nucleus (Yang et al., 2007). It is 
therefore possible that UL32 could bind stably to the assembled terminase complex in the 
cytoplasm and thereby be co-transported into the nucleus. In the context of an HSV-1 
infection, this would provide a mechanism by which UL32 is localised to the RCs for 
correct DNA cleavage and packaging to occur. These results suggest that UL32 binds to 
UL15 weakly, but may also interact with the UL28 subunit, so that when these two 
proteins are assembled within the terminase complex, UL32 makes contact with both 
proteins, thereby stabilising the interaction. Alternatively, the binding of UL15 to UL28 
may alter the conformation of UL15, allowing UL32 to bind more stably, possibly by 
exposing other binding sites within UL15.  
It is important to note that although the immunofluorescence data indicate that UL15 (and 
potentially UL28) influence the localisation of UL32, it does not necessarily demonstrate a 
direct interaction. There are a number of ways in which one protein may influence the 
other in the absence of a direct physical interaction, for example, an interaction may be 
mediated by other (cellular) proteins or the presence of DNA. Alternatively, one protein 
may affect the localisation of another by altering post-translational modifications or signal 
sequences on the target protein.  
Since a panel of mutants had previously been generated (chapter 4), each of these was 
analysed to determine whether they could interact with the terminase complex. The ability 
of each mutant UL32 protein to support viral replication and DNA packaging and to 
interact with the terminase is summarised in table 5.1. The interactions were classified into 
three types. In class 1 interactions, UL32 was entirely nuclear and completely co-localised 
with the terminase, in class 2, UL32 was distributed throughout the cell and appeared to  
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Table 5.1: The ability of UL32 mutants to interact with the terminase proteins in 
an immunofluorescence assay.
The ability of UL32 mutant proteins to co-localise with the terminase proteins in the 
immunofluorescence assay is displayed, along with previous data showing their ability 
to support DNA packaging and virus growth.
Y = Functional; ability to support growth and packaging to over 10% that obtained 
with pUL32. 
N = Non-functional; ability to support growth and packaging to less than 10% of 
pUL32.
1 = complete colocalisation with the terminase (UL32 entirely nuclear). 
2 = partial colocalisation with the terminase (UL32 nuclear and cytoplasmic).
3 = no colocalisation with the terminase (UL32 entirely cytoplasmic)
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mutant Ability to support DNA packaging and viral growth Colocalisation with terminase
pUL32 Y 1
in5 Y 1
in12 Y 1
in40 N 3
in55 N 2
in67 Y 1
in93 Y 1
in95 Y 1
in136 N 2
in155 N 2
in177 N 3
in187 Y 1
in198 N 3
in220 Y 1
in232 Y 1
in302 Y 1
in309 N 2
in328 Y 2
in332 Y 1
in338 N 1
in376 Y 2
in377 Y 1
in378 Y 1
in398 N 1
in407 N 3
in414 N 2
in435 N 3
in449 N 2
in475 Y 1
in486 N 3
in490 N 3
in494 N 2
in498 N 2
in512 N 3
in558 N 2
in572 N 3
in580 N 3
in592 N 3
CxxC1 N 3
CxxC2 Y 1
CxxxC3 N 2
UL32∆C N 3
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partially co-localise, and in class 3, UL32 remained cytoplasmic and its localisation was 
not affected by co-transfection of the terminase.  
Virtually every mutant that supported the growth and DNA packaging of hr64 behaved 
indistinguishably from wt UL32 (class 1), being completely transported to the nucleus in 
the presence of the terminase. The only exceptions were mutants in328 and in376 which 
showed a partial nuclear localisation (class 2). Similarly, all mutants that failed to interact 
with the terminase (class 3) were defective in the functional assays. Nearly all of the other 
non-functional mutants exhibited only a partial relocalisation in the presence of the 
terminase (class 2; mutants in55, in136, in155, in309, in414, in449, in494, in498, in558 
and UL32CxxC3). The observation that all the mutants defective in the interaction with the 
terminase components were also defective in growth and packaging suggests that this 
interaction is essential for the function of UL32 within the DNA packaging process. 
However, the interaction is not sufficient to allow packaging to occur. Two particularly 
interesting mutants (in338 and in398) showed the same localisation as wt UL32 but were 
non-functional, and therefore may have a further defect that prevents these from supporting 
viral growth and DNA packaging. The twelve mutants that were only partially re-localised 
by the terminase (class 2) may have weaker interactions with UL15 and/or UL28, or may 
exist in different forms or conformations, only some of which can interact with the 
terminase.  
The regions of UL32 important for the interaction with the terminase do not map to a 
particular part of the protein, but are spread throughout. This perhaps supports the theory 
that UL32 binds to both UL15 and UL28, with different regions of the UL32 protein 
required for different interactions. Alternatively, the folding of UL32 may be such that 
these different regions are close to each other in the native protein, or some of the 
mutations may have long-range effects on the structure of the protein. 
Ideally, the interaction between UL32 and the terminase needs to be confirmed within the 
context of virus infection, for example by co-immunoprecipitation of UL32 along with one 
or more of the terminase components from HSV-1 infected cells. The generation of 
HA32EP should prove useful for this, as the anti-HA antibody is extremely potent and can 
be used for immunoprecipitation. Furthermore, it would be interesting to examine the 
localisation of UL32 in infected cells in the absence of UL15, to determine whether the 
UL15-UL32 interaction is necessary for the correct localisation of UL32 in replication 
compartments. Unfortunately, the current lack of a potent antibody capable of specifically 
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recognising untagged UL32 in HSV-1 infected cells means that this is presently difficult. 
The introduction of a UL15 deletion into HA32EP should circumvent this problem. 
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6 Characterisation of the UL32 protein 
This chapter describes a number of experiments undertaken to further characterise the 
UL32 protein, and attempt to identify its role within HSV-1 DNA packaging. Firstly, a 
new recombinant HSV-1 was created with an extensive deletion within UL32, to confirm 
the packaging defect of hr64. The ability of UL32 homologues from other herpesviruses to 
substitute for HSV-1 UL32 was also analysed. The UL32 protein itself was then examined 
in greater detail, to investigate the nature of the protein in solution, analyse and quantify its 
zinc-binding ability and investigate whether UL32 was capable of interacting with DNA. 
 
6.1 Generation of a new UL32 null mutant 
The UL32 mutant virus used in these studies up until now, hr64, was constructed by the 
insertion of an ICP6:lacZ cassette at amino acid 274 of UL32. None of the UL32 sequence 
was deleted from this virus, and hr64 was shown to express a 30 kDa protein 
corresponding to the N-terminus of UL32 (Lamberti & Weller, 1998). It is possible that 
this N-terminal fragment may affect the phenotype of hr64 and therefore it was decided to 
generate and analyse a new mutant HSV-1, with as much as possible of the UL32 gene 
deleted. Furthermore, hr64 is HSV-1 strain KOS mutant, whereas the parental UL32 gene 
used in my mutagenesis is derived from HSV-1 strain 17+. I therefore considered it would 
be useful to generate the new mutant in a strain 17+ background. 
6.1.1 Red/ET recombination 
The approach to generating the new UL32 deletion mutant employed the Counter-
Selection BAC modification kit from GeneBridges, which utilises the Red/ET 
recombination enzymes. This kit induces homologous recombination in vivo in E. coli to 
introduce mutations into Bacterial Artificial Chromosomes (BACs). BACs are DNA 
constructs based on the fertility plasmid (F-plasmid) and so can replicate stably in E. coli. 
These BACs can harbour up to 300 kbp foreign DNA and so are suitable for cloning long 
DNAs such as the full-length 152 kbp HSV-1 genome. The BAC used in this study was 
fHSV-1∆pac, containing the complete HSV-1 strain 17 syn+ genome, but lacking the 
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packaging signals (Saeki et al., 1998). The BAC vector also includes the selectable 
chloramphenicol resistance gene (camR). 
In the Red/ET system, homologous recombination is mediated by two phage proteins Redα 
and Redβ, which act as an exonuclease and DNA annealing protein respectively. The 
plasmid pSC101-BAD-gbAtet expresses the Redγαβ operon under the control of the 
arabinose inducible BAD promoter and confers tetracycline resistance (tetR).  
This recombination is used to recombine a specifically constructed cassette containing the 
rpsL and neo genes flanked by short regions of homology into the desired locus. By 
choosing homology arms corresponding to either end of the UL32 gene, the bulk of the 
gene will be replaced by DNA encoding the rpsL and neo genes. The presence of neo 
confers resistance to kanamycin (kanR) whilst rpsL results in sensitivity to streptomycin 
(strepS) which allow identification of the desired recombinant BAC. 
6.1.2 Generation of mutant rpsL-neo cassette 
In order to target the recombination to the UL32 gene in fHSV-1∆pac, a PCR product 
(rpsL-neo-32) containing the rpsL-neo cassette flanked by sequences homologous to UL32 
was generated (figure 6.1). As UL32 overlaps with the 5’ ends of both the UL33 and UL31 
genes, the entire UL32 ORF could not be removed from fHSV-1∆pac without disrupting 
these genes. It was therefore decided to retain approximately 200 bp at each terminus of 
UL32, so that upstream regulatory sequences that may be needed for expression of UL33 
or UL31 should not be affected. The sequences of the primers used to amplify the rpsL-neo 
cassette are listed in figure 6.1C. PCR was expected to produce a 1.4 kbp fragment, with 
nucleotides 151-201 and 1600-1650 of UL32 at either end. The rpsL-neo cassette replaced 
nucleotides 202 to 1599 of UL32. 
 
6.1.3 Insertion of rpsL-neo cassette into fHSV-1∆pac BAC DNA 
E. coli DH10B cells containing fHSV-1∆pac and pSC101-BAD-gbAtet were cultured at 
30°C overnight, and the Redα and Redβ recombination enzymes induced by addition of L-
arabinose and a temperature switch to 37°C (section  2.2.13.1). The cells were made 
competent for transformation and the rpsL-neo-32 PCR product transformed into the cells 
using electroporation (section  2.2.13.2). To allow recombination to occur, the cells were  
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Figure 6.1: Generation of rpsL-neo cassette with homology arms for 
recombination.
A. rpsL-neo cassette. The 1319 bp cassette, encoding the rpsL and neo genes, was 
used as a template for PCR, using primers BAC-PCR-F and BAC-PCR-R. Each 
primer consisted of sequences complementary to the rpsL-neo cassette (shown 
in orange) and sequences homologous to the UL32 gene (blue).
B. PCR generated the rpsL-neo-32 cassette, of 1420 bp. This contained the rpsL-
neo cassette with 50 bp homology to UL32 at the 5’ and 3’ ends (shown in 
blue) . The nucleotides positions of those sequences within the UL32 ORF are 
indicated. These homology arms then allowed the rpsL-neo-32 cassette to be 
recombined with fHSV-1∆pac DNA, with the rpsL-neo cassette replacing 1399 
nucleotides of the UL32 gene.
C. 5’ – 3’ sequences of PCR primers used, indicating those sequences 
complementary to the rpsL-neo cassette in orange and those complementary to 
the UL32 gene in blue.
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recombination into fHSV-1∆pac
151
rpsL (strpS) neo (kanR)
1650201 1600
1430 bp
addition of UL32 homology 
arms to rpsL-neo cassette
rpsL (strpS) neo (kanR)
1319 bp
BAC-PCR-F
BAC-PCR-R
TGAGGGCACGCAACGCTATGCAGACACGCCCCTCGAACTCGTTCCCG
CAGGTCAGAAGAACTCGTCAAGAAGGCGBAC-PCR-R
TGACGGCCAGTCACGTGATAGGTGTGCCGCCCGTCGGTACGCTCGA
CGAGGGCCTGGTGATGATGGCGGGATCGBAC-PCR-F
5' - 3' sequence
A.
B.
C.
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incubated at 37°C for 70 min. Bacteria with the rpsL-neo-32 cassette integrated into fHSV-
1∆pac should be camR/kanR/strpS and so the bacteria were plated first onto LB-agar plates 
containing cam and kan. Ten colonies were picked and these were each further plated onto 
cam/kan/strp plates to confirm that the rpsL-neo-32 cassette was intact and conferred the 
strp sensitivity. Two colonies (f∆pacC and f∆pacG) showed the expected antibiotic 
resistance phenotype of camR/kanR/strpS, and therefore were analysed in further detail.  
BAC DNA was prepared from overnight cultures of these clones and each was screened 
for the presence of the kanamycin resistance gene by Southern blotting as follows. The 
BAC DNA was digested with EcoRI, along with two other samples of BAC DNA to act as 
controls; BAC fHSV-1∆pac (the parental BAC) and BAC O (an fHSV-1∆pac derivative 
with the rpsL-neo cassette inserted into gene UL23 (Tong & Stow, 2010)). The DNA was 
separated by agarose gel electrophoresis and Southern blotted. The inserted rpsL-neo 
cassette was detected using 32P labelled rpsL-neo, provided by Lily Tong.  f∆pacC and 
fHSV-1∆pac BAC DNA was also similarly screened to confirm the deletion of the UL32 
gene, but using 32P labelled pUL32 as a probe. 
Figure 6.2A shows the EcoRI sites around the UL32 locus in fHSV-1∆pac and f∆pacC/G 
(with the rpsL-neo cassette inserted), and indicates the expected sizes of fragments 
recognised by the kanamycin and pUL32 probes. EcoRI cuts the HSV-1 genome at 
nucleotides 64130, 68201 and 69697, and so pUL32 should hybridise to two fragments of 
approximately 4.1 kb and 1.5 kb if the UL32 gene is intact (as expected in fHSV-1∆pac). 
In this case, the kanamycin probe should not hybridise, as the rpsL-neo cassette has not 
been inserted. If, however, the UL32 gene has been replaced by the rpsL-neo cassette 
(which does not contain any EcoRI restriction sites), then only one fragment of 5.6 kb is 
expected from this region. This should be detected by both the kanamycin and pUL32 
probes due to the presence of the rpsL-neo cassette and residual UL32 sequences at either 
end of the gene respectively. 
The two Southern blot membranes are shown in figure 6.2B and C. The kanamycin probe 
did not hybridise to the fHSV-1∆pac DNA in lane 2, confirming that the parental BAC 
does not contain the kanamycin resistance gene. Lane 1 containing BAC O DNA, showed 
a single band of approximately 5 kbp, corresponding to the kamR gene inserted into EcoRI 
N (Tong & Stow, 2010). The kanamycin probe also hybridised to a fragment of 5.6 kb 
from both f∆pacC and f∆pacG, confirming that the rpsL-neo-PCR cassette had been 
successfully inserted into these constructs. When probed with pUL32, fHSV-1∆pac (lane  
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Figure 6.2: Confirmation of the insertion of the rpsL-neo-32 cassette, and 
corresponding deletion of UL32 ORF in f∆pac DNA.
A. Diagrammatic representation of the region of fHSV-1∆pac and f∆pacC/G 
surrounding the UL32 gene. The UL32 gene is shown in blue with the HSV-
1 nucleotides indicated above. The orange box represents the expected 
position of the rpsL-neo-32 cassette within f∆pacC/G . The red arrows show 
the positions at which the genome is cleaved by EcoRI, and the expected 
sizes of fragments generated by EcoRI digestion of the two BACs are 
indicated.
B. BAC DNA was prepared from bacteria containing the indicated BACs. The 
DNA was digested with EcoRI and separated by agarose gel electrophoresis. 
Samples were Southern blotted and the inserted cassette visualised by 
probing with α-32P labelled rpsL-neo. The positions of size markers (kb) 
are indicated.
C. BAC DNA from f∆pacC and fHSV-1∆pac was digested and separated by 
electrophoresis as above. The samples were probed using 32P labelled 
pUL32 and the sizes of fragments generated are indicated.
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6) and f∆pacC (lane 5) show the patterns expected for a wt genome and one in which the 
rpsL-neo cassette has been inserted into the UL32 gene, respectively. 
6.1.4 Isolation of UL32 mutant virus 
BAC DNA was prepared from clone f∆pacC for transfection into mammalian cells for 
generation of the UL32 mutant HSV-1. Monolayers of the UL32 complementing cell line, 
UL32-5, were transfected using the calcium phosphate method with 2 µg f∆pacC BAC 
DNA together with 2 µg BamHI cleaved pGX2 (containing the HSV-1 BamHI K fragment 
which is needed to repair the packaging signals deleted from fHSV-1∆pac). The cells were 
incubated at 37°C for 3 days, the cells and media harvested and then used to infect fresh 
plates of UL32-5 cells. After 48 hours, the plate showed clear evidence of CPE. The cells 
and media were harvested, and a stock of this virus (∆32EP) prepared. 
6.1.5 Characterisation of ∆32EP 
The newly created ∆32EP virus was next characterised, to determine whether the 
phenotype was the same as hr64.  
6.1.5.1 Growth curve for ∆32EP 
The replication of ∆32EP on complementing and non-complementing cell lines was 
compared to wt HSV-1 and hr64 in a single-step growth curve. 35 mm dishes of BHK and 
cells were infected with 10 p.f.u. per cell wt HSV-1, hr64 or ∆32EP, and UL32-5 cells 
infected with hr64 or ∆32EP. One hour post infection, the cells were washed once with 
0.14 M NaCl, exposed to acid glycine wash for one minute, then washed with EC5 or 
EFC5 as appropriate, followed by continued incubation in EC5 or EFC5 at 37°C. Cells 
were harvested at 4, 8, 12, 16, 20 and 24 hours post infection and the cells and media 
sonicated before being titrated on UL32-5 cells for 3 days. Plaques were counted and virus 
yields determined. This growth analysis (figure 6.3) indicated that ∆32EP did not replicate 
on non-complementing BHK cells, producing very low yields, comparable to those of 
hr64. However, provision of UL32 in the UL32-5 complementing cell line allowed ∆32EP 
to grow to titres comparable to wt HSV-1 and hr64 in these cells. 
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6.1.5.2 Amplicon packaging assay 
The ability of ∆32EP to support DNA packaging was also tested in a transient amplicon 
packaging assay. BHK cells were transfected with 1 µg pCMV10 or pUL32 along with 0.5 
µg pSA1, and superinfected with 5 p.f.u. per cell wt HSV-1, hr64 or ∆32EP. Cells were 
harvested 18 hours post infection and total and DNase resistant DNAs prepared. The DNA 
samples were digested with EcoRI and DpnI and separated on a 0.8% agarose gel. The gel 
was Southern blotted and probed using 32P labelled pAT153, and the membrane is shown 
in figure 6.4. wt HSV-1 was able to efficiently replicate and package amplicon DNA, but 
as previously shown, hr64 could package DNA only in the presence of pUL32 (lanes 1-3). 
∆32EP replicated DNA at levels similar to wt HSV-1, but was not able to package the 
replicated DNA in the presence of pCMV10 (lane 5). Addition of pUL32 restored the 
DNA packaging ability of ∆32EP (lane 4). 
Together, these results all confirm that ∆32EP has a phenotype indistinguishable from 
hr64. The virus cannot replicate on non-complementing cells, or cleave and packaged 
DNA, but the provision of exogenous UL32 can repair these defects. 
 
6.2 Testing the UL32 homologues of VZV and HCMV for 
their ability to complement ∆32EP 
A number of reports have investigated the ability of the pseudorabies virus (PrV) and 
HSV-1 packaging proteins to functionally complement each other. It was found that HSV-
1 UL32 was able to support the growth of a UL32-negative PrV, but this functional 
complementation was not reciprocal (Fuchs et al., 2009). 
I therefore examined whether ∆32EP could be complemented by the homologues of UL32 
encoded by two other human herpesviruses, varicella-zoster virus (VZV; another 
alphaherpesvirus) and HCMV (a betaherpesvirus). The VZV homologue is a 585 amino 
acid protein, encoded by gene 26 (referred to here as VZV26). The HCMV homologue is a 
668 amino acid protein, named UL52 (referred to here as HCMV52), and has previously  
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Figure 6.4: Amplicon packaging by ∆32EP.
BHK cells were transfected with 1µg pCMV10 or pUL32, along with 0.5 µg pSA1 
using the calcium phosphate method, followed by superinfection with 5 p.f.u./cell 
wt HSV-1, hr64 or ∆32EP. 18 h.p.i., cells were harvested and total and DNase
resistant DNA prepared. The DNA was digested with EcoRI and DpnI and 
separated by agarose gel electrophoresis and Southern blotted. pSA1 was detected 
by probing the membrane with 32P labelled  pAT153.
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been characterised as essential for virus growth and for cleavage and packaging of HCMV 
DNA (Borst et al., 2008). 
6.2.1 Generation of plasmids expressing HA-tagged versions of 
VZV26 and HCMV52 
As no antibodies were available in the laboratory specific for VZV26 or HCMV52, 
constructs encoding HA-tagged proteins were generated by PCR. As with the generation of 
HA-UL32 (section  5.2), the primers were designed such that the HA tag was encoded 
between the second and third amino acids of VZV26 and HCMV52, generating constructs 
named HA-VZV26 and HA-HCMV52 respectively. The forward primers for each 
construct contained an introduced KpnI site which was used during subsequent cloning as 
described below. The reverse primers for HA-VZV26 and HA-HCMV52 introduced XbaI 
and HindIII sites respectively, again used for further cloning. The primer sequences are 
listed in table 6.1. 
The template for the PCR construction of the HA-tagged VZV-UL32 was plasmid pVZV-
KpnI f, which contains the KpnI f fragment of VZV, spanning nucleotides 43943 to 49984 
of the VZV genome, with gene 26 specified by nucleotides 44506 to 46263 (Davison & 
Scott, 1986). The template for the PCR construction of HA-HCMV52 was plasmid 
pHCMV-HindIII f containing the HindIIII f fragment of HCMV strain AD169. This 
fragment spans nucleotides 65813 to 86163 with UL52 encoded from nucleotides 75087 to 
77093. 
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5' - 3' sequence 
inserted 
site 
HA-VZV26 
    
HA-VZV-F GGGCGGTACCCCATGGATTACCCTTACGACGTGCCTGACTACG CTCGGGTAGAATCAGAAGAACC  KpnI 
VZV-R CCGGCAGCTCTAGACCTAGACATACTTCGATAGGGTGTG XbaI 
HA-
HCMV52 
  
  
HA-
HCMV-F 
GGGCGGTACCCCATGAATTACCCTTACGACGTGCCTGACTAC 
GCTCCGAGTACCCACGTGAGC  KpnI 
HCMV-R CCGGGGTCGCCCAAGCTTGGGACGCTAGACATACTTGTCTACACG HindIII 
 
Table 6.1: Sequences of primers used for generating HA-VZV26 and HA-HCMV52. 
5'-3' sequences of the primers used for generation of HA-VZV26 and HA-HCMV52, 
showing the sequences encoding the HA tag in red and those complementary to the VZV26 
and HCMV52 genes in blue. The introduced restriction sites are listed and underlined in 
the primer sequences. 
 
 
 
Each PCR was carried out using the forward and reverse primers as described in section 
 2.2.3.8. The PCR fragments were then digested with the appropriate restriction enzymes 
(KpnI and XbaI in the case of HA-VZV26; KpnI and HindIII in the case of HA-HCMV52) 
and ligated into pCMV10 digested with the same enzymes, to generate pHA-VZV26 and 
pHA-HCMV52. 
6.2.2 Functional analysis of pHA-VZV26 and pHA-HCMV52 
Firstly, it was essential to verify that pHA-VZV26 and pHA-HCMV52 did indeed express 
the appropriate HA-tagged proteins. This was done by western blotting of transfected cells 
with F-7 (anti-HA). Figure 6.5A confirmed that each plasmid expressed a protein 
consistent with the predicted size of 64 kDa for VZV26 and 75 kDa for HCMV52. 
The two proteins were next tested for their ability to complement the growth and DNA 
packaging of the UL32 null mutant ∆32EP, using a complementation yield assay and 
transient amplicon packaging assay as previously described. 
As before, pUL32 supported the growth of ∆32EP in the complementation yield assay, 
giving a mean titre of 4.3 x 104, whereas pCMV10 did not, giving a titre of 40 (0.1% of the 
pUL32 value). Similarly, neither pHA-VZV26 nor pHA-HCMV52 could complement  
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Figure 6.5: Expression of HA-VZV26 and HA-HCMV52, and analysis of their 
ability to support packaging of amplicon DNA by ∆32EP.
A. BHK cells were transfected with 1 µg pHA-VZV26 or pHA-HMCV52 using the 
calcium phosphate method and harvested after 18 hours. Cells were lysed and 
proteins separated by SDS-PAGE. Proteins were western blotted and the 
membranes immunoblotted with F-7 (anti-HA) followed by HRP-conjugated 
anti-mouse IgG and developed using ECL substrate.
B. BHK cells were transfected with 1 µg pCMV10, pUL32, pHA-VZV26 or pHA-
HCMV52 along with 0.5 µg pSA1 using the calcium phosphate method, 
followed by superinfection with 5 p.f.u./cell ∆32EP. 18 h.p.i., cells were 
harvested and total and DNAse resistant DNA prepared and analysed as in the 
legend to figure 6.4.
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∆32EP, giving mean titres which were 0.1% and 0.15% of that obtained with pUL32 
respectively. 
The results of the amplicon packaging assay are shown in figure 6.5B. All samples showed 
similar levels of total (replicated) DNA, with packaged DNA seen in the samples 
containing pUL32 (lane 1) but not pCMV10 (lane 2). Neither pHA-VZV26 nor pHA-
HCMV52 supported detectable packaging of amplicon DNA (lanes 3 and 4), with mean 
values from duplicate experiments of less than 0.1% of that packaged in the presence of 
pUL32.  
These results together demonstrate that neither pHA-VZV26 nor pHA-HCMV52 can 
substitute for HSV-1 UL32 and functionally complement the defect of ∆32EP. 
 
6.3 Investigation of a possible interaction of UL32 with 
UL12 
As previously discussed, the HSV-1 UL12 gene encodes the alkaline nuclease, a protein 
involved in the resolution of branched structures in concatemeric viral DNA resulting from 
recombination during genome replication. Many bacteriophage also encode nucleases 
performing this function. One of these is endonuclease VII of phage T4, which is required 
at late points during infection to resolve branchpoints before packaging of DNA into the 
phage head (Kemper & Garabett, 1981; Kemper & Janz, 1976).  
Endonuclease VII has been shown to have a modular organisation of structure and 
function, with the C-terminal portion providing the endonuclease and the N-terminal 
portion thought to be involved in the DNA binding properties of the protein (Giraud-Panis 
et al., 1995). The N-terminal region contains four cysteine residues distributed in a CxxC 
pattern reminiscent of that in HSV-1 UL32. Endonuclease VII was also found to 
coordinate zinc atoms. This similarity between the N-terminal portion of endonuclease VII 
and UL32 led me to speculate whether UL32 could work in concert with UL12 to perform 
a similar function in HSV-1.  For example, UL32 might encode the DNA binding subunit 
(analogous to the N-terminus of endonuclease VII) with UL12 being equivalent to the C-
terminus and performing the nuclease function. 
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6.3.1 Co-immunoprecipitation analysis of UL32 and UL12 from 
baculovirus-infected cells 
The possibility of a direct interaction between UL32 and UL12 was investigated by 
immunoprecipitation from insect cells infected with baculoviruses expressing these 
proteins. Sf21 cells were mock infected or infected with AcUL32 and AcUL12 (expressing 
the UL12 protein) either alone or together. Forty-eight hours post infection, soluble protein 
extracts were prepared. An aliquot of each of these was immunoprecipitated using 
monoclonal antibody Q1 (anti-UL12), followed by incubation with protein-A-sepharose. 
Soluble extracts and immunoprecipitates were separated by SDS-PAGE and 
immunoblotted using R1 or Q1 (1:500), followed by HRP-conjugated protein-A. The 
resultant western blot is shown in figure 6.6. 
As shown in panel A, UL12 was expressed in cells infected with AcUL12 either alone 
(lane 3) or together with UL32 (lane 4), but not cells that were mock infected or infected 
with AcUL32 alone (lanes 1 and 2). Similarly, UL32 could be only detected in cells 
infected with AcUL32 alone or dually infected with AcUL12 (lanes 5-8). As would be 
expected, the UL12 antibody Q1 successfully precipitated the UL12 protein from infected 
cells (lanes 11 and 12). However, Q1 did not co-precipitate UL32 from the dually infected 
cells (lane 16). The reciprocal experiment, using R1 for the immunoprecipitation, gave the 
same result (data not shown). This indicates that UL32 and UL12 do not form a complex in 
baculovirus-infected cells.  
 
 
6.3.2 Pulsed-field gel analysis of the structure of replicated DNA 
in ∆32EP infected cells 
Gel electrophoretic techniques have previously been used to analyse the structure of 
replicative concatemers of HSV-1 DNA, and while conventional gel electrophoresis can 
resolve fragments of only approximately 40 kbp, pulsed-field gel electrophoresis (PFGE) 
enables resolution of much larger DNA molecules, of up to 2000 kbp in size. Previous 
work showed that replicative intermediates generated by wt HSV-1 remain in the wells of a 
pulsed-field gel, due to their branched structure, whereas the cleaved unit-length genomes 
can enter the gel. Restriction enzyme digestion followed by PFGE analysis of DNA from 
cells infected with a UL12 null mutant demonstrated that the replicative intermediates  
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A. Soluble protein extracts
B. Immunoprecipitation with Q1
Figure 6.6: Immunoprecipitation of UL12 and UL32 from recombinant baculovirus-
infected cells.
A. Sf21 cells were mock infected or infected with 2.5 p.f.u./cell of the indicated 
recombinant baculoviruses. 48 h.p.i., soluble protein extracts were prepared. 
Samples of these extracts were separated on an 8 % polyacrylamide gel and 
western blotted. The membranes were incubated with either Q1 (anti-UL12; lanes 
1-4) or R1 (anti-UL32; lanes 5-8). This was followed by incubation with HRP-
conjugated protein-A which was detected using ECL substrate. The positions of 
size marker proteins are indicated (kDa).
B. Samples of the soluble protein extract were immunoprecipitated with Q1 and the 
immune complexes harvested by incubation with protein-A-sepharose. These 
immunoprecipitated samples were separated by SDS PAGE and immunoblotted as 
above with either Q1 (lanes 9-12) or R1 (lanes 13-16). The positions of size marker 
proteins are indicated (kDa).
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produced by this virus were more complex than those of wt HSV-1, and apparently 
contained a higher level of branched structures (Martinez et al., 1996a). 
It was therefore decided to carry out pulsed-field gel analysis of the replicated DNA 
produced by ∆32EP, to determine whether UL32 may, like UL12, be involved in the 
resolution of branched structures. 
Duplicate plates of BHK cells were infected with 5 p.f.u. per cell wt HSV-1, ∆32EP or 
ambUL12, which contains an amber stop codon at position 129 of the UL12 ORF (Patel et 
al., 1996b). 18 hours post infection, cells were harvested into the medium and the cells 
from each plate embedded in agarose blocks (as described in  2.2.14.1), so that the DNA 
could be manipulated in situ to avoid shearing high molecular weight molecules. Total 
DNA was prepared by incubation in proteinase K, and the plugs (corresponding to 
approximately 6.5 x 105 cells each) were incubated with either SpeI, XbaI, HindIII or left 
undigested. The DNA was then separated by electrophoresis in a 1% PFGE agarose/0.5 x 
TBE gel at 6 V/cm for 16 hours at 14ºC with a ramped switch time of 1 – 15 sec (section 
 2.2.14.3). The DNA was Southern blotted and HSV-1 DNA detected by hybridisation to 
32P labelled fHSV-1 pac+ BAC DNA (a recombinant BAC encoding the entire HSV-1 
genome). The Southern blot is shown in figure 6.7. 
As previously reported (Martinez et al., 1996a), undigested DNA from wt HSV-1 infected 
cells produced two bands corresponding the released unit-length genomes of 152 kbp and 
the high molecular weight DNA that failed to enter the gel (lane 1). Neither ambUL12 nor 
∆32EP produced detectable genomic length DNA, with most of the undigested DNA 
remaining in the wells (lane 2 and 3). This is consistent with the known inability of UL32 
mutant HSV-1 to cleave concatemers and the reduced packaging of “poor quality” DNA 
by ambUL12 (Porter & Stow, 2004b; Sherman & Bachenheimer, 1987) . 
SpeI cleaves the HSV-1 genome once. Complete digestion of concatemeric DNA with this 
enzyme is expected to produce three fragments of sizes 186 kbp, 152 kbp and 118 kb, due 
to the potential isomerisation of the genome (Martinez et al., 1996a). These bands could be 
very faintly seen in the wt HSV-1 DNA sample, along with four prominent smaller bands 
generated from unit length genomes containing the L segment in either orientation. These 
were 80 and 70 kbp from the prototype orientation and 100 and 50 kbp from the inverted 
orientation (lane 4). In contrast to wt HSV-1, SpeI cleaved ambUL12 DNA was fully 
retained within the well, as the more branched nature of the DNA prevented fragments  
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Figure 6.7: PFGE analysis of viral DNA from cells infected with wt HSV-1, ∆32EP 
or ambUL12.
BHK cells were infected with 5 p.f.u./cell wt HSV-1, ∆32EP or ambUL12 for 18 hours. 
Cells were harvested and embedded in agarose blocks. Total DNA was prepared in 
situ. The DNA within each block was digested with the indicated restriction 
endonuclease or left undigested. The samples were separated by PFGE  using the 
following parameters: 1% PFGE agarose/0.5 x TBE gel at 6 V/cm for 16 hours at 14ºC 
with a ramped time of 1-15 sec. The gel was Southern blotted and the membrane 
probed with 32P labelled fHSV-1 pac+ BAC DNA (encoding the HSV-1 genome). The 
positions of molecular markers are indicated (in kbp). 
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from entering the gel or running as discrete bands (lane 6). The DNA produced in the 
∆32EP infection generated the three fragments predicted for wt concatemeric DNA, 
indicating that in this case the SpeI fragments generated from concatemers could enter the 
gel (lane 5). 
Cleavage of unit length DNA with XbaI is predicted to produce seven fragments from the 
four possible isomers (11, 34, 25, 29, 55, 36 and 29 kbp). Concatemers should lack four of 
these, corresponding to terminal fragments (11, 55, 36 and 29 kbp), but yield three novel 
fragments (65, 84 and 47 kbp) resulting from L segment inversion within the concatemer. 
The 84, 65, 55 and 11 kbp bands are clearly visible for the wt HSV-1 DNA in lane 7, along 
with an intense band falling within the predicted sizes of 25-47 kbp. Only a feint smear of 
DNA could be seen from ambUL12 infected cells rather than discrete bands, again 
showing that this DNA has a more complex structure than wt HSV-1 (lane 9). The ∆32EP 
DNA was similar to wt HSV-1, showing discrete bands, although the sizes were in some 
cases different because only concatemeric DNA was present in the ∆32EP infection (lane 
8). A similar result was seen when the DNA was digested with HindIII, which is a more 
frequent cutting enzyme. Again, the wt HSV-1 DNA showed discrete bands of 
approximate sizes 4 to 40 (lane 10), whereas ambUL12 yielded fragments that were 
somewhat smeared and poorly resolved (lane 12). As before, the DNA from the ∆32EP 
infected cells behaved similarly to the wt DNA, yielding a similar set of discrete bands 
(lane 11). 
This result confirms that the structure of ambUL12 is different to that of wt HSV-1 DNA, 
and that the frequency of cross-links or other abnormalities is sufficiently high that even 
when the DNA is cleaved into small fragments (e.g. by HindIII) sharp bands are not 
produced. In contrast, even though terminal fragments are not generated, the overall 
structure of ∆32EP DNA appears much more similar to wt HSV-1 DNA and discrete bands 
result from digestion with each of the three enzymes. Therefore, consistent with its lack of 
interaction with UL12, UL32 does not appear to be involved in resolution of branched 
structures prior to DNA encapsidation. 
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6.4 Estimation of the size of UL32 by size exclusion 
chromatography  
Previous work presented in chapter 3 showed that baculovirus-expressed UL32 protein 
could be partially purified from other baculovirus and cellular proteins using anion 
exchange chromatography. It was decided to further this chromatography work to 
determine whether UL32 exists as a monomer or higher-order structure in solution. This 
was done using a 24 ml Superose 12 HR 10/30 column (Amersham).  
Before the sizing of UL32, the column was first calibrated with standard proteins of known 
molecular weight; IgG (160 kDa), BSA (67 kDa) and ribonuclease A (13.7 kDa). The 
Superose column was equilibrated with buffer A and a filtered sample of the three proteins, 
each at a final concentration of 2 mg/ml was applied to the column. The proteins were 
eluted from the column with 24 ml buffer A. Examination of the UV absorbance trace 
showed that IgG, BSA and ribonuclease A eluted from the column at 11.41 ml, 11.98 ml 
and 15.78 ml respectively (data not shown). These standard sizes were then used as 
molecular markers for the sizing of UL32.  
For the sizing of UL32, five flasks of Sf21 cells were infected with 5 p.f.u. per cell 
AcUL32. Forty-eight hours post infection, soluble protein extracts were prepared and 
filtered (section  2.2.9.1). This extract was applied to the MonoQ column and the fractions 
containing UL32 collected, as in section  3.4. The UL32 containing fractions were pooled 
and 200 µl applied to the Superose 12 column and eluted using exactly the same conditions 
as the markers. 0.5 ml fractions were collected for analysis. These samples were separated 
by SDS-PAGE and western blotted. UL32 was detected by incubation with R1 followed by 
HRP-conjugated protein-A and detection with ECL. The UV absorbance trace is shown in 
figure 6.8A, with the positions of the markers from the previous run marked. 
This trace showed a number of discrete peaks. Analysis of all of the fractions on a 
Coomassie stained gel revealed that the majority of UL32 protein was in fractions B1-B11 
(data not shown). A western blot of fractions A15-B13 immunoblotted with R1 is shown in 
figure 6.8B. Based on the elution of standard proteins, monomers and dimers of UL32 
would be expected to elute at approximately fractions B10 and B8 respectively. Although 
some UL32 is present in these fractions, it is present in the largest amounts in fractions B1-
B3 (equivalent to the peak at 7.79 ml) which correspond to the exclusion volume of this  
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Figure 6.8: Size exclusion chromatography of UL32.
UL32 protein was harvested from AcUL32-infected Sf21 cells and fractionated using 
a MonoQ column, as in the legend to figure 3.3. The peak UL32-containing 
fractions were pooled and 200 µl applied to a Superose 12 column. Proteins 
were eluted with 24 ml buffer A and 0.5 ml fractions collected.
A. UV absorbance trace of the Superose fractionation, showing the positions at 
which each peak was eluted from the column (ml). The positions at which 
standard molecular marker proteins were eluted from the column on an 
identical run are marked by the red arrows.
B. 20 µl samples from fractions A15-B13 were boiled in the presence of SDS and 
separated by electrophoresis on an 8% polyacrylamide gel and western blotted. 
The membrane was immunoblotted with R1. The position of UL32 is marked 
and the positions of size markers are indicated (kDa).
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column. Since the exclusion limit of the Superose 12 HR 10/30 column is approximately 
2x106 kDa, this suggests that the UL32 protein exists predominantly as higher order 
multimers or aggregates which are too large to be separated by this column. However, a 
heterogeneous range of smaller complexes (monomers, dimers, trimers etc.) also appears to 
be present. 
 
6.5 Analysis and quantification of the zinc binding 
properties of UL32 
UL32 has CxxC/CxxxC motifs reminiscent of those in many zinc binding proteins and has 
previously been reported to bind to zinc (Chang et al., 1996). However, the radioactive 
zinc blot assay used in this study required the electrophoresis of UL32 using a denaturing 
gel, transfer of the protein onto a blot, and renaturation before the zinc-binding ability 
could be analysed. It was therefore an indirect method which did not allow for 
quantification of the zinc-binding. For this reason, I decided to investigate the binding of 
UL32 to zinc in more detail and attempt to quantitate this interaction. This was done by 
means of spectroscopic measurement of the zinc displaced from UL32 by p-
chloromercuribenzoic acid (PCMB). The concentration of the displaced zinc was 
determined by chelation with 4-(2-pyridylazo) resorcinol (PAR). PAR changes from a 
yellow to orange colour with increasing zinc concentrations which can be measured by 
absorbance at 492 nm (Giraud-Panis et al., 1995; Hunt et al., 1985; Hunt et al., 1984)  
6.5.1 Titration of zinc standard solutions 
Firstly, it was necessary to determine the range of zinc concentrations over which a linear 
response was measured and also to confirm that the addition of PCMB had no affect on 
this reading. Duplicate samples of a range of zinc concentrations were made up and PAR 
added to a final concentration of 100 µM. One of each sample also included 2 mM PCMB 
(final concentration). 300 µl of each sample was transferred to the wells of a 96-well plate 
and read at 492 nm using a Titertek Multiskan Plus plate reader. Zinc concentrations were 
tested in the range 0-1 M zinc (final concentration), and it was found that the linear range 
for detection was 0-8 µM. A representative experiment covering this range is shown in 
figure 6.9. 
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Figure 6.9: Titration of standard zinc chloride concentrations with PAR.
Duplicate samples were made up containing 100 µM PAR and the indicated final 
concentrations of zinc chloride, with and without 2 mM PCMB. 300 µl of each was 
transferred to the wells of a microtitre plate and the absorbance measured at 492 nm. 
Those samples with PCMB are shown in blue, and those without are shown in pink. 
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6.5.2 MonoQ fractionation of proteins expressed by AcUL32 and 
pac6 baculoviruses 
Peak UL32-containing fractions from the MonoQ fractionation of baculovirus-expressed 
UL32 were used for the zinc-release assay. However, as this purification is incomplete and 
these fractions also contain other baculovirus and cellular proteins, an appropriate control 
needed to be included. This was the parental baculovirus pac6, which is indistinguishable 
from AcUL32 except that it encodes lacZ rather than UL32. Equivalent fractions eluted 
from MonoQ purification of protein extracts from AcUL32 and pac6 should differ only in 
the UL32 or β-galactosidase protein content. Therefore, any difference in zinc release 
found between the two samples should be due to the binding of zinc by UL32 protein. As 
the Sf21 growth medium used for culture of the Sf21 cells contained no additional zinc, the 
media was supplemented with zinc during the infections. 
Ten 175 cm2 flasks of Sf21 cells were infected with either AcUL32 or pac6 and incubated 
in growth medium supplemented with 10 µM zinc acetate for 48 hours (section  2.2.16.1). 
Cells were harvested and soluble protein extracts prepared as before, in a total volume of 
10 ml buffer A. The protein samples were dialysed against buffer A to remove the unbound 
zinc from the medium. The two protein extracts were filtered and separately fractionated 
on a MonoQ column, with 0.5 ml fractions collected.  
Figure 6.10 shows the two superimposed UV absorbance traces from the MonoQ 
fractionations. These are very similar in pattern but a clear peak can be seen in the UL32 
sample (brown dashed line) eluted at approximately 0.3 M NaCl (approximately 35 ml), 
which is not present in the pac6 sample. The two traces are slightly offset relative to one 
another and so the equivalent fractions from each needed to be identified. This was done 
by comparing the peaks in the UV absorbance traces and also examination of the pattern of 
eluted proteins on Coomassie-stained gels for all fractions collected each sample. 25 
fractions surrounding and including the UL32 peak, and the corresponding fractions from 
the pac6 gradient, were renumbered 1-25 and a Coomassie-stained gel of these fractions is 
shown in figure 6.11. The UL32 protein can be clearly seen in fractions 13 to 21 with the 
greatest amounts in fractions 13 to 16 (which corresponded to the peak seen at 35 ml on 
the UV absorbance trace). 
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A. pac6
UL32
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B. AcUL32
Figure 6.11: Coomassie gel of MonoQ fractionation of pac6 and AcUL32extracts.
UL32-containing fractions and the equivalent pac6 fractions eluted from the MonoQ
fractionation shown in figure 6.10 were collected. 20 µl samples were boiled in the 
presence of SDS and separated by electrophoresis on an 8% polyacrylamide gel. 
Proteins were detected by staining with Coomassie. The positions of size markers 
(kDa) and the UL32 protein are indicated.
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The total protein concentration of fractions 13-16 from both gradients was determined 
using a Bradford assay (section  2.2.9.3) and the concentration of UL32 protein in these 
fractions estimated by subtraction. The UL32 protein was approximately 20% pure and 
ranged between 100-300 µg/ml, equivalent to a molar concentration of approximately 1.5-
4.5 µM UL32. 
6.5.3 Quantification of zinc binding of UL32 
Work by other groups using similar zinc-release assays has found that four molar 
equivalents of PCMB are required to remove 1 mole zinc from its bound protein if the zinc 
is chelated by four cysteine residues (Giraud-Panis et al., 1995; Hunt et al., 1984; Wojtyra 
et al., 2003). However, as it was not known how much zinc was bound to the UL32 
protein, or to any other proteins present in the AcUL32 and pac6 samples, I decided to use 
an excess of PCMB in these experiments to ensure that all of the zinc would be removed 
from the proteins, and available to chelate the PAR.  
Duplicate 200 µl samples of each protein fraction, 1-25, were mixed with 100 µM PAR, 
with and without 2 mM PCMB in a total volume of 300 µl, as described in section 
 2.2.16.2. The absorbance was measured at 492 nm after 5 minutes. The amount of zinc 
released by each protein sample was determined by comparison with a standard zinc curve. 
The results from fractions 1-25 are shown in figure 6.12, with the zinc release from the 
UL32 samples shown in blue and from the pac6 samples shown in pink. A clear peak can 
be seen in the zinc release from the UL32 gradient fractions 13-16 that is not present in the 
equivalent pac6 fractions. These are the fractions containing the greatest amount of UL32, 
and confirm that UL32 does indeed bind to zinc. The stoichiometry of zinc in the UL32 
protein was calculated for each of these fractions and is listed in the table below:  
Fraction 
Concentration of 
UL32 protein 
(nmoles) 
Concentration of 
zinc released 
(nmoles) 
Ratio 
zinc:UL32 
13 1.08 1.2 1.11 
14 1.22 1.26 1.04 
15 0.81 0.93 1.15 
16 0.54 0.81 1.5 
 
Table 6.2: Concentration of zinc released from UL32. 
The zinc released from samples collected from the fractionation of AcUL32 and pac6 was 
measured as described in figure 6.12. The zinc released specifically from the UL32 protein 
was determined by the difference between the UL32 and pac6 values for each equivalent 
fraction. 
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This zinc release assay was repeated, with similar results. In the second experiment, the 
peak fraction eluted from the MonoQ contained 0.45 nmoles UL32, and 0.36 nmoles zinc 
was released specifically from the UL32, giving a ratio of zinc:UL32 of 0.8. 
These results from two independent experiments show an approximate 1:1 ratio of zinc 
release to UL32 protein, suggesting that each molecule of protein binds to one molecule of 
zinc.  
Fraction 16 from the first experiment has a slightly higher zinc:UL32 ratio, but further 
examination of the Coomassie-stained gel (figure 6.11) showed that the pac6 fraction 16 
had an additional band of between 38 and 52 kDa, which is not as prominent in the UL32 
fraction 16. It is not known what this band is, but its presence may have led to a small 
underestimation in UL32 concentration in fraction 16. Using a more highly purified 
preparation of UL32 in these experiments would be desirable to eliminate such problems, 
however the attempts to further purify UL32 using a Superose 12 column were 
unsuccessful (section  6.4). 
6.6 Investigation of the DNA binding properties of UL32 
For a number of reasons, it was next decided to investigate whether UL32 was able to bind 
to DNA. Firstly, many zinc-binding proteins have been shown to bind DNA, both sequence 
specifically and non-specifically. Secondly, data presented in chapter 5 showed that UL32 
co-localises with the terminase complex, which is postulated to be directly involved in the 
recognition, cleavage and packaging of DNA, and therefore UL32 might bind DNA as part 
of this complex. To analyse the DNA binding properties of UL32, an electrophoresis 
mobility shift assay (EMSA) was utilised, in which radiolabelled DNA and protein sample 
are allowed to form protein-DNA complexes that are separated by electrophoresis on non-
denaturing gels. This assay relies on the ability of bound protein to reduce the mobility of 
DNA in the gel, so that protein-DNA complexes will migrate more slowly than the 'free' 
DNA. 
Simultaneous AcUL32 and pac6 infections of Sf21 cells were carried out as in section 
 6.5.2, extracts were fractionated using a MonoQ column and equivalent 0.5 ml fractions 
collected. 20 µl samples from fractions covering the UL32 peak were analysed by SDS-
PAGE and Coomassie staining (as shown in figure 6.13). UL32 was expressed and eluted  
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Figure 6.13 : MonoQ fractionation of soluble proteins expressed from AcUL32 
and pac6.
Sf21 cells were infected with 5 p.f.u./cell pac6 or AcUL32 and soluble proteins 
harvested after 48 hours. Proteins were applied to a MonoQ column and fractionated 
as described in the legend to figure 6.10. 20 µl samples of fractions containing UL32 
and the equivalent pac6 fractions were separated on 8% polyacrylamide gels and 
proteins stained using Coomassie Brilliant blue. The position of size makers (kDa) 
and UL32 are indicated. Note that these fractions are not the same as those in figures 
6.10-6.11.
A. pac6
B. AcUL32
1 2 3 4 5 6 7 8 9
225
>
76>
52>
UL32
1 2 3 4 5 6 7 8 9
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Chapter 6  247 
 
from the MonoQ column in fractions 4-9, with the greatest amount of UL32 in fractions 4-
7. 
The protein concentration of fractions 1-9 (and the equivalent fractions from the pac6 
fractionation) was determined using a Bradford assay. The total protein concentration of 
the fractions ranged from 200-300 µg/ml, with the peak fractions (4-7) containing 
approximately 20-30 µg/ml UL32. 10 µl of each protein fraction was used in each 
experiment, corresponding to approximately 200-300 pg UL32 protein.  
6.6.1 Analysis of UL32 binding to the minimal packaging signal 
Firstly, the ability of UL32 to specifically bind to the packaging sequences of HSV-1 was 
analysed, using DNA encoding the minimal packaging signal, Uc-DR1-Ub, excised from 
pSA1. As previously discussed, the amplicon plasmid pSA1 encodes an HSV-1 origin of 
replication and also the minimal packaging signal (Abbotts et al., 2000). The 200 bp Uc-
DR1-Ub sequence was excised from pSA1 by digestion with EcoRI and HindIII and 
purified after separation using agarose gel electrophoresis. 
400 ng of the double-stranded Uc-DR1-Ub DNA fragment was 3' end-labelled using 20 
µCi α-32P dCTP as described in section  2.2.15.1. This was diluted in H20 and 3 µl 
(corresponding to approximately 4 ng DNA) used in each DNA binding reaction. The 
DNA was incubated with protein fractions to allow binding to occur and protein-DNA 
complexes were separated by electrophoresis on a non-denaturing polyacrylamide gel 
(section  2.2.15.2). Gels were fixed and dried and exposed to a phosphorimage screen. A 
representative gel is shown in figure 6.14. 
The free probe migrated predominantly as a sharp fast-migrating band, although some 
label was detected near the top of the gel, which may have been pSA1 backbone 
contaminant. The only fractions significantly different to this were 5 and 6 where a 
complex of intermediate mobility was present. This represents DNA that is present in a 
protein-DNA complex, showing that proteins within these fractions can bind to the Uc-
DR1-Ub DNA fragment. However, no difference was seen between the DNA binding 
ability of the equivalent UL32 and pac6 fractions, indicating that the DNA binding activity 
seen was due to baculovirus-expressed or cellular proteins, rather than UL32. Longer 
exposure of the gel to the phosphor screen did not show any other DNA-protein 
complexes. 
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Figure 6.14: UL32 does not bind to the minimal packaging sequence.
Equivalent protein fractions (10 µl each) from the MonoQ fractionation of AcUL32 
and pac6 were incubated with 4 ng 32P 3’ end-labelled Uc-DR1-Ub for 30 minutes at 
RT in the presence of buffer M. Samples were separated by electrophoresis on a non-
denaturing 8% polyacrylamide gel, fixed and dried. The gel was exposed to a 
phosphorimage screen.
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This experiment was repeated with varied protein and DNA amounts, and varying the 
concentrations of salt and zinc in the buffer, but no evidence of UL32 binding to the 
minimal packaging signal Ub-DR1-Uc was seen. 
An almost identical result was obtained when the extracts were tested for their ability to 
bind to a control non-HSV-1 DNA fragment of 200 bp excised from pCMV10 (data not 
shown). This suggests that at least one protein in fractions 5 and 6 binds non-sequence 
specifically to dsDNA, but that UL32 itself does not show any DNA binding properties. 
 
6.7 Discussion 
This chapter describes further experiments I performed to characterise UL32, in an attempt 
to better understand its role in the HSV-1 DNA packaging process.  
A new UL32 null mutant virus (∆32EP) was constructed, in which all but 391 bp of the 
UL32 gene was deleted. This is in contrast to hr64, which retains all of the UL32 coding 
sequence, disrupted by an ICP6:lacZ cassette (Lamberti & Weller, 1998). hr64 produces a 
product of 30 kDa that is recognised by UL32 anti-sera which presumably corresponds to 
the 273 N-terminal amino acids of UL32, whereas the corresponding product of ∆32EP 
should contain only 67 N-terminal amino acids. The single step growth curves and 
amplicon packaging assay showed that ∆32EP is defective for viral growth and DNA 
packaging, but confirmed the ability of exogenously provided UL32 to complement these 
defects to levels near to that of wt HSV-1. This indicates that ∆32EP has the same 
phenotype as hr64 and also that the defects seen in ∆32EP were solely due to the deletion 
of the UL32 gene. These results also confirm that the inserted rpsL-neo-32 cassette had no 
detrimental effects on the virus. This work has confirmed the packaging-null phenotype for 
an independently created UL32 mutant HSV-1, indicating that it is unlikely that the N-
terminal fragment encoded by hr64 performs any function. Finally, the generation of 
∆32EP also supports the UL32-null phenotype using a different HSV-1 strain.  
The GeneBridges Counter-selection system was a convenient method of generating the 
UL32 mutant virus. By using homologous recombination between the target gene and a 
selectable marker, it overcomes many of the limitations associated with conventional 
methods of cloning. It allows direct introduction of new sequences at any target site within 
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a cloned full length HSV-1 genome. The mutants can then be easily recovered by 
transfection of the DNA into mammalian cells. The GeneBridges Counter Selection kit is 
also designed to allow a second step counter selection, where the selectable marker (rpsL-
neo cassette) can be replaced by the original wt gene or a copy carrying a specific 
mutation. Thus, potentially any of the mutations described in chapter 4 could be 
recombined into the f∆pac C BAC (section  6.1.4) and viruses generated for further study. 
The abilities of UL32 homologues VZV26 and HCMV52 to support the growth and DNA 
packaging of ∆32EP were analysed, but neither protein was able to substitute for HSV-1 
UL32 in these assays. There may be a number of explanations for this which are discussed 
below. 
HCMV is a member of the Betaherpesvirinae, and the UL52 protein exhibits relatively 
poor similarity compared to UL32, with only 17% identical residues, and some large 
stretches of amino acids that are not present in HSV-1 UL32. UL52 has previously been 
characterised and was shown to be essential for the cleavage and packaging of HCMV 
DNA (Borst et al., 2008). However, some differences were reported between HSV-1 UL32 
and HCMV UL52. UL52 appears to have a different sub-cellular localisation to HSV-1 
UL32, being present in the nucleus but surrounding the replication compartments rather 
than within them. This might possibly indicate different functions for HCMV UL52 and 
HSV-1 UL32 and explain the inability of UL52 to substitute for HSV-1 UL32. UL52 also 
contains a putative nuclear localisation signal not present in HSV-1 UL32 and can enter the 
nucleus in the absence of other HSV-1 proteins, and so perhaps establishes different 
protein-protein interactions. 
VZV26 has not yet been characterised, but as expected for two viruses belonging to the 
same sub-family, the VZV and HSV-1 UL32 proteins show a much greater degree of 
conservation. The two proteins show approximately 45% amino acid identity and this is 
distributed evenly throughout the protein. Despite being much more similar to HSV-1 
UL32 than UL52, VZV26 was still not able to functionally substitute for the HSV-1 
protein. A possible explanation is that interactions with other viral proteins are required for 
UL32 to participate in DNA packaging, and VZV26 may not be able to form these 
interactions. Although such interactions have not yet been reported in the literature, the 
possible interaction with the terminase complex described in this thesis may be important.  
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Previous studies by Mettenleiter's group analysing the functional conservation of some PrV 
and HSV-1 packaging proteins found that PrV UL32 does not complement the growth of a 
UL32 mutant HSV-1, but that the HSV-1 UL32 can successfully complement a PrV UL32 
mutant virus (Fuchs et al., 2009). PrV and HSV-1 UL32 proteins show approximately 40% 
amino acid identity (close to the 45% shared by HSV-1 and VZV). It might therefore be 
interesting to do reciprocals of the experiments I have presented here and examine whether 
HSV-1 UL32 can similarly support the growth of a UL32 VZV mutant. 
I next investigated whether UL32 may have been working in conjunction with the viral 
alkaline nuclease, UL12, to contribute to the resolution of branched structures in the 
replicated HSV-1 DNA. However, the two proteins did not interact in an 
immunoprecipitation assay. Furthermore, the replicated concatemeric DNA produced by 
∆32EP showed no evidence of being structurally abnormal when analysed by restriction 
digest and PFGE. Therefore the CxxC-containing UL32 protein does not appear to 
contribute towards the alkaline nuclease function of UL12 in an analogous function to the 
CxxC domain to the phage T4 endonuclease VII protein. This may not be too surprising in 
view of the different phenotypes of the UL12 and UL32 mutant viruses in non-
complementing cells. Whilst hr64 and ∆32EP have a completely negative DNA packaging 
phenotype, the UL12 mutant ambUL12 shows only a relatively small reduction in DNA 
packaging but nevertheless exhibits a 200-1000 fold reduction in virus yield compared to 
wt HSV-1 (Porter & Stow, 2004b). 
Sizing analysis of UL32 using a Superose column suggested that the protein probably 
forms heterogeneous multimers and aggregates in solution. This also indicates that 
Superose 12 chromatography is unlikely to be useful for further purification of UL32.  
The zinc-binding ability of UL32 was investigated and quantified using a zinc-release 
colourmetric assay. Chang et al (1996) had previously reported that UL32 was able to bind 
zinc, as evidenced by the specific binding of radiolabelled zinc to a membrane containing 
virally-expressed UL32 or a baculovirus-expressed His-tagged UL32 protein. My approach 
demonstrated the presence of zinc in UL32 more directly, and unlike the zinc blot studies, 
did not require denaturing and renaturing of the UL32 protein. This was done by 
measuring the amount of zinc released by protein in solution, and revealed a molar ratio of 
close to 1:1 zinc:protein.  
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No zinc finger (ZnF) can be identified within UL32 using prediction programmes, 
although the region containing the most N-terminal CxxxC motif does show high similarity 
to the classical Cys2His2 (C2H2) ZnF motif, as shown below. 
 
 
 
Figure 6.15: Conserved sequence of a C2H2 classical Zinc finger motif. 
The conserved cysteine and histidines residues are highlighted in red. Ø represents a 
hydrophobic residue and the hydrophobic residues in UL32 are highlighted in blue.  
 
 
 
However, this motif within UL32 contains 14 residues between the second cysteine and 
first histidines (rather than the consensus 12), and also there is a polar glutamate (E) in the 
first hydrophobic position. Furthermore, these histidine residues are not well conserved 
within UL32, with the first His present in only four other herpesvirus sequences, whilst a 
short stretch including this histidine has been deleted from the Beta- and Gamma- 
herpesvirinae. This suggests that these histidines are not essential for the function of UL32 
and so are unlikely to be part of a conserved zinc finger.  
A number of other viral proteins have been identified containing conserved CxxC motifs 
that are involved in zinc-binding, including the E6 and E7 proteins of human papilloma 
virus (HPV). The zinc atoms bound to E7 are co-ordinated by the cysteine residues within 
the CxxC motifs (Patrick et al., 1992), showing that paired CxxC motifs alone can be used 
to coordinate zinc atoms, as may be the case in UL32. It is interesting to compare the zinc 
binding results with my mutational analysis of UL32 showing that the first and third 
CxxC/CxxxC motifs are absolutely essential for function, whereas when the central CxxC 
is mutated the UL32 protein retains a degree of function. This might suggest that the zinc 
atoms in UL32 are chelated by the outer CxxC/CxxxC motifs, and this will be discussed 
further in chapter 7. It would have been extremely interesting to have examined the zinc-
binding ability of the CxxC/CxxxC mutants, but unfortunately time constraints prevented 
this. 4 moles of PCMB are required to release zinc chelated by 4 cysteine residues and my 
results could be furthered by performing a titration of PCMB to determine how many 
cysteines are involved in chelating the zinc. 
C DPM C AITEMEVDPWVLFG H PPAT H 
C x 2 - 4 C XXX Ø XXXXX Ø XX -- H XXXX H ZnF 
UL32 
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A common feature of zinc binding proteins is their ability to bind DNA. Since the work 
presented in chapter 5 suggested that UL32 may form a complex with the terminase, and 
this enzyme is known to be directly involved in the cleavage and packaging of DNA, the 
ability of UL32 to bind to DNA was investigated. However an electrophoresis mobility 
shift assay found no evidence that UL32 bound to either the 200 bp HSV-1 minimal 
packaging sequence (Uc-DR1-Ub) or a non-HSV-1 control fragment. 
EMSAs provide a useful initial study of the DNA binding properties of a protein. 
However, the fact that these results were negative does not completely eliminate the 
possibility of UL32 being involved in DNA binding. The UL28 subunit of the terminase 
was previously reported to bind to a novel DNA confirmation formed by the heat treatment 
of pac1, whereas it did not bind to the dsDNA sequence (Adelman et al., 2001). Although 
these results have not been repeated, this raises the possibility that the Uc-DR1-Ub 
sequence may adopt a different structure within cells which is required for protein binding. 
In addition, the UL28 homologue in HCMV, UL56, has been shown to interact with single 
stranded DNA sequences bearing the pac1 and pac2 motifs (Bogner et al., 1998). It might 
therefore be interesting to determine whether UL32 exhibits DNA binding activity in the 
presence of the terminase, or when alternative DNA fragments are examined. Another 
method of detecting DNA binding that could be employed is using chromatin 
immunoprecipitation (ChIP) which has the advantage of allowing an in vivo determination 
of DNA binding activity. The epitope-tagged recombinant HSV-1 HA32EP might prove 
useful for testing whether UL32 interacts with DNA in vivo and, if so, to which sequences 
it binds. 
Several of the experiments described in this chapter would have benefitted if the UL32 
protein was of a higher purity than that achieved by MonoQ column fractionation. This 
might be possible to achieve by employing additional columns for example hydrophobic 
interaction chromatography. Alternatively, protein from a different source could be used, 
for example a bacterially-expressed protein that could be purified by virtue of a suitable 
cleavable affinity tag (e.g. GST or 6xHis tag). The availability of more highly purified 
UL32 would also allow alternative zinc-binding assays to be employed, for example 
atomic absorption spectroscopy or Extended X-ray Absorption Fine Structure spectroscopy 
(EXAFS). EXAFS has been used along with biochemical approaches for examining the 
zinc binding properties of HPV E7 (Patrick et al., 1992) and a number of other proteins. 
These techniques, along with examination of the CxxC/CxxxC mutant proteins, could give 
a more accurate determination of how the zinc is chelated within the UL32 protein. 
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7 Discussion 
Previous work had identified UL32 as a predominantly cytoplasmic HSV-1 protein 
essential for the growth of HSV-1 and DNA packaging, although dispensable for viral 
DNA replication (Chang et al., 1996; Lamberti & Weller, 1998; Sherman & 
Bachenheimer, 1987; 1988). The work presented in this thesis has in some parts supported 
this previous characterisation, providing clues as to the function of UL32 within HSV-1 
DNA packaging, and also characterising other properties of UL32. 
Chapter 4 described the isolation of a panel of 37 insertional mutants and four site-specific 
mutants of the UL32 protein, in an attempt to characterise the structure-function 
relationship of UL32 and provide some insight into its role in HSV-1 DNA packaging. The 
ability of each mutant to support DNA packaging correlated precisely with their capacity 
to complement the growth of a UL32 mutant virus, hr64. This suggests that the only 
essential function of UL32 involves the DNA packaging pathway. Perhaps unsurprisingly, 
the functionality of mutants in these two assays also correlated with the degree of 
conservation within the UL32 protein, with those mutants in the most conserved regions 
being non-functional and those in areas of low conservation being more tolerant of 
insertions. The site-specific substitution of the cysteine residues within the conserved 
CxxC/CxxxC motifs showed that whilst the outer motifs were absolutely essential for the 
function of UL32, mutation of the central CxxC does not completely abrogate DNA 
packaging. This is discussed later in greater detail in the context of the zinc-binding 
properties of UL32. The deletion of the extreme C-terminus (four amino acids) also 
generated a non-functional protein. 
The generation of a recombinant HSV-1 expressing an HA-tagged UL32 protein allowed 
analysis of the localisation of UL32 within virus infected cells and it was found that UL32 
localised entirely to the replication compartments (RCs) at 6 hours post infection. As 
discussed in section 5.7, this is in contrast to previous reports in which UL32 was found to 
be either entirely cytoplasmic or predominantly cytoplasmic with a small portion within 
the RCs. My results indicate that UL32 shows a similar localisation to the other packaging 
proteins and capsids during infection, as would be expected for a protein involved in DNA 
packaging. As UL32 is cytoplasmic when expressed alone, there must be a mechanism by 
which it is directed to the RCs during HSV-1 infection. One possibility was identified by 
examination of the interactions between UL32 and other HSV-1 proteins. 
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Immunofluorescence data presented in chapter 5 suggested that UL32 may interact with 
the terminase complex, as UL32 was relocalised to the nucleus in the presence of the three 
putative terminase subunits, UL15, UL28 and UL33. Co-transfection with UL15 alone also 
caused the partial relocalisation of UL32 to the nucleus, indicating that these two proteins 
might interact with each other perhaps weakly or transiently. It was found that UL15 and 
UL28 together are sufficient for the complete relocalisation of UL32 to the nucleus, with 
UL33 appearing to play a minor or no role. The requirement for UL28 suggests that UL32 
may also bind to UL28 (possibly using different regions of the protein for interacting with 
UL15 and UL28), or that the addition of UL28 alters the conformation of UL15, allowing 
it to interact more strongly with UL32. Co-immunoprecipitation analysis from baculovirus-
infected insect cells demonstrated no interaction between UL32 and any of the terminase 
components proteins alone, supporting the idea that more than one of these subunits are 
required for stable interaction with UL32. 
A recent paper from Yang (2007) showed that the terminase complex forms in the 
cytoplasm of cells and then is directed into the nucleus by virtue of the NLS within UL15. 
This might provide the mechanism for the localisation of UL32 to RCs as well, if UL32 
can bind to the cytoplasmic terminase complex and be transported into the nucleus. This 
could be tested by the introduction of a UL15 deletion into HA32EP, to visualise the 
localisation of UL32 in the absence of UL15. 
The localisation of each of the mutants generated in chapter 4 was then examined in this 
assay and the colocalisation of the mutant UL32 proteins with the terminase proteins 
correlated almost exactly with their functionality, with 13 of the 15 functional mutants 
showing complete relocalisation to the nucleus, and the remaining two (in328 and in376) 
showing partial relocalisation. These data suggest that the interaction with the terminase is 
essential for UL32 function. Interestingly, however, mutants in328 and in376 were not 
impaired at all in the complementation and packaging assays. It may be that in these 
transfection/superinfection assays, enough of these mutant UL32 proteins is localised to 
the nucleus to allow full functionality. The presence of UL32 in the nucleus is nevertheless 
not sufficient for packaging to occur, as two mutants (in338 and in398) were both able to 
completely co-localise with the terminase, but did not support viral growth or DNA 
packaging. It would be interesting to examine all four of these mutants in the context of a 
full viral infection to compare their phenotype to wt UL32. 
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If UL32 does indeed form part of the terminase complex, a number of possibilities can be 
envisaged for what role it might play. These include: (i) it may ensure that the terminase 
complex is correctly folded and assembled; (ii) it may mediate the interaction of the 
terminase with the DNA (iii) it may mediate the interaction of the terminase/DNA complex 
with the capsid; (iv) it may have an enzymatic role per se; (v) it may regulate the 
enzymatic activities of the terminase. I consider that my results are more consistent with 
possibilities (iv) or (v), as discussed below. 
The three terminase components UL28, UL15 and UL33 have been shown to interact using 
immunoprecipitation of proteins expressed by recombinant baculoviruses (Beard et al., 
2002). This shows that they can form a stable complex in the absence of other HSV-1 
proteins and that UL32 is not required to allow the terminase proteins to associate. It may 
of course be that the situation in infected cells is different, but it seems unlikely that UL32 
is required for association of the terminase components. Furthermore, my 
immunofluorescence data showed that UL33, UL28 and UL15 all localised to the RCs 
during hr64 infection. The terminase proteins UL15 and UL28 have been shown to interact 
with the portal protein, UL6 and it was proposed that this is the mechanism by which the 
terminase interacts with the pre-formed capsid (White et al., 2003). I found no interaction 
between UL32 and UL6, suggesting that UL32 has no involvement in mediating the 
terminase-capsid interaction. 
Possibilities (iv) and (v) appear more likely, in which UL32 either performs an enzymatic 
activity itself, or in some way activates or regulates the enzymatic activity of the terminase. 
Bioinformatic analysis failed to reveal any sequence similarity between UL32 and the 
DNA packaging proteins of either bacteriophage or other DNA viruses excluding 
herpesviruses. Indeed, BLAST analysis of the UL32 protein sequence retrieved only 
herpesvirus UL32 gene homologues from the RefSeq protein database. These analyses 
therefore provided no further clues regarding the function of UL32 and any possible 
enzymatic activities it might possess. The EMSA presented in section 6.6 did not identify 
any dsDNA binding activity of UL32, possibly indicating that UL32 does not play a DNA 
binding role within the terminase. However, as previously discussed, the only DNA 
binding reported for UL28 required a novel conformation of the DNA (Adelman et al., 
2001). Therefore, more work needs to be carried out with varying DNA substrates and 
possibly investigating the DNA binding of UL32 in the context of the terminase before this 
possibility can be completely rejected. 
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A number of accessory proteins have been identified in bacteriophage (especially phage λ) 
which are directly involved in regulating the packaging process and act in concert with the 
terminase, for which analogous proteins have not been identified in herpesviruses. One of 
these is gpFI in phage λ, which is not required for DNA replication but is essential for 
cleavage at the cos sequence and DNA packaging. The exact role of gpFI is unknown but it 
is thought to be required for the transition of the terminase from a stable but inactive 
complex to a packaging machine that is capable of translocation of the DNA into the 
capsid (Catalano & Tomka, 1995). This involves activation of the ATPase subunit (gpA in 
phage λ) and switching the terminase complex from a form that is specifically bound to cos 
to one which can bind tightly but non-specifically to DNA to allow packaging. An 
additional protein required in bacteriophage λ packaging is the host protein IHF, which 
binds to a specific sequence of viral dsDNA and introduces a 180° bend into the DNA, to 
bring the terminase binding sites into the correct orientation (Ortega & Catalano, 2006). It 
is possible that UL32 might play a role analogous to one of these proteins in HSV-1 DNA 
packaging, as an accessory protein for the cleavage and packaging reaction. 
Other possibilities do exist, for example UL32 might be required to make capsids 
competent for DNA packaging to occur. Procapsids and B capsids are produced in the 
absence of UL32, but these may be unsuitable for packaging. It might be that a transitory 
association of UL32 with the procapsid is required, for example to "activate" the portal. An 
interaction between UL32 and the capsid has not been demonstrated making this seem 
unlikely, but it could be investigated by determining the structure of the capsids produced 
during wt HSV-1 and hr64 or ∆32EP infections by cryo-electron microscopy, to see if they 
have an altered structure.  
It has also previously been suggested that UL32 may act as a chaperone protein involved in 
the correct localisation of capsids or the capsid proteins VP19C and VP23 to replication 
compartments (Lamberti & Weller, 1998). CxxC motifs are common in redox chaperone 
proteins, where they are used for the formation and reduction of disulphide bonds in target 
proteins, and disulphide bonds have been reported in HSV-2 capsids (Zweig et al., 1979). 
As previously mentioned, a number of proteins have been identified in viruses such as 
Sindbis virus and African swine fever virus (ASFV), which act as redox chaperones, using 
conserved cysteine residues to aid the correct folding of virion components (Cobbold et al., 
2001; Parrott et al., 2009). However, unlike UL32, these proteins have well-documented 
interactions with their target proteins. Furthermore, both of these viruses assemble their 
capsids in the cytoplasm of cells, which is a much more reducing environment than the 
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nucleus, and so the requirement for redox chaperones may be different. Sequence analysis 
of UL32 using the BLAST programmes did not yield any further similarities to proteins 
involved in redox reactions. This is in contrast to one of the chaperones from ASFV, 
pB119L, which shows similarity to the Erv1p/Alrp family of sulfhydryl oxidases and so 
could clearly be identified as a redox-chaperone (Rodriguez et al., 2006). In the work 
presented here, I found no evidence of mis-localisation of capsids or capsid proteins in 
hr64-infected cells. Furthermore, no disulphide bonds have been found within HSV-1 
capsids, and capsid proteins VP19C and VP23 or VP19C and VP5 do not appear to be 
disulphide-linked (Dr F. Rixon, personal communication). Taking all this data together, it 
seems unlikely that UL32 acts as a chaperone for the folding or localisation of capsid 
components. 
As discussed in section 5.7, there may be a number of ways in which one protein might 
influence the localisation of another without a direct interaction, and so it is essential to 
verify the UL32-terminase interaction using an independent assay. Recent work in our 
laboratory using insect cells multiply-infected with recombinant baculoviruses encoding 
UL32, UL28, UL15 and UL33 has demonstrated that UL32 and UL28 can be co-
precipitated, although other possible interactions have not yet been studied (Dr N. Stow, 
personal communication). This supports the theory that UL32 can stably interact with the 
terminase but not its individual subunits. This work will be furthered to identify the direct 
interactions between the four proteins.  
Work presented in chapter 6 confirmed and quantified the zinc-binding properties of 
UL32. It was calculated that UL32 bound zinc at an approximate molar ratio of 1:1 zinc: 
UL32. This work did not identify the residues involved in the zinc chelation, but the 
cysteine residues are likely to be involved. As previously discussed, many zinc binding 
proteins chelate the zinc atom using a combination of cysteines and histidines, with four 
residues (Cys or His) often involved in the chelation of one atom of zinc. As discussed in 
section 6.7, UL32 does not correspond to a classical C2H2 zinc finger (ZnF) protein, but it 
does show similarity to some C4-containing ZnFs. These encompass a wide range of 
proteins that chelate the zinc atoms using 4 cysteines distributed within two CxxC motifs, 
as reviewd by Grant (2007). However, a number of factors appear to separate UL32 from 
these identified ZnF proteins. These proteins commonly contain the cysteines residues 
within close proximity, whereas the CxxC/CxxxC motifs in UL32 are much more widely 
separated. Many of these proteins also contain multiple ZnF motifs chelating multiple zinc 
atoms, whereas UL32 encodes only three conserved CxxC/CxxxC motifs. A fourth motif 
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(CAKC in HSV-1 UL32) is separated from the N-terminal CxxC by only 23 aa, but this 
fourth motif is not conserved within the herpesviruses, possibly indicating that it is not 
essential for the function of UL32. However, caution must be applied when using relative 
conservation in interpreting the zinc-binding properties of UL32, as none of the other 
herpesvirus UL32 homologues have yet been shown to bind zinc. 
The mutational analysis of the CxxC/CxxxC motifs presented in chapter 4 provided 
information on which residues might be important for zinc binding. Although the second 
and third CxxC/CxxxC motifs are reminiscent of those found in ZnFs, the functional 
analysis indicates that the central CxxC is not absolutely essential for a functional protein. 
Instead, knock-out of either of the outer motifs was sufficient to abrogate function, 
suggesting that these are the more important residues. If the zinc-binding ability of UL32 is 
essential for its function, it may be that this central CxxC motif is not involved. A situation 
can be envisaged in which the native structure of the protein is such that the two terminal 
regions loop round in close proximity to each other. In this case, the cysteines within the 
two outer motifs might be involved in zinc chelation, explaining why these are absolutely 
essential for function of the protein. It would be interesting to introduce the panel of CxxC 
mutations into baculovirus so that the zinc-binding abilities of these mutated proteins could 
be examined, in order to determine whether this is the case. Mutational analysis of T4 
endonuclease VII revealed that the outer cysteines within the paired CxxC/CxxxC motifs 
were essential for the zinc-binding(Giraud-Panis et al., 1995), and a similar more detailed 
mutational analysis could be carried out with UL32 to determine which individual cysteine 
residues are essential for the function of UL32.  
 
7.1 Future perspectives 
While the work presented in this thesis has provided a number of interesting insights into 
the function of UL32, it also raises many future possibilities to further this work. 
A number of other experiments can be designed in order to verify whether there is a direct 
interaction between UL32 and the terminase complex, and if this is required during normal 
HSV-1 infection, many of which can be performed using reagents generated in this thesis. 
The generation of a functional HA-tagged UL32 protein, and its introduction into virus 
provided a sensitive way to examine the localisation of UL32 during infection. Deletion of 
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UL15 and/or UL28 from this virus would allow the study of whether the terminase proteins 
are essential for the correct localisation of UL32. The HA-tag could also be used for 
immunoprecipitation from HSV-1 infected cells, to examine whether UL32 can interact 
with the terminase. Some of the non-functional mutants that did not co-localise to the 
nucleus of transfected cells with the terminase proteins could also be introduced into virus 
using the Red/Et counter selection method, to analyse their localisation during normal 
virus infection. 
It would be extremely useful to generate a more highly purified preparation of UL32 
protein than that which was achieved by MonoQ fractionation. The size exclusion 
chromatography did not allow for further purification due to the aggregation of UL32, but 
as mentioned in section 6.7, other chromatography approaches could be used, or affinity 
purification by use of a tagged-UL32 protein. The generation of the rabbit antisera 
described in chapter 4 show that by nature, the UL32 protein is immunogenic. A panel of 
mouse monoclonal antibodies could therefore be isolated (using the immunogen from 
MonoQ fractionation) which might be useful sensitive reagents. These might possibly 
provide further information on structurally important regions, for example by testing 
whether they can block the UL32/terminase interaction. 
If a large enough amount of purified UL32 could be obtained, it might be possible to 
determine the crystallographic structure, which would provide useful insights into the 
analysis of my mutagenesis experiments by indicating which residues lie near to each other 
in the native protein. This would allow functional regions of the proteins to be more easily 
identified, and further site-specific mutagenesis could be carried out. The crystallographic 
structure would also provide important information as to where the cysteines lie and how 
the zinc is chelated. 
A major step forward would be the development of a cell-free system for HSV-1 DNA 
packaging similar to those reported for several dsDNA bacteriophage, although this will 
not be easy because of the poor solubility of several of the HSV-1 proteins. Development 
of such a system might allow the role of each terminase protein to be confirmed and could 
also provide a useful assay to investigate whether UL32 is directly required for the 
cleavage of DNA, or has an alternative role in packaging.
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